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Summary 
Cardiovascular disease (CVD) is the most common cause of death worldwide, 
accounting for 31% of the annual deaths per year. The term cardiovascular 
disease refers to many different disorders of the heart and blood vessels, the 
most prolific of which is coronary heart disease (CHD). The root cause of CHD is 
atherosclerosis, which is the build-up of plaque in the intima of the arteries, 
restricting the blood supply which reaches the heart. 
If left untreated, the plaques lining the vessel can rupture and cause thrombosis 
and myocardial infarction (MI). Taking into account an individual’s risk-benefit 
ratio, a suitable treatment is considered with the aim to prevent MI from 
occurring. The two main revascularisation strategies are coronary artery bypass 
graft (CABG) and percutaneous coronary intervention (PCI), the latter being the 
most frequently used; within the UK 80% of revascularisation is performed by 
PCI. 
A PCI procedure is non-invasive and involves the deployment of an intravascular 
stent into the diseased vessel, which acts as a permanent scaffold that 
mechanically re-widens the vessel. However, despite the prolific use of 
intravascular stents within the clinic, there are significant problems associated 
with this revascularisation technique, such as in-stent restenosis (ISR) and late 
stent thrombosis (LST). 
ISR is the re-narrowing of arteries after stent deployment, characterised by a 
neointima growth within the lumen of the vessel. ISR is a significant clinical 
problem, because it can lead to repeat revascularisation procedures and often 
patients present frequently with unstable symptoms, fulfilling the criteria for an 
MI diagnosis. ISR occurs as a complex wound healing response caused by the 
stent deployment. Denudation and tearing of the endothelium and the 
mechanical stress endured by the vascular smooth muscle cells (VSMC) is a 
stimulus for hyperplasia. VSMC de-differentiate from the contractile to synthetic 
states and proliferate and migrate into the lumen of the vessel, secreting ECM 
which forms the bulk of the neointima. The neointima growth will continue to 
form until the endothelium has re-established itself.  
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As a treatment to prevent ISR, drug-eluting stents (DES) were introduced which 
were coated with anti-proliferative drugs, to prevent ISR from occurring. DES 
proved to be very successful at preventing ISR; however elevated rates of LST 
were associated with these stents. This caused the initial gains in lower event 
rates, 6 months after DES deployment to be lost after higher event rates were 
reported when compared to BMS, after the 6 month time point (Lagerqvist et 
al., 2007, Pfisterer et al., 2006). This elevated event rate for DES by LST is 
thought to be caused as a result of delayed re-endothelialisation and by 
inflammatory reactions to the polymer used in the coating of DES (Virmani et 
al., 2004, Joner et al., 2006).  
The aim of this study was consequently to investigate methods for delivery and 
coating of novel therapeutics, adenoviruses and miRNA onto stent surfaces. This 
would allow investigation into the prevention of ISR using these therapeutics, 
taking advantage of the localised stent setting. It was hoped that local delivery 
would provide significant advantages over systemic delivery by decreasing the 
dosage required, avoiding systemic side-effects and increasing delivery to the 
targeted area, thereby enhancing the therapeutic effect. 
For the development of coating methods for adenovirus eluting stents, the 
majority of the work conducted was done using Ad5 as a model virus vector. 
Three different methods were investigated and evaluated in vitro; deposition 
onto polyelectrolyte multilayer (PEM) surfaces, by direct conjugation with a 
modified poly(lactic acid) (PLA) surface through covalent bond formation and 
collagen gel entrapment. 
The development of coating methods for miRNA eluting stents focussed initially 
on collagen gel entrapment; however it was discovered that direct application 
onto a PLA surface provided a system whereby excellent delivery of the miRNA 
could be achieved. This methodology was extensively investigated and evaluated 
in vitro from stent material surfaces, and in vivo in both the porcine and murine 
stenting models.  
The results presented here have extended current methodology for both miRNA 
and adenovirus eluting stents. To the best of our knowledge, this is the first time 
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that miRNA eluting stents have been used in these animal models and therefore 
contributes significantly to the field of miRNA-based therapeutics.  
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1 Introduction 
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1.1 Cardiovascular disease 
Cardiovascular disease (CVD) is the leading cause of death globally; in 2012 the 
World Health Organisation (WHO) reported 31% of all deaths each year were 
caused by CVD (WHO, 2015). Within the UK, the British Heart Foundation (BHF) 
reported the number of deaths per year to be 160,000 which is roughly a quarter 
of the annual death toll. Therefore, CVD remains a serious medical issue both 
globally and locally (BHF, 2015).  
The term CVD refers to a number of different disorders of the heart and blood 
vessels, the four main types are coronary heart disease (CHD), stroke, peripheral 
artery disease and aortic disease. The most prolific of these is CHD, which is a 
disease that affects the blood vessels supplying the heart. CHD is caused by a 
build-up of plaques (fatty deposits), which accumulate in the lumen of the 
coronary arteries, restricting the blood flow within these vessels. Since the 
coronary arteries supply the myocardium with blood, restriction of blood flow 
can cause angina (chest pain) or if the coronary arteries become completely 
blocked, myocardial infarction (MI) (NHS, 2015). CHD is the UK’s single biggest 
killer and accounts for 73,000 deaths per year (BHF, 2015).  
Atherosclerosis, which can be defined as the build-up of plaque in the intima of 
arteries, is the root cause of CHD. The term ‘atherosclerosis’ has Greek roots 
and stems from the terms ‘atheroma’, meaning a tumour which is composed of 
material that looks like gruel and ‘sclerosis’ meaning hardening, which comes 
from the Greek word skleros. Atherosclerosis is therefore a descriptive term 
which provides us with an image of what a diseased artery would look like. The 
plaques are formed from the accumulation of lipids and fibrous elements in large 
arteries. Atherosclerosis is a chronic inflammatory condition that can lead to an 
acute clinical event by plaque rupture and thrombosis (Lusis, 2000).  
Figure 1-1 shows the anatomy of a healthy and a diseased artery.  A normal 
artery has three distinct regions, the intima, media and adventitia. The intima, 
is predominantly composed of endothelial cells (EC), and is the innermost 
cellular region in the artery, directly in contact with the blood flow. 
Development of atherosclerotic plaques is initially characterised by changes to 
these intimal ECs, causing them to express adhesion molecules which promote 
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white blood cell (leukocyte) adhesion. This abnormal adhesion of leukocytes to 
the ECs is in response to inflammatory stimuli such as hypertension or 
dyslipidaemia (elevated levels of low-density lipoprotein (LDL)). The intima 
permits LDL entry and retention within the arterial wall, in parallel; the bound 
leukocytes migrate into the intima by chemoattractant mediators such as 
monocyte chemoattractant protein-1 (MCP-1) and lymphocyte chemokines, IFN-
inducible protein 10 (IP-10), monokine induced by IFN-gamma (Mig) and IFN-
inducible T-cell alpha chemoattractant (I-TAC) (Gu et al., 1998, Boring et al., 
1998, Mach et al., 1999). The predominant type of leukocyte which binds to the 
ECs are monocytes, which after recruitment to the intima, differentiate into 
tissue macrophages and work to engulf the LDL, forming foam cells (Libby et al., 
2011). 
Resident smooth muscle cells (SMCs) within the intima and SMCs from the media 
are recruited into the intima through mediators, such as platelet derived growth 
factor (PDGF). These cells secrete extra-cellular matrix (ECM) over the 
macrophage derived foam cells, to form a fibrous cap, as a preventative 
measure to avoid plaque rupture (Libby et al., 2011, Lusis, 2000). Unstable 
plaques however, can rupture, the clinical manifestation of this being 
thrombosis and MI, as shown in (Figure 1-1) (Robertson et al., 2012). Prevention 
and treatment of CHD is discussed in the following section.  
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Figure 1-1 Structure of a healthy artery (left) and a diseased artery (right) showing a 
build-up of atherosclerotic plaque and plaque rupture. 
Morphology of a large artery, showing the three distinct layers; intima, media and adventitia. The 
intima has an endothelial layer of cells which form a barrier between the blood flow and the artery, 
elastic fibre and internal elastic lamina layers. The medial layer is made up primarily of vascular 
smooth muscle cells, but also contains collagen and elastin. The adventitial layer is composed of 
mainly collagen and elastin and is separated from the media layer by the external elastic lamina.  
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1.2 Treatment of coronary heart disease 
Atherosclerosis is an age related condition, with increasing age being identified 
as an independant risk factor for the disease (Wang and Bennett, 2012). It is 
thought it can start when damage is endured to the inner surface of the arteries 
which could be through smoking, high blood pressure, high amounts of fats or 
cholesterol in the blood, and high amounts of sugar in the bloodstream as a 
result of diabetes and insulin resistance (NIH, 2015).   
Optimal Medical Therapy (OMT) is used to control and treat early stages of CHD, 
which involves the implementation of lifestyle changes and taking medication 
(Boden et al., 2007). Healthy lifestyle changes include stopping smoking, healthy 
eating, losing and maintaining a healthy weight and undertaking regular 
exercise, all of which are factors contributing to atherosclerosis. Since the 
atherosclerotic lesions have the effect of narrowing the artery lumen and 
therefore increasing blood pressure, medications are prescribed to counteract 
this by reducing blood pressure and re-widening arteries. There are many 
different classes of medication that are used for this purpose, the main classes 
being Angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers, 
β-blockers (Chobanian et al., 2003). More than two thirds of hypertensive 
patients’ blood pressure cannot be controlled with a single drug, and therefore 
dual therapy is often required, whereby the patient receives drugs from 
different classes (Chobanian et al., 2003). 
If the symptoms cannot be controlled by OMT, interventional procedures will be 
considered to restore blood flow to the affected area. A coronary angiogram, 
which is the ‘gold-standard’ for diagnosing CHD is carried out to image and 
measure the blood flow through the vessels in the heart. For this, a catheter is 
inserted through an artery in the arm or groin and directed into the heart using 
X-rays to guide it. Once in the heart, a radiocontrast dye is pumped through the 
catheter and images of the vessels are taken using X-rays, these images will help 
to decide the treatment that the patient will receive.  
The two main types of surgical intervention for the treatment of CHD are 
Percutaneous Coronary Intervention (PCI) and Coronary Artery Bypass Grafting 
(CABG). The decision for the best treatment to use is decided by taking into 
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account the risk-benefit ratios, weighting the risks of periprocedural death, MI, 
and stroke against improvements that could be gained in the quality of life,  by 
prevention of future MI and further revascularisation (Windecker et al., 2014). 
Different models are used to assess the various risks associated with the 
revascularistion strategies and aid the decision making depending on the 
particular situation, such as the SYNTAX (Mohr et al., 2013) and EuroSCORE II 
systems (Nashef et al., 2012).  
The SYNTAX system was developed using the results from randomised clinical 
trials comparing the outcomes of patients with complex coronary artery disease 
receiving either CABG or PCI treatments with a first-generation paclitaxel-
eluting stent. For the initial trial the end point was defined as death, MI, repeat 
revascularisation and stroke at 1 year post-operation. The findings from this trial 
enabled a scoring system to be developed to help predict the severity of the 
disease, the outcome of which is used to decide whether a patient would 
respond better to a CABG or PCI treatment (Serruys et al., 2009). Under the 
current guidelines patients with an intermediate or high SYNTAX score are 
recommended for CABG, whereas patients with low SYNTAX scores or left main 
coronary disease are recommended for PCI (Mohr et al. 2013).  
The EuroSCORE system was used to predict early mortality in cardiac surgery 
patients in Europe and used many patient-related factors (such as, age, chronic 
pulmonary disease, extracardiac arteriopathy, neurological dysfunction, previous 
cardiac surgery, serum creatinine >200 micromol/L) to generate a score which 
could be used to predict the risk of mortality caused by cardiac surgery (Nashef 
et al. 1999). This system has now recently been updated as it was thought that 
EuroSCORE over-estimated patient mortality, so consequently EuroSCORE II is 
now used (Mohr et al., 2013). Often clinicians refer to both of these scores when 
determining an appropriate treatment for the patient, depending on the specific 
condition (Capodanno et al., 2010).       
Of the two revascularisation strategies, CABG is the older of the operative 
procedures and was first used in 1968 (Favaloro, 1968). The procedure for CABG 
surgery involves the grafting of a healthy artery or vein, (usually from chest, legs 
or arms) around the blocked coronary artery. This allows the blood to be 
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diverted around the obstructed region, which restores blood flow to the heart 
and provide relief from angina (Figure 1-2).  
Percutaneous coronary intervention (PCI) was introduced in 1977, initially as a 
treatment for a single coronary artery with no involvement of side branches 
(Grüntzig, 1978, Grech, 2003). At this time, the operation involved inserting a 
balloon catheter percutaneously into the diseased vessel, inflating the balloon 
re-widened the occluded vessel mechanically (Figure 1-2). The equipment used 
to do this initial operation, did not benefit from the years of experience and 
research that modern-day PCI apparatus benefits from and this limited its 
application within the clinic; initially only 10% of cases would be suitable for this 
new type of revascularisation technique, it did however have the advantage of 
being a non-invasive procedure (Grech, 2003).  
 
Figure 1-2 Revascularisation procedures, PCI and CABG. 
 
As the technology advanced, the number of patients treated with PCI grew, the 
technology advanced as more complex lesions were able to be treated. Initially 
the guide catheters and balloons were large in comparison to today’s standards 
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and guide wires and stents were not used (Grech, 2003). The main drawback for 
this new technology was restenosis, which is the re-narrowing of the artery 
lumen; it was found that the PCI procedure could trigger elastic recoil of the 
vessel and promote negative re-modelling (de Feyter et al., 1994). Negative 
remodelling describes shrinkage in the external elastic membrane (EEM) area at 
the diseased site, which can be measured by IVUS (Schoenhagen et al., 2001). 
Elastic recoil occured as a result of the mechanical stress inflicted upon the 
elastic fibres within the vessel wall by the process of balloon inflation, which 
caused them to overstretch. Recoil occurred minutes after balloon deflation and 
was reported to cause up to 40% lumen loss (Kraitzer et al., 2007). It was in this 
context that intravascular stents were introduced.    
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1.2.1 Stent Technology 
The first time intravascular stents were deployed in humans was in 1986 (Sigwart 
et al., 1987). The intravascular stent was made from a stainless steel (SS) mesh 
that was crimped around the balloon catheter. The balloon catheter was 
positioned so it traversed the narrowed region in the artery and then inflated; 
this would cause the stent to expand. The balloon was then deflated; however 
the stent was left in the artery as a permanent scaffold (Figure 1-3). 
 
Figure 1-3 Revascularisation by deployment of a coronary stent. 
The first randomised studies comparing PCI using the stent technology against 
traditional balloon angioplasty methods demonstrated a profound decrease in 
restenosis rates ~30%. This was caused by a decrease in elastic recoil and a gain 
in the initial lumen size after the stenting (Grech, 2003, Smith Jr et al., 2001, 
Fischman et al., 1994, Serruys et al., 1994). It was as a result of the initial 
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comparative trials showing stenting to vastly improve the outcomes for 
restenosis when compared to balloon angioplasty PCI, which caused the rapid 
growth in the field and prolific use of the stents in the clinic. It took longer 
however, for the burden of the ISR to be realised and exposed as the Achilles 
heel to this treatment (Serruys et al., 1994, Fischman et al., 1994, Duckers et 
al., 2007).  
Since their introduction into the clinic in 1986, there has been an exponential 
growth in the number of stents deployed, as device technology and anti-
thrombogenic drugs have advanced. Initially, they were thought of as a 
temporary solution to acute vessel occlusion; however, they proved to be more 
effective than balloon angioplasty, reducing the number of patients requiring 
repeat revascularisation and are now a key part of treatment for CHD (Serruys et 
al., 2012, Moliterno, 2005, Sigwart et al., 1987). 
 In 2012, the British Cardiovascular Intervention Society recorded that 80% of 
patients requiring treatment after the angiogram findings received PCI rather 
than CABG, which is in line with the NICE guidelines (NICE, 2003, Ludman et al., 
2014). Despite the intravascular stents’ prolific use within the clinical setting, 
there are still significant problems associated with it such as in-stent restenosis 
(ISR) and late stent thrombosis, stenting therefore it is by no means the optimal 
treatment.  
1.2.1.1 In-stent restenosis 
ISR is the re-narrowing of arteries after stent deployment, characterised by the 
formation of a neointima in the lumen of the artery, formed as a response to the 
injury caused by the stent on the arterial wall. Neointima can be defined as 
simply the ‘new’ (neo) thickened arterial intima. Restenosis rates caused by 
deployment of bare metal stents (BMS) have been reported to be between ~16% 
and 44% (Farooq et al., 2011). Initially, clinical presentation of ISR was thought 
to be benign and generally stable with acute presentation being treated 
satisfactorily with repeat revascularisation procedures (Alfonso, 2010). However, 
recently studies suggest that patients present frequently with unstable 
symptoms and exhibit markers fulfilling the criteria for an MI diagnosis (Alfonso 
et al., 2014, Chen et al., 2006).    
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There are multiple factors which govern ISR which result in neointima formation, 
giving a complex physiopathology to understand. ISR has proved difficult to study 
due to the scarcity of human tissues, and the animal models not being 
sophisticated enough to represent advanced atherosclerotic vessels (Geary and 
Clowes, 2007, Welt and Rogers, 2002). Nevertheless, much progress has been 
made in this field and there is now a good understanding of the process within 
the scientific community.  
ISR is initiated during stent deployment, as a consequence of disruption and 
injury to the cells within the diseased vessel. It was Forrester and co-workers 
who proposed the paradigm for ISR the result of a complex wound healing 
response (Costa and Simon, 2005, Forrester et al., 1991). Mechanical stress 
induced to the vascular smooth muscle cells (VSMCs) (Leung et al., 1976, Clowes 
et al., 1989) and denudation of the endothelium (Sanborn et al., 1983) provides 
the stimuli for hyperplasia; this has been shown in many animal studies. The 
observation that intimal hyperplasia (abnormal increase in the number of cells 
within the intima), occurred in both atherosclerotic and normal segments after 
angioplasty, within humans, indicated that hyperplasia formation was not 
dependant on the presence of atherosclerosis; this therefore added weight to 
the animal studies, which observed the formation of hyperplasia as a vascular 
response to injury (Forrester et al., 1991). Figure 1-4 depicts the process of in-
stent restenosis from stent deployment to the neointima formation. 
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Figure 1-4 Cross-sectional representation of an artery undergoing in-stent restenosis. 
 
The wound healing response triggering ISR can be thought of as three stages: 
inflammation, granulation & matrix formation. The inflammatory response is 
triggered instantly in response to the injury endured by stent implantation, 
which can denude endothelium. The inelasticity of the atheroma can also cause 
tears to develop as the pressure required to compress the plaque and deploy the 
stent can rupture and damage the cellular architecture (Forrester et al., 1991). 
At the site of injury, platelets aggregate (Lobb, 1988) and release growth factors 
and other substances including an endoglycosidase, which are responsible for the 
cleavage of heparin proteoglycan from the surface of endothelial cells (ECs) and 
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smooth muscle cells (SMCs) making them receptive to action of the growth 
factors (Castellot Jr et al., 1987, Campbell and Campbell, 1986, Forrester et al., 
1991).  
The granulation phase occurs from days 3-5 after stent implantation and is 
characterised by SMC’s phenotype switching from the contractile to the 
synthetic state; this causes them to proliferate and then migrate into the 
injured area and secrete ECM (Kocher et al., 1991, Forrester et al., 1991). 
Characterisation of phenotype switching of VSMCs from contractile to synthetic 
states following vascular injury can monitored by viewing a change in cell 
morphology, with contractile phenotypes displaying a long-spindle like form 
whereas synthetic phenotypes exhibit a distinct epithelioid morphology (Walker 
et al. 1986). This change is also accompanied by decreased expression of 
proteins α-SMA and SM-MHC relative VSMC phenotype expression can be 
monitored by IHC staining methods (Kocher et al., 1991, Kuro et al., 1991). Early 
ECM is rich in fibronectin from the coagulated blood. Endothelial cells will also 
begin to migrate from the edges of the injury site in response to the growth 
factors release from the injury response and ECM (Forrester et al., 1991, 
Folkman and Klagsbrun, 1987).  
Once the cells have migrated into the site of injury, matrix formation begins to 
take place, converting the initial fibronectin matrix to a proteoglycan rich 
matrix, this process is regulated predominantly by transforming growth factor 
beta (TGF-β) (Bentley, 1967, Sprugel et al., 1987). When the endothelial cells 
have covered the injured area they stop proliferating and synthesise and release 
heparin proteoglycan. SMCs bind to the proteoglycan with high affinity and this 
has the effect of making them unresponsive to the proliferative growth factor 
stimuli (Bassols and Massague, 1988). The SMCs then gradually revert back to 
their contractile state (Forrester et al., 1991).  
The degree of ISR has been directly correlated to the severity of the mechanical 
stretch and injury which the vessel receives. The formation of neointima 
hyperplasia is reliant on how quickly re-endothelialisation occurs, therefore 
when the injury is severe and the endothelium is severely denuded, neo-intima 
formation will be exaggerated (Forrester et al., 1991).  
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1.2.1.2 Late stent thrombosis 
Following the high incidence of restenosis with BMS and the discovery that ISR is 
not as benign as it was once thought and often requires repeat revascularisation 
procedures (Chen et al., 2006, Alfonso et al., 2014); much research has focused 
on stent design, materials and surface treatments to try and minimise ISR from 
occurring (O’Brien and Carroll, 2009). 
In the early 2000’s drug-eluting stents (DES) were at the forefront of 
cardiovascular research. DES’s promised to reduce ISR by eluting therapeutic 
drugs which targeted cell proliferation and migration to eliminate the formation 
of the neointima. Early clinical results showed excellent results with respect to 
reduced ISR. Stone et al. conducted double-blind, multi-centred, randomised 
clinical trial which compared the safety and efficacy of paclitaxel-eluting stents 
to BMS. Paclitaxel induces cytostasis by stabilising microtubules which in turn 
inhibits VSMC division (Axel et al., 1997). The site-specific delivery of paclitaxel 
from the DES demonstrated a marked decrease in restenosis rates from 26.6% to 
7.9% at 9 months (Stone et al., 2004). Similar findings were also shown with 
sirolimus eluting stents when directly compared to BMS at 9 months (Moses et 
al., 2003). Sirolimus (rapamycin) was chosen as it was identified to induce VSMC 
cycle arrest by decreasing cell-cycle kinase activity at the G1/S and G2/M 
transitions (Marx et al., 1995).   
Shortly after these studies were conducted, a new problem emerged with the 
DES; late stent thrombosis, which often resulted in fatalities (Shedden et al., 
2009). It was found that the window for thrombotic risk was much longer for DES 
than for the BMS, and therefore the initial 9 month clinical trials did not detect 
the elevated rate of late stent thrombosis during the timescale of the trials. 
Studies comparing late stent thrombosis rates between BMS and both sirolimus 
and paclitaxel eluting stents showed an elevation in the incidence of late stent 
thrombosis with DES between 1-3 years, however no overall increase in 
cumulative rate of death was recorded between the BMS and DES groups (Stone 
et al., 2007c). Although DES have been shown to be effective against limiting 
restenosis; late stent thrombosis presents a formidable clinical problem in terms 
of patient safety. The difference in the cumulative death rate between BMS and 
DES at 4 years is negligible; therefore an optimal treatment which will 
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demonstrate an improvement in the cumulative death rate is yet to be 
developed.   
Late stent thrombosis is multifactorial and is thought to arise from a 
combination of incomplete endothelialisation of the stent struts, incompatibility 
with dual antiplatelet therapy and an inflammatory response caused by the 
polymer coating (Robertson et al., 2012, Virmani et al., 2004). 
One of the main issues which has plagued the advances made with DES is the 
lack of specificity that the anti-proliferative drugs have. DES are unable to 
distinguish between the two main cell types involved in neointima formation; 
ECs and SMCs, preventing the proliferation of both and hence decreasing in stent 
restenosis. This suppression of cell proliferation, ultimately results in delayed 
re-endothelialisation which is thought to be an underlying cause of late stent 
thrombosis (Babapulle et al., 2004, Shedden et al., 2009). Histologic findings 
from human autopsies of patients who had died after receiving DES compared 
with patients that had received BMS revealed that there was a marked 
difference in arterial healing between the BMS and the DES (Joner et al., 2006). 
The BMS showed near complete re-endothelialisation and an absence of fibrin 
around the struts, whereas for the DES, poor endothelialisation and peri-strut 
fibrin was observed. Incomplete re-endothelialisation of the stent struts 
therefore poses as a potent thrombogenic stimulus and could account for the 
observed trend in elevated late stent thrombosis rates associated with DES. 
Despite the issue of late stent thrombosis which has limited the success of DES, 
the concept, of localised delivery from the stent surfaces, clearly works 
extremely well; as demonstrated by the marked decrease in restenosis (Stone et 
al., 2004). Taking advantage of the site-specific delivery which can be achieved 
from stent surfaces is likely to feature in new stent technologies. 
It is apparent that administering sirolimus and paclitaxel, which both inhibit cell 
proliferation, has a profound effect on the local SMC and EC populations 
surrounding the stent; although the overall lack of specificity of these drugs, has 
unfortunately led to an increased incidence of late stent thrombosis by delayed 
re-endothelialisation(Joner et al., 2006). Understanding the mechanisms which 
underlie the process of ISR and designing an elegant treatment, which would 
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selectively target specific biological pathways could provide a treatment with a 
highly specific mode of action, more finely tuned to specific cell types. An 
optimal treatment would prevent ISR but not cause late stent thrombosis. The 
biological mechanisms for neointima hyperplasia and potential therapeutic 
targets which have been identified are discussed in the following section. 
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1.3 Mechanisms for neointima hyperplasia 
The formation of neointima hyperplasia is a complex wound healing process, 
which stimulates multiple biological cascades to occur concurrently. A successful 
treatment for the prevention of ISR is likely to employ multiple approaches 
which target the different underlying molecular mechanisms that result in 
neointima formation. This is apparent from the implementation of DES, which 
aimed to prevent cell proliferation by administrating a single anti-proliferative 
drug; this highlighted the complex nature of the disease pathology as the 
unwanted effect of late stent thrombosis emerged as a result of hindering re-
endothelialisation (section 1.2.1.2). In order to design a suitable treatment 
which accounts for the complexity of the process, understanding the 
mechanisms which cause neointima formation will be integral to its success. The 
following section will give an overview of the disease process that underpins 
neointima hyperplasia.  
During stent deployment (Figure 1-3), damage can be inflicted upon the vessel 
as a result of the mechanical force needed to inflate the stent. As the stented 
vessel will be atherosclerotic and therefore harder, the radial force required to 
expand the stents is often high; tearing of the endothelium can therefore easily 
occur. The resulting damage to the endothelium causes platelet aggregation and 
activation (McDonald et al., 2012). Under normal circumstances platelets 
flowing within the blood stream do not interact with ECs, which inherently 
prevents thrombus from forming within the vessels. Upon disruption to the EC 
layer, exposure of the platelets to the sub-endothelial matrix stimulates them to 
aggregate together (Rumbaut and Thiagarajan, 2010). Fibrin is also deposited at 
the site of injury (Indolfi et al., 2000). The activated platelets express adhesion 
molecules which can bind to leukocytes from the blood, the platelet-leukocyte 
complexes then begin to roll along the injured surface (Welt and Rogers, 2002).   
Activated platelets will release many growth factors and cytokines, such as 
PDGF, TGF-β1, IL-1, IL,6, IL-8 and thrombin, which aids infiltration of the 
leukocytes into the vessel wall and begin to interact with the SMCs (McDonald et 
al., 2012). Sustained release of adhesion molecules, growth factors, cytokines, 
and chemoattractants by the platelets, SMCs and leukocytes leads to further 
leukocyte recruitment and infiltration into the sub-endothelial layer (Mitra and 
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Agrawal, 2006b) and directs phenotypic modification of SMCs from their 
contractile to synthetic state (Indolfi et al., 2003). 
Adult VSMCs are usually quiescent and in the G0 phase of the cell cycle. 
However, when they are injured they change from their usual non-proliferative 
state to G1/S phase of the cell cycle. G1 progression is regulated by cyclin-
cyclin-dependent kinases (CDKs) which become active through binding with the 
regulatory protein, cyclin (Indolfi et al., 2003). CDK inhibitors can therefore be 
used to prevent proliferation of VSMCs by blocking this pathway. The two main 
CDK inhibitor groups active within the cardiovascular system are the INK4 and 
Cip/Kip families (Nabel, 2002, Tanner et al., 1998). 
Another way in which proliferation of VSMCs is stimulated is through the 
activation of nuclear transcription factors. The main signalling cascade which 
has been identified that controls this is through the ras-raf-mitogen-activated 
protein kinases (MAPK). Growth factors, such as PDGF initially bind to the growth 
factor tyrosine kinase (TK), which is located in the cell membrane and begins 
the cascade by multiple phosphorylation of tyrosine. The phosphorylated 
tyrosine then connects to ras receptor upon activation by growth factor receptor 
bound 2 (GRB-2) and son of sevenless (SOS) molecules. This promotes binding of 
guanosine triphosphate (GTP) which activates ras which binds raf, which 
culminates in the activation of MAPK (Indolfi et al., 2003). 
In addition to these pathways, a hormone dependent route also contributes to 
the promotion of the VSMCs from contractile to synthetic state. Hormones bind 
to seven loop receptors within the VSMC cell membrane, which triggers the 
cyclin adenosine monophosphate (cAMP) pathway, through activation of the G-
protein cascade. Upon hormone activation the α-subunit of trimeric G-protein 
complex is inactivated, this consequently drives the action of adenylate cyclase 
which catalyses the conversion of adenosine triphosphate (ADP) to cAMP. 
Activation of protein kinase A (PKA) through binding with cAMP, releases an 
active catalytic subunit C (C) that phosphorylates many substrates in the 
cytoplasm. A part of C also migrates into the nucleus and has the effect of 
activating transcription factors by phosphorylation, such as cAMP-responsive 
element binding protein (CREB). Activation of CREB has the effect of promoting 
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the transcription of cAMP regulated genes which ultimately act to promote cell 
proliferation (Indolfi et al., 2003). 
Once the VSMCs are in the synthetic state they release a collagen rich ECM, 
which forms the bulk of the neointima. A potent stimulator for this process is 
TGF-β1, which is synthesised and expressed by the VSMCs themselves as well as 
infiltrating macrophages expressing IL-1 (Chamberlain et al., 2001). 
Re-endothelialisation is an important process in neointima hyperplasia formation 
as it marks the end of the wound healing process. The rate at which an injured 
vessel is re-populated with ECs has been shown to be one of the governing 
factors which acts to determine the extent of the neointima growth (Mayr et al., 
2006). A recent study directed by Keith Channon, which used a mouse stenting 
model, revealed that ECs involved in the repopulation of the injured area come 
primarily from non-stented regions of the vessel and include endothelial 
progenitor cells (EPCs) (Douglas et al., 2013). These findings therefore provide 
insight into another process which could be targeted in order to develop a 
therapeutic strategy to combat ISR.    
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1.4 Therapeutic strategies for prevention of in-stent 
restenosis 
As described previously, (Section 1.3), the process of ISR is incredibly 
complicated and involves a plethora of molecular mechanisms that lead to the 
formation of the neointima. There are, therefore, a number of different 
approaches that can be taken to prevent ISR, employing the use of drugs, genes, 
RNA and cells for therapeutic gain. In the following section an overview of 
different treatment strategies is given; for clarity, ISR pathways have been 
grouped into the different stages of the process chronologically, with anti-
inflammatory approaches first, followed by anti-proliferative approaches and 
then re-endothelialisation.    
1.4.1.1 Anti-inflammatory approaches 
The deployment of stents will inevitably cause an inflammatory response, in 
response to the placement of a foreign object into the vessel. In 1998, 
Kornowski and co-workers published a study which used the porcine stent 
restenosis model, and found a significant correlation between the extent of 
inflammation and the subsequent neointima formation (Kornowski et al., 1998). 
These findings were mirrored in the human clinical setting exhibiting a strong 
correlation between stent associated inflammation and the degree of neointima 
formation (Farb et al., 1999). Taken together, these results highlighted that 
using an anti-inflammatory approach could provide a useful prevention strategy 
for ISR. 
TGF-β1, the inflammatory cytokine is one of the targets aimed to suppress this 
inflammatory response. Decorin and fibromodulin are both proteoglycans which 
act as antagonists for various isoforms of TGF-β1. Using an adenovirus-mediated 
gene transfer system, decorin and fibromodulin were delivered to human 
saphenous vein segments as a strategy to inhibit neointima formation through 
inhibiting TGF-β1’s action. It was found that fibromodulin was a more potent 
inhibitor for the formation of neointima hyperplasia than decorin (Ranjzad et 
al., 2009). 
The drug pioglitazone has also been reported to exhibit anti-inflammatory 
actions. In an atherosclerotic rabbit stenting study, pioglitazone was 
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administered orally and a 21% reduction of neointima formation was observed 
compared to the placebo control group. In addition, an 82% decrease in CCL2 
was observed (Marx et al., 2005). CCL-2 is a key chemokine that regulates the 
migration and infiltration of monocytes as part of the early inflammatory 
response; inhibition of its action could therefore account for the decrease in the 
decrease in neointima formation observed.     
1.4.1.2 Suppression of VSMC proliferation 
The phenotype-switching of the SMCs in response to the injury endured by the 
stent implantation can be inhibited to prevent and minimise neointima 
hyperplasia. The proliferation of SMCs can be targeted by expressing several 
anti-proliferative genes, such as thymidine kinase, and cytosine deaminase, 
these all work by inducing cell cycle arrest of SMCs in the S phase of the cell 
cycle, thereby providing a therapy which effectively prevents neointima 
hyperplasia in balloon injured vessels (Guzman et al., 1994, Simari et al., 1996, 
Yin and Agrawal, 2014). 
Inhibition of the migration of the SMCs can be achieved by degrading the ECM, 
which is regulated by matrix metalloproteinases (MMPs) and tissue inhibitors of 
matrix metalloproteinases (TIMPs) (Yin and Agrawal, 2014, Osherov et al., 
2011).Inhibition of MMPs has been shown to have a profound effect on the 
prevention of neointima hyperplasia using marimastat, a broad spectrum MMP 
inhibitor. Neointima formation was reduced when marimastat was applied to 
human saphenous vein grafts, indicating it would be a good candidate as an anti-
ISR drug candidate. Clinical trials of marimastat however, were halted at stage 
III due to high toxicity of the drug (Sparano et al., 2004  Forough et al., 1996).  
Inhibition of MMPs using TIMPs was therefore an attractive venture for gene 
therapy, providing a more sophisticated solution to limit MMP activity. Baker et 
al. in demonstrated the versatility of this approach, using an adenoviral delivery 
system to overexpress TIMP 1, 2 & 3 in rat VSMCs, the findings showed that all 
three TIMPs effectively inhibited chemotaxis of the SMCs. TIMP-1 did not affect 
SMC proliferation, TIMP-2 exhibited a dose dependent inhibition of cell 
proliferation, and TIMP-3 induced DNA synthesis and promoted cell death by 
apoptosis (Baker et al., 1998). The unique capabilities of the TIMP-3 expressing 
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virus were then explored to prevent neointima formation in a porcine stenting 
model at 28 days. This study indicated that the overexpressing TIMP-3 using an 
adenovirus vector provided a therapy which could effectively inhibit neointima 
formation, by promoting apoptosis and dysregulation of the MMPs (Johnson et 
al., 2005b). 
In addition to delivering and targeting specific genes, RNA can also be used to 
provide a method for controlling neointima formation. One of the first examples 
of RNA based therapies within the context of prevention of neointima formation 
was demonstrated by directing the inhibition of SMC proliferation and migration 
has using an oligonucleotide (ODN) sequence that was complementary to the 
mRNA of the c-myc gene (Biro et al., 1993). The c-myc gene had been previously 
implicated in encoding for a protein which modulates cell division. Using the 
RNA based therapy, the ODN sequence was delivered, which blocked the 
translation of the mRNA. This had the effect of downregulating the protein 
associated with cell proliferation, as well as a 50% decrease in VSMC 
proliferation and a >90% decrease in migration, when tested in vitro. A detailed 
overview of targeting mRNA using miRNA for the purpose of preventing ISR can 
be found in section 1.6.2.     
Inhibition of VSMC proliferation is the main method for prevention of ISR used 
with DES, with rapamycin and sirolimus being two of the most prolifically used 
drugs to this effect. As discussed in section 1.2.1.2, using these anti-
proliferative drugs yielded a profound decrease in restenosis rates when used in 
the clinic, however late stent thrombosis has hindered the progress of such 
therapies as these drugs delay the re-endothelialisation process, through their 
anti-proliferative modes of action. These findings have helped to define re-
endothelialisation as a critical part of the wound healing process following stent 
implantation and deployment.     
1.4.1.3 Promotion of re-endothelialisation 
Several studies have focused on promoting re-endothelialisation as a strategy to 
prevent ISR. Injury sustained to the vessel by stent implantation causes 
significant damage to the endothelium as this is the first point of contact with 
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the stent. Encouraging re-endothelialisation using a variety of different 
techniques has therefore been extensively studied.  
The vascular endothelial growth factors (VEGF) are a group of powerful 
endothelial mitogens which have been used as therapeutic agents for the 
prevention of ISR after injury. Expression of VEGF-D using an Adenovirus vector 
was used to decrease neointima growth by 50% following balloon denudation of 
rabbit aorta at 14 days (Rutanen et al., 2005). Adenovirus mediated delivery of 
VEGF-C has also been shown to have a therapeutic effect on balloon injured 
rabbit aortas by reduction of a neointimal formation (Hiltunen et al., 2000). 
Another target for re-endothelialisation is nitric-oxide (NO), which is synthesised 
by nitric-oxide synthase (NOS). NO is a very important molecule for maintaining 
vessel homeostasis, it is a vasodilator and has been shown to promote re-
endothelialisation, it inhibits platelet adhesion and aggregation as well as SMC 
proliferation and migration (Barbato and Tzeng, 2004). Using a lipopolyplex 
plasmid delivery system, endothelial NOS (eNOS) has been delivered from stent 
surfaces to rabbit arteries with the result of reduced neointima formation (Brito 
et al., 2010). Due to NO’s short half-life ~2.5 seconds, gene therapy in this 
instance is particularly attractive, as the short life span of NO can be 
circumvented by directing the synthesis of NOS. Localised delivery from the 
stent surface is also beneficial as it avoids systemic side-effects (Brito et al., 
2010). 
As described in section 1.3, the discovery that the ECs which repopulate the 
injured area from stent implantation come from a combination of EPCs and ECs 
adjacent to the injured vessel and the relationship between an increased rate of 
re-endothelialisation brings a decrease in neointima formation (Douglas et al., 
2013) provides the grounds for EC based therapy. Technologies such as EPC 
seeded stents are being investigated as a means to kick-start the re-
endothelialisation process and have been successful using in vitro models 
(Shirota et al., 2003), however the real challenge lies in translation of these 
methods so that they are efficacious from in vivo settings.      
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1.5 Vectors for cardiovascular gene therapy 
As our understanding of the biological mechanisms which underlie neointima 
formation and ISR advance (detailed in section 1.3); the therapeutic strategies 
used to prevent ISR have become increasingly more specialised as demonstrated 
by the use of gene and cell therapy for treatment of the disease (section 1.4). 
These therapies promise to offer a level of specificity which cannot be matched 
by traditional drug candidates. However, in order to employ gene therapy 
effectively as a therapeutic for the prevention of ISR, careful design and 
consideration is needed in the design of the gene delivery vector. An optimal 
gene delivery vector would possess the following characteristics; low toxicity 
and immunogenicity, efficient transduction of vascular cells with minimal 
transduction of non-target cells and appropriate longevity in order to achieve 
transgene expression to ensure a therapeutic effect (Baker, 2002). In 2011, it 
was reported that the most common method for delivery of genes into cells and 
tissues was by using virus vectors (68.8%), the second most reported method was 
naked/plasmid DNA (18.6%), non-viral chemical vectors accounted for 6.4%, and 
physical delivery methods (0.3%) were the least common (Su et al., 2012). Each 
method has various advantages and disadvantages associated with it which are 
discussed in the following section.  
1.5.1 Non-viral vectors 
The main disadvantage of using non-viral vectors for delivery of genetic material 
is the fact that the transfection efficiency is low in comparison to using viral 
vector delivery systems. This is because virus’ are the product of millions of 
years of evolution, specifically designed by nature to transport and express 
genetic material by infecting cells (Baker, 2002). On the other hand our immune 
systems have also benefitted from millions of years of evolution, to recognise 
the virus as a foreign body and prevent its action. Therefore using a non-viral 
delivery method should provide a method to circumvent a lot of the problems 
such as immunogenic responses and oncogenesis which plague the progress of 
virus vectors for their application in gene therapy on a practical level (Su et al., 
2012).     
Chapter 1  48 
 
Perhaps the most promising of the non-viral vector strategies is the liposome, 
integrin targeting peptide, plasmid DNA, (LID) delivery system. Initially it did not 
contain the liposome component and was known as ID delivery system. The 
transfection efficiency of the ID delivery system was limited by endosomal 
degradation. The ID complex was shown to transfect many different cell types, 
however, this methodology was dependent on chloroquine to be present in the 
medium, which is an endosomal buffer (Hart et al., 1997, Hart et al., 1995). The 
incorporation of liposome, lipofectin, to form an LID delivery system was 
developed as a method to prevent endosomal degradation. Hart et al. 
demonstrated that including the liposome into the formulation of the non-viral 
vector, much higher transfection efficiency could be achieved when compared to 
the ID complexes. Transfection increased from 1-10% to over 50%, in three 
different cell lines (Hart et al., 1998). 
The scope of the LID delivery system was expanded by altering the integrin 
targeting peptide motif, to tune the properties of the LIDs so they selectively 
targeted certain cell types. Integrin receptors are membrane proteins, which are 
important for attachment of cells to ECM, cell-cell interaction and signal 
transduction. They are also the main route of entry for pathogenic viruses such 
as Ad, echovirus and the foot and mouth disease virus. Therefore inclusion of an 
integrin peptide motif in the self-assembling liposome delivery system was 
hoped to create a delivery vector which mimics viral methods of cell 
penetration.  
The integrins on the VSMC and EC cell surface are α5β1 and αvβ3. Therefore 
Parkes et al. modified the LID vectors so they contained peptide binding motifs 
complementary to the VSMC and EC integrins to enhance transfection efficiency 
to these cell types making them suitable for cardiovascular gene therapy 
applications. Primary porcine VSMC and ECs were transfected with 40% and 35% 
transfection efficiency respectively. They demonstrated transfection using 
reporter genes GFP, luciferase and overexpression of TIMP-1, a potential 
therapeutic candidate for prevention of neointima hyperplasia (Parkes et al., 
2002). 
Adapting the formulation of the LID system formulation furthermore by 
modifying the liposome composition, a wider family of receptor-targeted 
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nanocomplexes were developed (RTNs) and screened for their ability to 
transfect cultured vascular cells as well as rabbit aorta ex-vivo (Irvine et al., 
2008). Transfection of the rabbit aorta with the reporter gene peaked at 5 days, 
and was present up to day 14. This RTN composition was then used in the rabbit 
vein graft model to inhibit neointima hyperplasia. Using a therapeutic plasmid 
which encoded for inducible Nitric Oxide Synthase (iNOS), which was delivered 
adventitially, a 50% reduction in neointima thickness and a 64% reduction in 
neointima area was measured at 28 days when compared to the surgery control 
groups (Meng et al., 2013). 
Sharif and co-workersreported the use of stent surfaces as a platform to deliver 
lipoplexes in vivo to rabbits to prevent neointima hyperplasia (Sharif et al., 
2012). The lipoplexes were less sophisticated than the liposomal delivery system 
reported by Meng et. aland contained plasmid DNA encoding for either a 
reporter gene (LacZ) or therapeutic gene eNOS and lipofectin. Importantly, they 
did not contain an integrin targeting peptide (Meng et al., 2013). Previously, 
Sharif et al. had reported delivering Ad encoding eNOS from the stent delivery 
platform, and had observed a decrease in neointima hyperplasia and an increase 
in re-endothelialisation when compared to the surgery only control at 28 days 
(Sharif et al., 2008). Therefore direct comparisons could be made with the 
lipoplex eluting stent, and the adenoviral eluting stent. At 28 days, an increase 
in the re-endothelialisation of the vessel was evident, however inhibition of 
neointima hyperplasia was not, compared to surgery only control.  
Further investigation showed that the lipoplexes were targeting macrophages 
and not the SMCs, which was not the case with the Ads. It was hypothesised 
therefore, that the different targeting profiles of the Ad and the lipoplex could 
explain the different effects on the inhibition of neointima hyperplasia (Sharif et 
al., 2012). Since the lipoplexes naturally targeted macrophages from the stent 
setting, a plasmid carrying anti-inflammatory genes could be carried to 
modulate the immune response post-stenting. It would also be interesting to see 
the inclusion of a targeting peptide for SMC integrins, using the RTN delivery 
system implemented by Meng, to see whether the effect of reducing neointima 
hyperplasia could be achieved with the non-viral vector as effectively as with 
the Ad vector from the stent setting (Meng et al., 2013).        
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1.5.2 Adenoviral vectors 
The adenovirus (Ad) is a non-enveloped DNA virus, which contains a linear 
double stranded 36 kb genome. They have an icosahedral capsid, made up of 
hexon, penton and fibre domains (Law and Davidson, 2005) (Figure 1-5). 
Different Ad serotypes are classified into different groups, A-G. This 
classification is dependent on the DNA sequence, the virus’ ability to agglutinate 
erythrocytes and the serological profile of the virus (Russell, 2009, Bradshaw and 
Baker, 2013).   
 
Figure 1-5 Structure of Adenovirus 5. 
 
For use in the clinic, Ads have many properties which make them attractive 
candidates, for gene delivery vectors; they can be manipulated relatively easily, 
they can be made at high titres under GMP conditions, they do not insert their 
DNA into the host genome and can transduce a wide variety of quiescent and 
proliferating cell types. The most common serotype of Ad vector for use in 
clinical trials is replication deficient Ad5 (subgroup C), which has been 
extensively tested in vitro and in the in vivo setting (Bradshaw and Baker, 2013).  
In 2003, a pilot safety study using the Ad5 vector for treatment of partial 
orthinine transcarbmaylase (OTC) syndrome was halted after a patient on the 
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trial suffered an unexpected death. This was due to a systemic inflammatory 
response to the Ad5, which caused multiple organ failure (Raper et al., 2003). 
The tragic death of Jesse Gelsinger in this trial highlighted the limitations in 
animal studies to predict human responses and reinforced how important it is to 
understand the complex interactions and responses of the Ad.  
When Ad5 is administered systemically the interactions which can occur between 
the virus and the host are numerous, and should not be underestimated. These 
interactions need to be carefully considered when designing a study, to ensure a 
safe and therapeutic treatment. Ad5 infects respiratory epithelium and is 
therefore not a blood-borne virus, consequently it has not evolved strategies to 
stay within the circulatory system and is cleared rapidly; this presents many 
hurdles to overcome when using Ad5 vectors for gene therapy (Alemany et al., 
2000, Stone et al., 2007a). One of the first observations when Ad5 was 
administered intravenously was that it was sequestered by the liver within 24 h 
in mice (Worgall et al., 1997). Methods to minimise liver sequestration need to 
be taken therefore in order to create a vector suitable for cardiovascular gene 
therapy applications. Further detail on this sequestration mechanism was 
provided by Stone et al, who reported that intravenous administration of Ad5 
binds to circulating platelets which then directed uptake via the liver sinusoids 
with the result that the Ad5 particles are degraded by Kupffer cells (Stone et 
al., 2007a). 
If adenovirus vectors were judged on the criterion of their level of transduction 
for vascular cells they would not score highly, as innately they are targeted for 
the liver and spleen cells, they display limited abilities to transduce ECs, and are 
are not efficient at transducing SMCs. This phenomenon can be explained by the 
adenoviral vectors receptor and the cells co-receptor on the cell surface. It is 
the case for most adenovirus serotypes in groups A, C, E and F that their primary 
target is the coxsackie and adenovirus receptor (CAR). In hepatocytes this 
receptor is expressed highly, to a lesser extent on endothelial cells and is 
virtually absent on SMCs, which therefore accounts for the Ads natural tropism 
(Bergelson et al., 1997, Law and Davidson, 2005, Baker, 2002).  
For the Ad5 serotype, there are a variety of mechanisms which the virus can use 
to gain entry to cells. The primary method is initiated by the virus docking to the 
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CAR receptor through the fibre knob domain (Law and Davidson, 2005, Bergelson 
et al., 1997). Further interaction between an arginine-glycine-aspartic acid 
(RGD) motif on the penton base of the virus with αvβ3/αvβ5 integrins on the cell 
surface triggers endocytosis (Wickham et al., 1993, Li et al., 1998, Bradshaw and 
Baker, 2013). After systemic administration of Ad5, the primary target organ for 
Ad5 in rodents and non-primates is the liver (Alemany and Curiel, 2001, Martin 
et al., 2003). However the method of entry for liver transduction requires a 
blood coagulation factor X (FX), to form a bridge between the hexon proteins of 
the Ad capsid to the heparin sulfate proteoglycans (HSPGs) on the cell surface 
(Bradshaw and Baker, 2013, Waddington et al., 2008). 
The high seroprevalance of Ad5 vectors is an important limitation to Ad5 vector 
based gene therapy. In 2011, a large international seroepidemiology was 
conducted which revealed that Ad5 neutralising antibody (NAb) titres were high 
within Sub-Saharan Africa and South-East Asia human populations. These findings 
could have consequences on Ad5 efficacy if delivered to these populations sub-
sets as their action could be suppressed by the existing NAb’s circulating in the 
blood (Sumida et al. 2005). Although this effect could be overcome by dosing 
with higher amount of the vector, this would not be an ideal solution due to the 
risk of triggering an increased innate immune response (Barouch et al., 2011).   
The surprising discovery that human erythrocytes have CAR and complement 
receptor (CR1), which is not the case with murine and rhesus macaque 
erythrocytes, was reported in 2009 (Carlisle et al., 2009). The combination of 
CAR and CR1 on erythrocytes acts as a formidable defence for intravenous Ad5 
particles. This finding furthermore highlights the limitations of using murine and 
other animal models to predict human clinical outcomes.  
Finally, another issue with the Ad vector is their innate immunogenicity, causing 
the transduced cells to be cleared by T-cells, which results in a transient 
transgene expression profile (~4 weeks). Genetic modifications of the virus 
capsid can be performed to alter this and achieve longer-term gene expression 
in vivo (Baker, 2002, Oka et al., 2001). For the purpose of preventing ISR from 
stent surfaces, this may not be an important issue as the therapeutic window for 
transgene expression would be from 0-30 days, during the inflammation and 
granulation phases of the disease. 
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1.5.2.1 Clinical Trials using Ad vectors for Cardiovascular Gene Therapy 
Since the first human gene therapy clinical trial in 1990 (Rosenberg et al., 1990), 
which used a retrovirus to treat advanced melanoma, many more trials have 
conducted. In 2012 it was estimated that over 2000 gene therapy clinical trials  
had taken place, or been approved worldwide, with the third most common 
application being cardiovascular diseases (~8.4%), after cancer (64.4%) and 
monogenic diseases (~8.7%) (Ginn et al., 2013). 
In 2003, a clinical trial was conducted using Ad mediated transfer of VEGF to 
prevent ISR by promoting re-endothelialisation following stent deployment. The 
Ad-VEGF therapy was delivered locally to the stented vessel, immediately after 
stent deployment using a perfusion-infusion catheter. This was a randomised, 
placebo-controlled, double-blind clinical trial, which aimed to compare the Ad-
VEGF treatment against a non-viral delivery method using a VEGF plasmid 
liposome. The follow-up point of the trial was 6 months, with quantitative 
coronary angiographic analysis being used to judge whether the treatments were 
successful. At 6 months no significant improvement was observed between the 
groups (Hedman et al., 2003). In addition to the initial trial, a follow-up study 
was also conducted 8 years after the initial trial, with the aim to establish 
whether intracoronary gene delivery of VEGF was associated with increased risks 
of major adverse clinical events (MACE), arrhythmias, cancer, diabetes and 
other diseases. No significant differences were recorded, leading to the 
conclusion that both therapies both viral and non-viral delivery of VEGF were 
safe and well tolerated in the short and long-term setting although both were 
ineffective for their purpose (Hedman et al., 2009). 
The AGENT clinical trial (Angiogenic GENe Therapy) used Ad5 as a delivery 
vector to enhance angiogenesis by expression of the FGF-4 gene, with the aim to 
treat angina. After the successful in-vivoresults using a pig chronic induced 
stress ischemia model, which showed increased angiogenesis and left ventricular 
flow following administration of the Ad5-FGF4 vector. This provided promising 
data to validate proceeding with the clinical trial in humans (Gao et al., 2004). 
The findings from the pooled data from AGENT-3 and 4 trials failed to show 
significant differences between the groups, judged by the different end points of 
the study, which were primarily done on the basis of exercise tolerance testing 
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(ETT). A significant difference in improved ETT measurements was observed 
when the data was analysed on the basis of gender, indicating an improvement 
in the female subset of patients receiving the Ad5-FGF4 treatment, although this 
has been attributed to a difference in the placebo effect between the groups 
(Henry et al., 2007).      
Although these trials have demonstrated no long term safety issues and side-
effects which is a positive, the phase II and III randomised control experiments 
have, in general, failed to achieve the efficacy that was demonstrated so clearly 
in the earlier animal models and trials. Therefore, methods are needed to 
improve the efficacy of the vectors used so that the full potential of gene 
therapy can be unleashed and do justice to all the research and time taken to 
understand these diseases.    
1.5.2.2 Novel Ad Vectors for Cardiovascular Gene Therapy 
One method to increase transgene expression to the vasculature has been 
demonstrated by employing novel Ad serotypes which exhibits natural tropism 
for vascular cell types. Serotype D Ads show great variety with which receptors 
they use and their tropism; some use CAR, whereas others have been reported to 
use CD46 (Abbink et al., 2007) and sialic acid (Arnberg et al., 2000). Dakin et al. 
reported that using a novel Ad49 serotype (a species D Ad), they could transduce 
primary VSMCs, ECs and human CABG tissues, with remarkably higher efficiency 
compared to the Ad5 control (Dakin et al., 2015). These findings warrant further 
pre-clinical testing using this novel vector. Further investigation into the 
identification of the primary receptor and mechanism for entry into the cells, 
could also provide new ways in which higher VSMC targeting could be achieved 
using Ad vectors. 
1.5.2.3 Pseudotyping Ad vectors for Cardiovascular Gene Therapy 
Success has also been made to enhance Ad5 transduction of human VSMCs by 
pseudotyping to make a chimeric virus with enhanced properties. This was 
demonstrated very effectively in the context of cardiovascular disease by 
Havenga et al. A library of Ad5 based vectors carrying fibres from different Ad 
serotypes were created and screened against cells and tissues from different 
species. It was found that the Ad5 vector carrying the fibre molecules from the 
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Ad16 serotype (a class B Ad) was far superior at infecting human and rhesus 
monkey VSMCs and ECs, this effect was even more heightened when the vessels 
were used in organ culture, with comparison to Ad5 transduction as a reference. 
Interestingly this result was not found for pig and rat models indicating the 
method for viral attachment to the cells is not conserved between species 
(Havenga et al., 2001). 
After the important discovery of CD46 being the receptor for most class B Ads, 
being made in 2003 (Gaggar et al., 2003), Gaggar and co-workers designed a 
vector system which incorporated this receptor as a route of entry. This helped 
to create more chimeric Ad5 vectors which enabled enhanced gene expression in 
human SMCs. Since CD46 is highly expressed in hSMCs (60 to 100% cells stained 
positively for expression) whereas CAR is not (< 2% cells), Parker et. al 
rationalised that an Ad5 vector with Ad type B CD46 interacting structural 
components could enhance transduction efficiency to human vascular cells 
(Parker et al., 2013). Using Ad35 as the type B virus, a chimeric Ad5-Ad35 hybrid 
was made with Ad5 capsid and Ad35 penton and fibre (Ad5/F35/P35). The 
resulting vector exhibited enhanced transduction efficiency for HVSMCs but not 
for HECs. This vector could be useful for use within cardiovascular gene therapy, 
but specifically for CABG procedures and stenting, where discrimination between 
the two main cell types could provide a unique and fine-tuned therapy.       
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1.5.3 Adeno-associated vectors 
Adeno-associated viruses (AAVs) are part of the paroviridae family, which 
require helper viruses such as adenoviruses or herpes simplex viruses in order to 
facilitate infection and replication. They are smaller than Ads, with a diameter 
of 25 nm, and contain single-stranded DNA (ssDNA), 4.7 kb. In the absence of the 
helper viruses, they establish a latent infection by site-specific integration into 
the host genome (Wu et al., 2006).  
Adeno-associated viruses have the advantage of being a lot less immunogenic 
than the Ad vector. They also have the ability to express the target gene for the 
lifetime of the infected cell. This is because, unlike the Ad which is maintained 
episomally, the AAV vectors are able to integrate into the host genome. The 
natural tropism for AAV’s is neurones, skeletal muscle cells and hepatocytes; 
transduction of SMCs and endothelial cells is very low, limiting their application 
for cardiovascular gene therapy without structural modification (Baker, 2002). 
In order to increase the scope of the application of AAVs for cardiovascular gene 
therapy, different modifications and strategies have been employed to tune 
AAVs natural tropism, so they target cell types implicitly involved in 
cardiovascular diseases such as vascular endothelial and smooth muscle cells. 
Nicklin et al. genetically incorporated the EC targeting peptide SIGYPIP into an 
AAV capsid which enhanced the transduction efficiency to human ECs compared 
to the unmodified AAV wildtype vector (Nicklin et al., 2001). The same method 
was used to design an AAV which can transduce SMCs efficiently by incorporating 
a SMC selective targeting peptide sequence into the capsid, which was identified 
by phage bio-panning (Work et al., 2004).  
Each AAV interacts with different receptors on the cell surfaces which is thought 
to account for the different tropism exhibited by each AAV (Summerford and 
Samulski, 1998). Another strategy for generating vascular-targeted AAV vectors 
therefore, is to screen different AAV serotypes and measure their transduction 
efficiency on different vascular cell targets. Chen et al. reported that AAV 
serotypes 1 and 5 in particular, exhibited a much higher transduction efficiency 
for rat and human aortic endothelial cells, compared to AAV 2, which is the most 
commonly used AAV for gene therapy applications. This tropism was thought to 
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be due to a sialic acid residue mediated mechanism for cellular uptake (Chen et 
al., 2005). 
Translation into the clinic of the AAV 1 vector in the cardiovascular setting has 
shown promising results in terms of efficacy and safety. The CUPID trial used an 
AAV 1 vector encoding for Sarcoplasmic reticulum Ca2+-ATPase (SERCA) gene, 
which has been shown to be deficient in patients with heart failure. The virus 
was delivered to patients with advanced heart failure by an intracoronary 
infusion. Comparison against a placebo group enabled the conclusion that the  
overall condition of patients receiving the gene therapy treatment improved, 
indicated by a decrease in symptoms of heart failure and augmented heart 
functional status (Jessup et al., 2011).   
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1.5.4 Lenti-viral vectors 
Lenti-viral vectors are part of the retrovirus family which have an ssRNA genome 
with an 8 kb capacity. The most common vector for gene therapy is derived from 
HIV-1 serotype. These vectors are not inherently immunogenic which represents 
a significant advantage against other gene therapy vectors such as Ad5. Another 
advantage is that they are able to transduce quiescent cells making them 
suitable for cardiovascular gene delivery applications (Williams et al., 2010).  
Two major advances allowed for this vector to be considered as a possible gene 
therapy vector, firstly the U3 promotor region was inactivated, thereby reducing 
the chance of the generation of wildtype HIV-1 occurring (Miyoshi et al., 1998). 
Secondly, the tropism for this virus was vastly improved by pseudotyping via the 
attachment of glycoprotein from a vesicular stromatis virus (VSV-G) (Williams et 
al., 2010). This modification made expanded its suitability for vascular gene 
therapy. Efficient human saphenous vein SMC and EC transduction was reported 
using third generation lenti-virus vectors. Furthermore, the construction a lenti-
viral vector expressing TIMP-3 enabled comparisons to be made between Ad 
mediated gene transfer which showed that the lenti-viral vector performed to 
the same level as the Ad, inhibiting SMC migration and promoting apoptosis 
(Dishart et al., 2003).  
However, despite these advances on the bench level, there is still significant 
reluctance with regards to their safety which prevents the use of these vectors 
in the clinic. These concerns are well founded after 2 out of 10 patients 
receiving a gammaretrovirus therapy in a clinical trial developed T-cell 
leukaemia (Hacien-Bey-Abina, 2003).     
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1.6 miRNA 
Vascular injury induced by stent implantation has many implications on the 
surrounding area, which leads to the formation of the neointima 
(Section1.2.1.1). ECs and SMCs, which are the major cell types in arteries, are 
mainly affected; denudation of the ECs by stent placement and stimulation of 
the SMCs to proliferate and migrate, both contribute to the re-narrowing of the 
artery. In recent years much research has been focussed on the role of miRNAs 
in many different disease settings, as they have been shown to be key regulator 
molecules.  One potential therapeutic strategy for controlling and preventing 
the neointima formation is therefore to administer key miRNAs known to be 
involved in the disease pathway of ISR.  
1.6.1 Biogenesis of miRNAs 
miRNAs are small non-coding RNA molecules, ~22 nucleotides in length, which 
can regulate gene expression post-transcriptionally by binding to complementary 
strands of messenger RNA (mRNA). This induces cleavage or repression of the 
mRNA (Brennecke et al., 2005).  
The biogenesis of miRNA begins in the nucleus with the transcription by enzyme 
RNA polymerase II, and occasionally RNA polymerase III, which produces primary 
(pri)-miRNA transcripts, which are often over 1 kb in length(Lee et al., 2004, 
Borchert et al., 2006, Brodersen and Voinnet, 2009). Endolytic cleavage of the 
pri-miRNA transcripts is catalysed by RNAse III Drosha, to form several precursor 
(pre)-miRNA stem loop constructs which are ~65 base pair in length.(Kim, 2005, 
Yi et al., 2003, Lee et al., 2002).The pre-miRNAs are then transported out of the 
nucleus and into the cytoplasm by Exportin-5  (Yi et al., 2003), where the pre-
miRNAs are processed by RNAse III Dicer, which cleaves off the loop of the 
hairpin to give the mature miRNA, ~22 nucleotides in length, which is paired to a 
complementary miRNA strand, known as the passenger or * strand (Lee et al., 
2002). Trans-activating response RNA-binding protein (TRBP) mediates binding of 
the miRNA duplex to the Argonaute II complex (Ago II), which is the catalytic 
component of RNA-induced silencing complex (RISC) (Chendrimada et al., 2005). 
The duplex is unwound and the lead strand of the miRNA is stabilised, while the 
passenger strand is removed and normally degraded, although sometimes the 
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passenger strand has been shown to have biological activity as well (Meister, 
2013, Bartel, 2009). The mechanism for unwinding of the duplex is still unclear, 
however there is some evidence to suggest that the Ago proteins within RISC 
might possess dissociation activity to aid this process (Meister, 2013, Wang et 
al., 2009). 
The mature miRNA guides the RISC to target mRNA, and binds through the seed 
sequence of the miRNA to complementary sequences on the 3’ untranslated 
region (UTR) region of the mRNA through Watson-Crick base pairing. The seed 
sequence on miRNA is a sequence of 7 nucleotides in positions 2-8 from the 5’ 
end (Flynt and Lai, 2008). The degree of complementarity between the seed 
sequence and the mRNA target 3’UTR region is thought to be important in 
determining the fate of the mRNA and the regulatory mechanism, which will 
either be degraded or translationally repressed (Carthew and Sontheimer, 2009). 
If the miRNA seed sequence has perfect complementarity with the mRNA 3’UTR 
region this usually results in cleavage and degradation of the mRNA(Rhoades et 
al., 2002, Davis et al., 2005). In animals, the majority of miRNA binding with 
mRNA is imperfect, with G:U interruptions and single nucleotide bulges, which 
instead of cleavage, usually directs repression of translation of the mRNA (Zeng 
et al., 2003).  
In animals a single miRNA can have 10’s to 100’s of mRNA targets. miRNAs which 
have the same seed sequences, and a high degree of sequence homology are 
grouped together into miRNA families which will target similar sets of mRNA 
(Friedman et al., 2009, Baek et al., 2008, Selbach et al., 2008). The 3’UTR 
regions on mRNA are large enough to have multiple miRNA binding sites, it has 
been suggested that this could contribute to a cooperative effect between 
different miRNAs binding to the same 3’UTR region on the mRNA, adding 
complexity to the way in which miRNAs regulate mRNA translation (Davis et al., 
2008). A diagram of miRNA biogenesis is summarised in Figure 1-6. 
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Figure 1-6 miRNA biogenesis pathway. 
In the nucleus the pri-miRNA is transcribed by RNA polymerase II, which is then cleaved by Drosha 
to form preiRNA. The pre-miRNA strands are transported out of the nucleus by exportin5. The 
stem-loop is cleaved by dicer, to form the miRNA duplex. Association in the RISC complex unwinds 
the RNA and the passenger strand is either degraded or incorporated into another RISC complex. 
The lead strand is stabilised by the RISC complex and binds to target mRNA sequences through 
the seed sequence, which will either lead to mRNA translational repression or degradation 
depending on the complementarity of the interaction.   
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1.6.2 miRNAs involved in in-stent restenosis 
A number of miRNAs have been identified to be involved in the process of in-
stent restenosis and therefore modulating their expression could lead to a 
miRNA-based therapeutic to inhibit neointimal growth.  A summary of these 
miRNAs is given in (Table 1).  
References miRNA After injury Target 
Cell 
Molecular 
Targets 
(Ji et al., 2007b, 
McDonald et al., 
2015) 
miR-21 upregulated VSMC PTEN, PDCD4 
(Cheng et al., 
2009b) 
miR-145 downregulated VSMC ACE, KLF5 
(Cordes et al., 
2009b) 
miR-143 downregulated VSMC ELK1, FRA1 
(Davis et al., 2009) miR-221 upregulation VSMC p27, C-KIT 
(Iaconetti et al., 
2012) 
miR-92a upregulation EC KLF4, MKK4 
Table 1  miRNAs associated with neointima formation which could be targets for 
treatment of ISR. 
  
1.6.2.1 miRNA-21 
miRNA-21 has been identified as a potential miRNA which could be used to 
modulate the wound healing process inflicted from stent deployment. A 
microarray was conducted on rat arteries before and after balloon injury, which 
indicated several miRNAs were aberrantly expressed before and after injury. 
miRNA-21 was one of the miRNAs which exhibited a dramatic change in 
expression resulting in a 5 fold increase at 7 days after injury. Therefore, 
knockdown of this miRNA was hypothesised as a strategy to inhibit neointima 
formation using antisense-miRNA-21. In vitro experiments confirmed a dose 
dependent response on antisense-miRNA-21 with decreased apoptosis and cell 
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proliferation, which was conformed in vivo using a ratballoon injury model, 
indicating that treatment of the vessel with antisense-miRNA-21 inhibited 
neointima formation (Ji et al., 2007b). 
miRNA-21 has also been shown to be dysregulated after porcine vein grafting at 
7 and 21 days, and has been identified as having a functional role in neointimal 
growth within this setting (McDonald et al., 2013). Using miRNA-21 knock-out 
(KO) mice, miRNA-21s role in neointima formation after vein graft surgery was 
investigated, indicating that the absence of miRNA-21 had positive effects on 
preventing neointima formation. Due to the similar pathologies between 
neointima formation in vein graft surgery and in-stent restenosis, it was likely 
that miRNA-21 may play a similar role in vessels which have been injured 
through stenting.  
In an in-vivo porcine study, both lead and passenger strands were shown to be 
upregulated 7 and 28 days after stenting, suggesting that this miRNA might play 
an important role in the post-stent injury response. A further investigation was 
conducted using miRNA-21 (KO) mice, which revealed that the neointima area, 
neointimal thickness and neointima/medial ratio was drastically decreased when 
compared to the WT controls, 28 days after stenting, giving support to the 
hypothesis that miRNA-21 could play a pivotal role in neointima formation. In 
order to investigate potential mechanisms which could help explain these 
observations, proliferation and migration assays were conducted with platelet 
derived growth factor (PDGF) as a stimulant on cultured miR-21 KO SMCs against 
wild type (WT) control cells. The miR-21 KO SMC showed attenuated 
proliferation and migration responses to this stimulus when compared to the KO 
control SMCs (McDonald et al., 2015). These results suggest that downregulating 
miR-21 expression locally to stented vessels could provide a therapy which could 
supress neointima formation and ISR. 
1.6.2.2 miR-145 and miR-143 
miR-145 is the most abundantly expressed miRNA in normal vascular walls and 
VSMCs which have been freshly isolated. However, expression of miR-145 is 
almost undetectable in ECs (Ji et al., 2007b, Cheng et al., 2009b). An interesting 
observation was made that the expression of miR-145 was supressed in vessel 
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walls with neointimal growth (Ji et al., 2007b), leading to the hypothesis that 
miR-145 may have a regulatory role in modulating the SMC phenotype.  
This theory was tested by monitoring the expression of miR-145 in PDGF 
stimulated VSMCs. PDGF is well-known to promote SMC proliferation and 
migration, by promoting a change in the SMC phenotype from contractile to 
synthetic states; this can be monitored by dedifferentiation markers such as SM 
α-actin, calponin and SM-MHC. It was observed that treatment of the cells with 
PDGF caused a decrease in mir-145 levels. Furthermore, overexpression of miR-
145 was found to inhibit PDGF-induced VSMC dedifferentiation. Conversely, 
inhibition of miR-145 expression resulted in increasing levels of PDGF-induced 
VSMC dedifferentiation (Cheng et al., 2009b).  
The role of miR-145 on phenotype modulation of VSMCs was then investigated in 
the absence of PDGF stimulation, with VSMCs in the contractile state and 
interestingly it was shown that overexpression and inhibition of miR-145 levels 
resulted in decrease and increase in the synthetic phenotype VSMC markers 
respectively (Cheng et al., 2009b). Inhibition of miR-145 immediately after 
stenting could therefore reduce neointima formation, by sequestering the VSMC 
response to injury and phenotype switching through the modulation of the miR-
145 expression. 
In the same year, other key findings were published with regards to the 
miR143/145 gene cluster role in SMC differentiation. Cordes et al. reported that 
myocardin upregulated miR-143 and 145 expression culminating in the induction 
of SMC marker gene expression and myofilament formation (Cordes et al., 
2009b). Boettger et al. demonstrated that, VSMCs from a miR-143/145 KO mouse 
exhibited VSMCs which did not express calponin, smoothelin, which are key 
contractile VSMC markers. The structure of the arteries also lacked 
myofilamentous cytoskeletal organisation, suggesting the key role that miR-
143/145 gene cluster plays in the development of the vasculature and again 
highlighting its potential use as a therapeutic to regain vessel homeostasis after 
injury (Boettger et al., 2009). 
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1.6.2.3 miR-221 
miR-221 has also been implicated as a potential key regulator of VSMC 
phenotype, through action via the PDGF signalling pathway. PDGF is well known 
to promote neointima formation inducing SMC phenotype switching.  In a study 
directed by Davis et al.,miR-221 was found to be transcriptionally induced by 
treatment of the VSMCs with PDGF, leading to downregulation of p27Kip1. The 
action of miR-221 on p27Kip1 was shown to be essential for PDGF induced VSMC 
proliferation (Davis et al., 2009). These findings provide another example of how 
miRNAs play an important role in the maintenance of SMC behaviour, which 
leads to the development of them being used as potential therapeutics within 
the setting of stent deployment. In this case, if a miR-221 inhibitor was 
administered immediately after stenting, this could act as a suppressor for the 
PDGF pathway. 
1.6.2.4 miR-92a 
Tackling ISR by promoting re-endothelialisation could be achieved by the 
administration of a miR-92a inhibitor. This has been shown to be highly 
expressed in ECs but not in VSMCs and has been identified to promote EC 
proliferation when downregulated in vitro, using a BrdU assay. Delivery of 
antago-miR-92a has also been shown to be effective at preventing neointima 
formation in vivo after balloon injury of rat carotid arteries. The mode of action 
that miR-92a was having on EC function was investigated and it was found that 
key EC intracellular signalling molecules, c-Jun NH2-terminal kinase (JNK) and 
extracellular signal-regulated kinase (ERK) were increasingly phosphorylated 
upon inhibition of miR-92a. In addition, through loss of function assays, mitogen-
activated protein kinase kinase 4 (MKK4) and Kruppel-like factor 4 (KLF4) were 
found to be mRNA targets for miR-92a (Iaconetti et al., 2012). 
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1.7 Delivery of therapeutic vectors from stent surfaces 
Despite a wealth of targets and mechanisms which have been identified to be 
involved in the process of ISR, and a multitude of different vectors tuned for 
cardiovascular delivery, the lack of an efficient localised delivery system hinders 
the progress within this field. In the following section delivery of viral vectors 
and miRNA from stent surfaces is discussed. 
1.7.1 Local delivery of virus vectors from stent surfaces 
Viral vector administration using catheters, whereby the virus is infused in the 
target vessel, was the first method of delivery used to treat ISR by gene therapy; 
however this has the disadvantages of suboptimal delivery and the possibility of 
distal spread of the virus which may cause many unwanted and potentially 
dangerous complications (Klugherz et al., 2002b). 
Therefore coating the stent with the virus vectors could provide a much 
improved system, which would achieve localised delivery to the stented vessel. 
Tethering viruses to stents was first reported by Klugherz; BMS were coated with 
a collagen matrix and then covalently linked to anti-adenoviral knob monoclonal 
antibodies. Covalent linkage was achieved by reacting collagen with N-
succinimydal 1-3-(2-pyridyldithiol)-propionate (SPDP), which enabled a covalent 
linkage to the antibody through the sulfhydryl moiety. This provided a surface 
upon which the adenovirus could be tethered to through antigen-antibody 
specific interactions. Using an Ad encoding green fluorescent protein (GFP), 
testing for localised delivery was achieved for rat arterial smooth muscle cells 
and porcine coronary arteries using fluorescent microscopy to detect the GFP 
transgene expression. GFP expression was monitored 7 days after deployment of 
the Ad5-GFP coated stents to the pig coronary arteries which revealed local 
transgene expression to the area around the stented region and additionally no 
distal expression of the transgene (Klugherz et al., 2002b).  
The concept of Adenoviral eluting stents was reported in 2002 using an Ad5-GFP 
reporter virus (Klugherz et al., 2002b). This paved the way for developing stents 
that elute therapeutic viruses. In 2005, Johnson et al. reported the first 
therapeutic virus eluting stent as a treatment for ISR. In previous work they had 
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used an Ad vector expressing TIMP3 (AdTIMP3) to effectively prevent neointima 
formation in porcine saphenous vein grafts (Johnson et al., 2005b). Due to the 
process of vein graft surgery, a window for treatment for the vein with 
therapeutic Ad is possible (after the vein has been excised but before it is 
sutured into the heart). For stenting however, this kind of delivery of the virus is 
not possible. Therefore they developed a method for coating the AdTIMP3 virus 
onto the stent surface to test whether this virus would be effective at 
transducing the stented vessel and importantly whether it would exhibit a 
therapeutic effect against ISR. 
The method for coating relied on using electrostatic interactions between the 
Ad, which is inherently negatively charged, and the stent surface, which was 
coated in a positively charged phosphorylcholine (PC) material. This stent 
coating  system had the advantage of being simpler than the method reported by 
Klugherz, as it utilised a commercial coating which already had safety records 
and FDA approval (Klugherz et al., 2002b, Johnson et al., 2005b). A 
disadvantage, however, is that relying solely on electrostatic interactions to bind 
the virus will result in a significantly weaker interaction than the antibody-virus 
attachment methodology. Nevertheless, the coating was robust enough to 
achieve localised delivery of the virus to the stented region of the vessel, and a 
therapeutic effect was observed. The AdTIMP3 PC coated stents were deployed 
into porcine vessels and after 28 days, a significant decrease in neointima area 
was recorded, compared to the AdlacZ PC coated control stents (Johnson et al., 
2005b).  
Using the rabbit stenting model, whereby a stent is deployed into the right iliac 
artery, the PC adenoviral delivery system was also used to deliver Ad5-eNOS. At 
day 28, enhanced endothelialisation and a reduction in neointima formation was 
observed in the arteries treated with the Ad5-eNOS eluting stent when compared 
to the control stenting groups (Sharif et al., 2008).   
Fishbein et al. reported a methodology for virus linkage to stents, using 
polyallylamine bisphosphonate (PAA-BP). The bisphosphonate groups on the 
polymer backbone were able to co-ordinate to the metal oxide surface of the 
bare metal stents, whilst the amine groups could be reacted with succinimydyl 
3-(2-pyridyldithio) propionate (SPDP), which allows covalent tethering of an 
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Anti-Ad antibody or recombinant Ad receptor protein, D1, through the formation 
of a disulfide bond. It was found that the D1 receptor protein allowed for a 
higher amount of virus vector to be bound to the surface and was therefore used 
in the in vivo model. Therapeutic efficacy was demonstrated with this system, 
by delivering Ad5 expressing iNOS (Ad-iNOS) to rat carotids from stent surfaces. 
At 16 days, the neointima areas were measured, and the treatment Ad-iNOS 
stent group demonstrated a decrease in the neointima/intima ratio by a half 
(Fishbein et al., 2006b). 
This methodology was then expanded so that it did not rely on Ad binding to the 
receptor protein, and instead incorporated a direct covalent linkage between 
the Ad vector and the stent surface. The rationale being that this delivery 
system would be more robust, more versatile (not specific for a single virus 
species) and have higher affinity. The new delivery system used polyallylamine 
bisphosphonate comprising latent thiol groups (PABT), to coordinate to the 
stainless steel stent surface through the bisphosphonate moieties. The 
disulphide bonds were then activated using a reducing agent (tris-(2-
carboxyethyl) phosphine) (TCEP), and then reacted with polyethyleneimine 
pyridyldithiol with PEI(PDT) to generate a higher density of thiol groups on the 
surface. A bi-functional cross-linking agent, HL, which has an amine functional 
group, that can be reacted with the lysine group on the Ad5 vector and a thiol 
functional group that can react with the activated stent surface, provides the 
bridge between the stent and the virus. In this way, the Ad was covalently 
anchored to the stent surface, however the HL crosslinking agent also has a 
labile ester group that enables vector release from the surface. This method of 
attachment and release was tested in vitro with rat SMC and in vivo by deploying 
stents into the carotid arteries of rats. When the stent was coated with Ad5-iNOS 
a significant reduction in ISR was observed indicating the potential for this type 
of coating (Fishbein et al., 2008). 
Further work by Fishbein et al. extended this methodology for covalent 
adenoviral attachment to stent surfaces, by using a library of different 
crosslinking agents, to tune the release profile of the Ads from the surface. 
Release of the Adenovirus from the surface depended on the hydrolysis kinetics 
of the ester groups within the crosslinker molecule, providing a route to fine-
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tune the release and transduction of the Ad by modifying the linker chemistry 
(Fishbein et al., 2014). 
A summary of these studies reporting a variety of different methods for virus-
eluting stents is detailed in Table 2. Having provided an overview from the initial 
concept using reporter viruses to deliver reporter genes from the stent surfaces, 
to efficacy studies, which demonstrated that the elution of viruses encoding 
therapeutic target genes can effectively be used to inhibit the process of ISR in 
this setting. It is clear that using the stent as a delivery platform not only 
provides an environment in which localised delivery can be achieved to the 
stented vessel, which will increase efficacy, it also limits safety problems as 
lower dosages of virus can be used and systemic interaction with the virus has 
been shown to be minimal. Identifying and using novel strategies for coating 
stents with viruses will be paramount for seeing the next generation of virus 
eluting stents which will hopefully result progress to the clinic. Current methods 
for generating virus eluting stents have required complicated surface chemistry 
providing bespoke stents which would be logistically very difficult to work with 
in the clinical setting. The quest for a simple, but effective virus delivery system 
from stent surfaces is therefore ongoing.  
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Reference Model Vector/ 
Gene 
Method of Attachment Outcome 
(Klugherz 
et al., 
2002b) 
Porcine 
Arterial 
Stenting 
in vivo 
Ad5-
GFP 
Collagen matrix 
covalently linked to 
anti-Ad antibodies 
 
Detection of GFP 
localised to stented area 
after 7 days 
(Johnson 
et al., 
2005b) 
Porcine 
Arterial 
Stenting 
in vivo 
Ad5-
TIMP3 
Electrostatic 
interactions with 
positively charged 
phosphorylcholine 
coated stent 
Significant decrease in 
neointima area was 
recorded after 28 days 
with the treatment group 
(Fishbein 
et al., 
2006b) 
Rat 
Carotid 
Stenting 
in vivo 
Ad5-
iNOS 
Bisphosphonate linker 
attached to D1 receptor 
protein 
Significant decrease in 
neointima area was 
recorded after 14 days 
with the treatment group 
(Fishbein 
et al., 
2008) 
Rat 
Carotid 
Stenting 
in vivo 
Ad5-
iNOS 
Bisphosphonate linker 
covalently attached to 
Ad modified with labile 
ester linker 
Significant decrease in 
restenosis after 14 days 
when treated with the 
Ad5-iNOS stent 
(Sharif et 
al., 2008) 
Rabbit 
Iliac 
Stenting 
in vivo 
Ad5-
eNOS 
Electrostatic 
interactions with 
positively charged 
phosphorylcholine 
coated stent 
Increased 
endothelialisation and 
decreased neointima 
formation at 28 days for 
treatment groups 
(Fishbein 
et al., 
2014) 
Rat 
carotid 
stenting 
in vivo 
Ad5-
GFP 
Bisphosphonate linker 
covalently attached to 
Ad modified with 
different labile ester 
linkers 
Different release profiles 
of the Ad were achieved 
depending on how prone 
the ester linkages were 
to hydrolysis 
Table 2  Summary of virus-eluting stents for prevention of in-stent restenosis studies. 
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1.7.2 Delivery of miRNA from stent surfaces 
It is well recognised that the bottleneck to developing a successful miRNA 
therapy is in the development of a suitable delivery method that will reach the 
target tissue and cells in vivo (Zhang et al., 2013). Delivering the miRNA from a 
stent surface therefore provides a unique platform for localised delivery for the 
prevention of ISR.  
Up until very recently localised delivery of miRNA from stent surfaces had not 
previously been reported, and therefore represented a novel and innovative 
strategy to circumvent issues which plague other delivery systems of miRNA such 
as inefficient delivery, off-target effects, high dosage and the need for viral 
vectors.      
To date the anti-miR-21 eluting stent reported by Wang et al.has been the only 
example of localised stent delivery (Wang et al., 2015), which was demonstrated 
to have significant advantages over the systemic delivery methodology. It was 
documented that administering the anti-miR-21 intravenously in rats, caused 
significant off-target effects, lowering miR-21 levels in the kidney, liver and 
heart, which could cause unwanted biological effects and acute toxicity which 
would need to be addressed before intravenous delivery of miRNAs is translated 
to the clinic. However, when the anti-miR-21 was coated onto a stent surface, 
at the same concentration as used for intravenous delivery to rats (5 mg/kg), 
off-target effects were not detected in the kidney, liver and heart. However, 
inhibition of neointima formation was not compromised with the local stent 
delivery, indicating its potential for therapeutic stent delivery of miRNA. 
The model used to investigate delivery of anti-miR-21 for the prevention of 
neointimal hyperplasia involved stenting human arteries coated with antimR-21 
and transplanting into rats, arteries which were balloon injured but not stented 
were also transplanted. Repressing miR-21 levels had the effect of inhibiting 
neointimal growth, without affecting re-endothelialisation. This work builds 
upon previous work, described in Section 1.6.2.1., which identified miR-21 as 
being upregulated immediately after stent injury, and has been proven to 
modulate SMC proliferation when overexpressed.  
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The method for coating the stent with antimiR-21, was by direct application to a 
Translumina YUKON DES system, which is a microporous BMS, that allows for the 
adsorption of drugs onto the surface without the need for a polymer coating 
(Deuse et al., 2008, Wang et al., 2015). This provided a successful method for 
local miRNA delivery to the vessel and paves the way for other miRNAs to be 
delivered in this manner, which ultimately brings us closer to seeing miRNA 
advancing to the clinic for the treatment of ISR, which could bring the next 
generation of stenting technology. Extending the methodology, so that delivery 
from other types of stent platform, such as biodegradable stents, could provide 
a novel delivery technology. Using a biodegradable material the stent would be a 
transient scaffold used to mechanically re-widening the vessel and neointima 
formation could be effectively prevented using localised miRNA therapy as 
discussed, and then over time the scaffold would dissolve. 
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1.8 Project aims 
In-stent restenosis is a major clinical problem characterised by excessive VSMC 
proliferation and neointima formation in response to the injury endured and 
inflammatory response caused by stent deployment. A deeper understanding of 
the biological mechanisms which drive ISR have allowed gene and miRNA 
therapeutic strategies to be developed which could provide an elegant 
treatments for the prevention of ISR; however localised delivery methods are 
needed in order to take advantage of these specialised treatments and prevent 
unwanted systemic effects. Drug-eluting stents have proved to be efficacious at 
delivering anti-proliferative agents from stent surfaces in vivo, although issues 
with the specificity of drugs used, has caused higher incidences of late stent 
thrombosis to be recorded. This thesis aims to investigate different methods 
which allow for local delivery of virus’ and miRNA from stent surfaces and 
evaluate the delivery methods in vitro and in vivo. The specific aims of the 
study are: 
 To develop a method for localised delivery of Ad vectors from stent 
surfaces in vitro. 
 To develop a method for localised delivery of miRNA from stent surfaces 
in vitro. 
 To evaluate successful delivery methods in vivo using murine and 
porcine stenting models. 
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2 Materials and Methods 
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2.1 Materials 
All chemicals were purchased from Sigma Aldrich (Poole, UK) and all cell culture 
reagents from Gibco (Paisley, UK) unless otherwise stated.  
2.2 Cell culture techniques 
Cells were maintained in a biological safety class II vertical laminar flow cabinet. 
Cells were grown as a monolayer in 25 cm2, 75 cm2, or 150 cm2 cell culture flasks 
and incubated at 37 oC, 5% CO2. The Human Embryonic Kidney (HEK) 293, rat A10 
SMC and HeLa cell lines were grown in Dulbecco’s Modified Essential Medium 
(DMEM) supplemented with L-glutamine (2 mM), penicillin-streptomycin (1% 
v/v), sodium pyruvate (1 mM) and foetal calf serum (10% v/v). Every 2-3 days 
the medium was replaced and cells were passaged when they reached 80% 
confluence to prevent overgrowth.  
Prior to passaging, the cells were washed with PBS twice to remove any dead 
cells and debris. For the A10 and the HeLa cells a solution of Trypsin-Ethylene 
Diamine Tetra Acetic acid (TE) (0.02% w/v, 4 mL) was applied, and incubated at 
37 oC until cells were detached. For HEK 293 cells a solution of 1x citric saline 
(2-3 mL) was applied and left at room temperature (RT) until detached. After 
the cells were dislodged the dissociation agent was quenched by adding an equal 
volume of cell media. Cells were then centrifuged (1500 RPM, 5 mins), the 
supernatant was discarded and the pellet re-suspended in an appropriate volume 
of medium for desired cell seeding density. For all experiments where cells 
needed to be plated at a precise seeding density, the re-suspended cells were 
counted using a haemocytometer and subsequently diluted to achieve the 
correct number of cells per well. 
2.3 Production of adenoviral vectors 
Serotype 5, replication defective recombinant adenovirus (Ad) containing the 
lacZ reporter gene (Ad5 CMV lacZ) was propagated in house as described by 
Nicklin et al. (Nicklin and Baker, 1999). Virus stock (50 μL, 5 x 1012 VP/mL) was 
added to a bottle of supplemented DMEM (500 mL) identical to that used for cell 
culture. The medium was replaced on 24 flasks of 70-80% confluent HEK 293 cells 
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in 150 cm2 cell culture flasks with Ad containing medium (23 mL) and left for a 
few days until a cytopathic effect was observed and the cells were peeling away 
from the bottom of the flask. At this point, the medium was harvested and 
centrifuged (2000 RPM, 10 mins); the cell pellet was re-suspended with PBS (6 
mL). An equal volume of Arklone P (trichlorofluoroethane) (6 mL) was added to 
remove excess non-viral proteins; this was shaken and then centrifuged (3000 
RPM, 10 mins). The top aqueous layer containing the crude Ad was removed and 
stored at -80 oC. 
Replication deficient serotype Ad49 and Ad5 carrying luciferase marker genes 
(Ad49 luc, Ad5 luc) were obtained from Crucell (Leiden, Netherlands).  
2.3.1 Adenovirus Purification 
Adenovirus purification was achieved by ultracentrifugation of the crude Ad 
solution through CsCl gradients. Ultracentrifuge tubes were sterilised by rinsing 
with 70% EtOH and then PBS (14 x 95 mm, Beckman Coulter Ltd, High Wycombe, 
UK). A CsCl solution was added to the centrifuge tube (1.40 g/mL, 2.5 mL) then 
a second solution of CsCl was added on top of this (1.25 g/mL, 2.5 mL), finally 
the Ad solution was dripped on carefully and the rest of the tube was filled with 
PBS. The centrifuge tube was placed into a Beckman SW40Ti rotor and spun 
(35,000 RPM, 1.5 h, 16 oC) using aBeckman Optima L-80 ultracentrifuge. The 
white virus band was removed using a 5 mL syringe with a 23 Gauge needle. A 
second CsCl gradient was prepared using a new sterilised centrifuge tube with 5 
mL, 1.34 g/mL CsCl, then Ad solution, and then PBS. The sample was spun 
overnight (35000 RPM, 16 oC) using the same rotor. 
The virus layer was extracted again and injected into a Slide-a-lyzer dialysis 
cassette with 10000 Da molecular weight (wt) cut off (Thermo Scientific, 
Leicester, UK). A 10xTris-EDTA stock was prepared (10 mM Tris-HCL and 1 mM 
EDTA, pH 8) and diluted to 1xTris-EDTA with sterile dH2O. The cassette was 
placed into 1xTris-EDTA buffer with stirring (2 L, 2 h, RT); this was then 
repeated for a further 2 h. Finally the cassette was placed in 1xTris-EDTA buffer 
with 10% v/v glycerol (2L, overnight, RT). The purified Ad solution was removed 
from the cassette and stored at -80 oC in 50 µL aliquots. 
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2.3.2 Virus Titration by End-Point Dilution Assay 
The Plaque Forming Unit (PFU) titre of each Ad preparation was determined by 
an end-point dilution assay.  293 and HeLa cells were seeded in 96 well plates 
and grown to 60% confluence. 293 cells were used to assess the titre of the virus 
because they express the E1 section of the Ad genome enabling virus replication 
for replication defective Ads. The HeLa cell line however, does not contain this 
region of the Ad genome and was therefore used as a control to ensure 
replication deficiency in the Ads.  A 10 fold serial dilution was made of the 
concentrated virus stock with DMEM, 100 µL of each titration was added to each 
well as 10 replicates. Cells were maintained 37 oC, 5% CO2 .The  medium was 
replaced every 2 days. The plates were examined under a 10x microscope and 
any wells exhibiting viral plaques were marked off. At 8 days the number of viral 
plaques was counted and the following calculation was made to determine the 
PFU titre: 
-X = logID50 (infectivity dose) = log (dilution above 50% + proportionate distance x 
dilution factor) 
Proportionate Distance = (%positive wells above 50% - 50%)/ (%positive wells 
above 50% - %positive wells below 50%) 
ID50=10-X 
TCID50 (Tissue Culture Infectivity Dose 50) = 1/10-X 
TCID50 / 100 µL = 10X 
TCID50 / mL = 10X x dilution factor (10) 
1 TCID50 = 0.7 PFU 
PFU/mL = TCID50 /mL x 0.7 
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2.3.3 Virus Particle Concentration Determination 
Virus Particle (VP) titre was determined by performing a microBCA assay 
(Thermo Scientific) as per manufacturer’s instructions. Briefly, a serial dilution 
of albumin standard in PBS were prepared (0.5, 1, 2.5, 5, 10, 20, 40 and 200 
µg/mL), 150 µL of each solution was added in duplicate to a clear bottomed 96 
well plate. In duplicate, 1 µL, 3 µL and 5 µL of virus stock was diluted with 150 
µL PBS, 150 µL PBS was used as a blank control and added to the 96 well plate. 
Working reagent (150 µL) was added to each well and the plate was incubated at 
37 oC, 2 h, in the dark. The absorbance at 570 nm was read using a Wallac 
Victor2™ Plate Reader (Wallac,Turku, Finland). A standard curve of the 
absorbance readings for the albumin standard was made and from this the 
relative amounts of protein was able to be determined for the virus samples. 
Using the relationship 1 µg protein = 1 x 109 VP the concentration of the virus 
stock was determined (Von Seggern et al., 1998).    
2.3.4 Labelling adenovirus 5 with Alexa Fluor™ 555 
Alexa Fluor™ 555 protein labelling kit was purchased from Life Technologies 
(Paisley, UK). The Alexa Fluor™ dye contains a succinimidyl ester which can 
react with primary amine residues on the virus capsid to form stable covalent 
bonds. The labelling procedure was carried out as outlined in the manufacturer’s 
protocol. Briefly, a solution of sodium bicarbonate (1 M, 50 µL) was added to the 
adenovirus stock (2 mg of protein/mL, 500 µL). This was transferred to a vial 
containing the Alexa Fluor™ 555 dye and a magnetic stirrer bar and left to stir in 
the dark for 30 mins, RT. To remove any unreacted dye the reaction mixture was 
inserted into a Slide-a-lyzer dialysis cassette with 10000 Da molecular wt cut off 
(Thermo Scientific). The cassette was placed into a 1xTris-EDTA buffer and 
stirred (2L, 2 h, RT) the buffer solution was replaced twice with fresh 1xTris-
EDTA after 2 h. If the labelled 555-Ad5 was not being used immediately the 
cassette was placed into 1xTris-EDTA buffer with 10% v/v glycerol (2L, 
overnight, RT). The 555-Ad5 solution was removed from the cassette and stored 
at -80 oC in 50 µL aliquots.   
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2.4 Formation of Polyelectrolyte Multilayers (PEMs) 
For the (chi-ha)8chi PEMs, chitosan was prepared 0.1% w/w, acetic acid 0.2% 
w/w in dH2O as described by Meng et al. (2009b). The hyaluronan solution was 
prepared at a concentration of 1 mg/mL. After optimisation for viral 
transduction, 0.006% wt acetic acid was used instead of 0.2% w/w acetic acid. 
The concentrations for the poly(allylaminohydrochloride) (PAH) and 
poly(styrenesulfonate) (PSS) solutions were prepared as follows: PAH (1mg/mL in 
0.1 M NaOH), PSS (1 mg/mL).   
To prepare the PEMs on glass microscope slides (Thermo Scientific), the slides 
were firstly cleaned by immersing in piranha solution for 15 mins (H2SO4 and 
H2O2 in a 3:1 ratio). The slides were then extensively washed with dH2O. After 
cleaning, the slides were dipped into the polycationic solution for 1 min, rinsed 
with dH2O and subsequently dipped into the polyanionic solution and then 
washed with dH2O. This was repeated until the desired number of PEM layers 
was reached; the slide was then dried with N2. 
To prepare the PEMs on Stainless Steel (SS) surfaces, 316L SS discs were used as 
a model for the SS Bare Metal Stents (BMS) (Agar Scientific, Essex, UK). The SS 
disc was sterilised by soaking in 70% EtOH overnight prior to coating. The (chi-
ha)8chi PEM was prepared in the same way as described above for the glass 
microscope slides. 
2.5 UV-visible light Spectroscopy to monitor build-up of 
PEMs 
To monitor the sequential build-up of the PEM formation, UV-visible light 
spectroscopy was used. The PEMs were prepared on quartz microscope slides (H. 
Baumbach & co ltd, Ipswich, UK). The slides were prepared in exactly the same 
way as described above (section 2.4). The UV spectra were taken after each 
deposition of a polyanionic or polycationic solution. The spectra were recorded 
for the range of 200-500 nm using a UV-3101PC UV-VIS-NIR scanning 
spectrophotometer (Shimadzu, Kyoto, Japan). As the concentration of PEM 
deposited onto the quartz microscope slide increased, the absorbance increased 
Chapter 2  80 
 
following the Beer-Lambert law: A = ε c l where A= absorbance, ε= molar 
absorption coefficient L mol-1 cm-1 , c= concentration mol L-1 l = pathlength cm.   
2.6 Visualisation of fluorescently tagged adenovirus on 
polycationic monolayers 
To enable the virus to be absorbed onto the PEM, the terminal layer must be 
polycationic. The polycationic solutions were chitosan and PAH prepared as 
described in section 2.4. For visualisation of the virus attached to the 
polycationic surface, fluorescently tagged Alexa Fluor™ 555-Ad5 was used (4.88 x 
1010 VP/mL, 25 µL). Fluorescent tagging of the Ad5 virus with Alexa Fluor™ 555 
was previously described in section 2.3.4. The virus solution was applied to the 
polycationic monolayer deposited on a glass microscope slide and left overnight, 
the PEM was rinsed thoroughly with PBS prior to visualisation under a Zeiss LSM 
510 confocal microscope (Zeiss, Cambridge, UK) using a 60x immersion 
objective. A negative control of PEMs with unlabelled Ad5 was prepared and 
visualised in exactly the same way (4.88 x 1010 VP/mL, 25 µL).      
2.7 Atomic Force Microscopy (AFM) 
To visualise the topography of the surface after adsorption of Ad5 onto the 
polycationic monolayers (PAH or chi) and PEMs ((PAH-PSS)8-PAH or (chi-ha)8chi), 
atomic force microscopy was used. The surfaces were prepared on piranha 
cleaned glass microscope slides as described in section 2.4. Ad5 was applied to 
the PEM (2.44 x 1010 VP/mL, 50 μL), left overnight and then washed extensively 
with PBS. Once prepared micrographs were taken in non-contact mode, at a scan 
rate 1.01 Hz, dimensions of the images were either 5 µm x 5 µm, with a 
resolution of 256 x 256 pixels. Micrographs were recorded using a NTEGRA 
Spectra machine (NT-MDT, Moscow, Russia). 
2.8 Adenovirus transduction in vitro 
2.8.1 Transduction of A10 cells with Ad5 CMV lac Z 
A10 cells were plated at a density of 2 x 104 cells/well in a 96 well plate and left 
overnight at 37 oC, 5% CO2. Ad5 CMV lac Z was applied to the cells at 
concentrations 500, 1000, 2500 and 5000 VP/cell for 3 h, the medium was then 
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replaced and left for 72 h. Each concentration was performed in triplicate. The 
cells were then harvested and a β-gal assay was completed to allow for 
quantification of virus transduction (section 2.9.2).   
2.8.2 Measuring the effect of polycationic solutions on adenoviral 
transduction 
In a 96 well plate, A10 cells were plated at density of 2 x 104 cells/well and left 
overnight at 37 oC, 5% CO2. Polycationic solutions, PAH and chi were prepared in 
the same way as described in section 2.4, but using DMEM as a diluent instead of 
dH2O. Solutions were made at concentrations 1, 0.5, 0.25, 0.125, 0 mg/mL. Ad5 
CMV lacZ(2500 VP/cell) was incubated with the polycationic solutions (PAH or 
chi, 50 µL, 15 mins, RT) and then added to each well and left for 3 h, each 
condition was performed in triplicate with one extra well for staining. For the 
negative control group, A10 cells were replaced with medium which did not 
contain virus or polycationic solution. After 3 h the viral polycationic solutions 
were removed and fresh medium was added to the wells. The cells were left for 
72 h at 37 oC, 5% CO2. The cells were lysed and a β-gal assay was performed 
(section 2.9), for each condition one well was fixed with 2% (w/v) PFA, (100 µL, 
10 mins, RT) and stained with X-gal solution (sections 2.9.2, 2.11&2.12).       
2.8.3 Measuring the effect of different concentrations of acetic 
acid on adenoviral transduction in a chitosan solution 
In a 96 well plate, A10 cells were plated at density of 2 x 104 cells/well and left 
overnight at 37 oC, 5% CO2. Chitosan solutions (0.1% w/w) were made up with 
MEM as a diluent, varying the concentration of acetic acid 0.2, 0.1, 0.05, 0.02, 
0.01, 0.006, 0.002, 0% w/w. Ad5 CMV lac Z (1000 VP/cell) was incubated with 
the chitosan solutions (50 μL) and applied to the A10 cells for 3 h, the medium 
was then replaced and the cells were left for 72 h, 37 oC, 5% CO2. A non-
treatment control of A10 cells which had not been treated with the adenovirus 
or chitosan solutions was used as a negative control. After 72 h the cells were 
lysed and a β-gal assay was performed (section2.9.2). Three biological replicates 
were run per condition. 
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2.8.4 Measuring adenoviral transduction from SS surfaces coated 
with PEMs 
SS discs were coated with a (chi-ha)8-chi PEM, chi monolayer, or left uncoated, 
as described in section 2.4. Ad5 CMV lacZ(1.6 x 1012 VP/mL, 30 µL) was added to 
the terminal layer of the PEM, chi monolayer or directly to the SS surface and 
left overnight at 4 oC. A non-treatment control was made by applying the 
uncoated SS disc to the cells without Ad5 CMV lac Z treatment.  The PEMs were 
then washed thoroughly in PBS prior to being placed facedown onto the plated 
out cells.  
A10 cells were plated in a 12 well plate at seeding density of 1 x 105 cells/well 
and maintained at 37 oC, 5% CO2 and left overnight. The next day the adenovirus 
coated surfaces were placed face down on the cells and left 72 h. The 
adenovirus coated surfaces were removed and the cells were washed thoroughly 
with PBS before harvesting and a β-galactosidase assay was performed on the 
cell lysates (section 2.9.2). 
Initially, a concentration 0.2% w/w acetic acid for the chitosan solution was used 
as described by (Meng et al., 2009b). However after optimisation (section 2.8.3) 
0.006% w/w acetic acid was used. 
2.8.5 Measuring adenoviral transduction from adenovirus 
encapsulated in collagen gel from PLA and SS surfaces 
In a 12 well plate, A10 cells were plated at a seeding density of 1 x 105 
cells/well and maintained 37 oC, 5% CO2 and left overnight. The following day, 
Ad5 collagen gels were prepared as described in section 2.15.1 and coated onto 
PLA or SS discs (sections 2.14.1&2.4) at a concentration of 6.6 x 109 VP/surface. 
PLA surfaces which were not coated with collagen but were coated with Ad5 
were also prepared. The surfaces were washed thoroughly with PBS before being 
placed face down onto the cells and left for 72 h. The cells were then harvested 
and a β-galactosidase assay was performed on the cell lysates (section 2.9.2). A 
positive control of Ad5 in solution applied directly to the cells was used (6.6 x 
109 VP). Non-treated cells were maintained in medium throughout the 
experiment. Each condition was run as a biological triplicate. 
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For Ad49 luc the same protocol was followed. However a luciferase assay was 
used to determine the levels of virus transduction instead of a β-galactosidase 
assay (section 2.13). 
For SS coated in PLA surfaces, PLA was dissolved in chloroform at concentrations 
10%, 15%, 20% wt/wt and spread onto SS surfaces as described in section 2.16.1. 
The protocol for transduction as described above was used to determine viral 
transduction from SS coated with different concentrations of PLA.   
2.9 Ex vivo transduction of Ad5 
2.9.1 Ex vivo transduction of Ad5 from stent surfaces coated with 
(chi-ha)8chi PEMs to rat aortas 
Gazelle BMS were expanded and removed from the balloon before being coated 
with (chi-ha)8-chi PEM, using the optimised concentration of acetic acid (section 
2.4). Ad5 luc (1.6 x 1012 VP/mL, 30 μL), was applied to the PEM coated stent and 
left overnight at 4 oC. Stents were then washed, crimped onto the balloon and 
deployed into rat aortas ex vivo and cultured for 72 h. Luciferase activity 
bioluminescence was quantified using an in vivo imaging system, (IVIS, Caliper 
Life Sciences, Massachusetts, USA) 25 mins after luciferin administration. 
Quantification of bioluminescence was recorded as an average radiance 
(photons/second/cm2/steradian).       
2.9.2 Ex vivo delivery of Ad5 CMV lacZ to mouse aorta 
2.9.2.1 Determining concentration for transduction of mouse aortas with 
Ad5 CMV lacZ ex vivo 
Mouse aortas were dissected from MF1 mice and incubated with solutions of Ad5 
(5 x 109 VP/mL, 5 x 1012 VP/mL, 5 x 1011 VP/mL in MEM) for 72 h, 37 oC, 5% CO2. 
The aorta was then cut open and fixed in 2% PFA and then stained with X-gal for 
4 h, 37 oC (as described in section 2.12). 
2.9.2.2 Transduction of mouse aortas from PLA coated with collagen Ad5 
gel 
Mouse aorta was dissected from MF1 mice cut longitudinally and placed in a 12 
well plate with the endothelial layer face up. An Ad5 CMV lacZcollagen gel was 
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applied to PLA squares using the method described in section 2.15.1, using a 
viral concentration of 5 x 1011 VP/mL. The squares were placed face down onto 
the endothelium. The aorta was left for 72 h in culture and fixed with 2% PFA for 
the Ad5 CMV lacZtreated aortas they were stained with X-gal (section 2.12).  
In order to model endothelium damage, a mini-trek balloon was expanded to 10 
atm in the aorta prior to adenoviral delivery from PLA surfaces. For each group 
two aortas were balloon damaged prior to exposure to the virus, and two were 
uninjured, the groups were non-treatment control, Ad5 in solution (5 x 1011 
VP/mL), and PLA-collagen-Ad5 gel (5 x 1011 VP/mL). After culture for 72 h, 
tissue was fixed and stained with X-gal (section 2.12). 
2.9.3 Ex vivo delivery of Ad5 CMV lacZ from PLA coated stents to 
porcine coronary arteries 
2.9.3.1 Preliminary testing of Ad5 CMV lacZ coated stents for transduction 
to porcine coronary arteries 
Pig hearts (from large white pigs) were obtained fresh from Shotts abattoir 
(Scotland, UK). The coronary artery was dissected from the heart and stored in 
PBS at 4oC until stent deployment. The stents used were human bare metal 
Gazelle™ stents (3.0 x 18 mm, Biosensors International, Singapore). The stents 
were coated with 20% w/w PLA dissolved in chloroform and then in the collagen-
Ad5 CMV lac Z gel, following same procedure as for in vitro testing (2.15.1) at a 
concentration of 1.25 x 1012 VP/mL. The stents were then deployed into the 
arteries and incubated for 72 h, they were then washed with PBS, cut 
longitudinally, fixed in 2% PFA (overnight, 4oC) and stained with X-gal (section 
2.12) to confirm whether virus transduction had been achieved.  
2.9.3.2 Effect of PLA concentration on efficacy of delivery of Ad5 CMV 
lacZto porcine arteries ex vivo 
PLA was dissolved in chloroform at concentrations (10%, 5%, 2.5%, w/w). The 
BMS were coated in the PLA solutions; they were then coated with Ad5 CMV 
lacZcollagen gel as described in section 2.15.1 at a concentration 1.25 x 1012 
VP/mL. Once deployed, the stents were left in culture for 72 h and then fixed 
with 2% PFA and X-gal stained (section 2.12). The stents were then evaluated on 
three criteria for their suitability to be used for in vivo application; whether 
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they were able to fit through a guide catheter, whether they were able to be 
expanded with a balloon, and whether virus transduction was observed.     
2.10 β-galactosidase transgene quantification 
Ad5 CMV lac Z has been genetically modified so that  it encodes for the enzyme 
β-galactosidase. Natively, this enzyme cleaves glycosidic bonds of β-
galactosidases into monosaccharides in E.coli, however it can also be used to 
cleave the glycosidic bond of X-gal (5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside). Cleavage of X-gal releases 5-bromo-4-chloro-3-
hydroxyindole, which dimerises and precipitates to form a blue solid; it is in this 
manner that it can be used as a reporter for virus transduction (Scheme 2-1). 
 
Scheme 2-1 Cleavage of X-gal glycosidic bond with β-galactosidase forms a blue 
precipitate which is used as a reporter for β-galactosidase expression. 
 
A Tropix Galacto-Light Assay kit (Applied Biosystems, Foster City, USA) was used 
to determine the amount of β-galactosidase expressed. The assay was carried 
out as per manufacturer’s instructions. After adenovirus transduction (sections 
2.8), the cell medium was removed and the cells were washed with PBS, the 
cells were then lysed by adding lysis buffer (1 mL Triton X in 500 mL PBS) (100 
μL for a 96 well plate, 1 mL per well for a 12 well plate). Cells were scraped and 
then freeze thawed to aid lysis. The cell lysate from each well (10 µL) was 
added to a black 96 well plate in triplicates. A 1:100 dilution of Tropix Galacton 
Plus: Galacto-light diluent mix was made and added to each well (100 µL). The 
plate was protected from light and left for 1 h, RT. Tropix Accelerator II was 
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added to each well (100 µL) and left for 2 mins. The luminescence was measured 
using a Wallac VICTOR2™ plate reader. Each sample was run as a technical 
triplicate. The luminescence readings were normalised to protein content of 
each of the samples giving values in relative light units/mg protein (rlu/mg). 
Protein content determination is described in the following section (section 
2.11).    
2.11 Protein concentration determination from cell 
lysates 
To establish the concentration of the cell lysate samples, a Pierce™ BCA assay 
kit was used (Thermo Scientific). A 1:50 dilution of BCA reagent B:BCA reagent A 
was made and added to each well of a clear 96 well plate (100 μL). The cell 
lysate (10 μL) was added to each well and incubated (30 mins, 37 oC, in foil). 
The plate was cooled to room temperature and absorbances were read using a 
Wallac VICTOR2™ plate reader at 562 nm. Each sample was run in triplicate. 
2.12 X-gal staining of cells and tissues 
After incubating cells/tissue with Ad5 CMV lacZ for 72 h (sections 2.8& add in 
tissue bit) medium was removed from cells or tissue and washed with PBS. Cells 
and tissue were fixed with 2% (w/v) PFA, for cells (100 µL, 10 mins, RT), for 
tissue (1 mL, overnight, 4 oC). The PFA was removed and cells/tissue washed 
with PBS and the X-gal stain (100 mM sodium phosphate pH 7.3, 1.3 mM 
magnesium chloride, 3 mM potassium ferricyanide, 3 mM potassium 
ferrocyanide, 1 mg/mL X-gal) was applied to the cells (100 µL, 4 h, 37 oC) or to 
the tissue (1 mL, overnight, 37 oC). Cells and tissues were imaged using a Nikon 
Eclipse TS100 microscope, 40x magnification for cells, 4x for tissue. 
2.13 Luciferase Assay 
Luciferase Assay Kit was purchased from Promega (Southampton, UK). Cells were 
lysed by adding 1 x lysis reagent (500 µL to each well of a 12 well plate). Lysis 
reagent solution is 25 mM Tris-Phosphate pH 7.8, 2 mM DTT, 2 mM 1,2-
diaminocyclohexane-N,N,N’,N’ tetra acetic acid, 10% glycerol, 1% triton X-100. 
The plate was frozen at -80 oC for 1 h. The plate was thawed, and cell lysate 
from each well (10 µL) was added to a white 96 well plate, with the luciferase 
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assay reagent (100 µL). The light emitted was meseaured immediately using a  
luminometer plate reader. The protein concentrations of each cell lysate (10 µL) 
were determined by performing a BCA assay (section 2.11). The luminescence 
readings were normalised to protein content of each of the samples giving values 
in relative light units/ mg protein (rlu/mg). 
2.14 Modification of PLA surface chemistry 
2.14.1 3D printing PLA squares 
PLA filament and 3D TouchTM printer was supplied by Bits from Bytes (Clevedon, 
UK). PLA Squares were designed using Autodesk software. The squares were 
printed using a layer deposition method and had the dimensions of 1.5 cm2 by 2 
mm. 
2.14.2 Measuring extent of hydrolysis of PLA by percentage 
weight loss 
3D printed PLA squares were prepared as described above (section 2.14.1). PLA 
squares were weighed and placed into NaOH(aq) (1 M, 1 mL, RT). The squares 
were left in the NaOH solution and removed at timepoints 5 mins, 30 mins and 
24 h. After removal they were dried under vacuum and weighed again. This 
enabled the %wt loss of PLA to be determined. A control PLA square was placed 
in dH2O for 24 h to control for water hydrolysis.    
2.14.3 Binding of hexamethyldiamine (HMD) to a PLA surface 
by EDC/NHS activation 
3D printed PLA squares (section (2.14.1)) were washed in ethanolic aqueous 
solution (1:1, v/v), and then washed with dH2O (10 mins). Activation of the PLA 
was performed by immersing the PLA in NaOH(aq) (1 M, 5 mL, 5 mins). The PLA 
squares were immersed in an aqueous solution of 1-ethyl-3(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC, 0.1 M) and  N-
Hydroxysuccinimide (NHS,0.2M) for 30 mins (2 mL). Activated PLA was then 
immersed in a solution of HMD dissolved in iPrOH (0.04 g/mL, 30 mins, 4 oC) then 
(20 h, RT). Before testing the PLA surface for primary amine functionality 
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(section 2.14.5), the PLA squares were washed with EtOH (3 x 10 min, 5 mL, 37 
oC). 
2.14.4 Binding of HMD to PLA surface by direct aminolysis 
PLA squares were washed in ethanolic aqueous solution (1:1 v/v) for 1 h, and 
then washed in 10 mL dH2O for 10 mins. PLA was immersed in a solution of 
hexamethyldiamine (HMD) (0.04 g/mL, 30 mins, 50 oC) in 2.5mL iPrOH. The 
squares were then washed with EtOH (3 x 10 min, 5 mL) and tested for primary 
amine functionality by ninhydrin assay (section 2.14.5).  
2.14.5 Ninhydrin assay to test for functionalisation of PLA 
with primary amine groups 
The two different methods for amine functionalisation of the PLA (after 
EDC/NHS activation (section 2.14.3) and by direct aminolysis (section 2.14.4)), 
were tested for the presence of primary amines on the surface by performing a 
ninhydrin assay. Briefly, a ninhydrin stock solution was prepared (0.35 g 
dissolved in 100 mL EtOH), 1 mL was added to each PLA square (stirred, 95 oC, 
15 mins). A deep purple colour on the PLA surface indicated a positive result for 
primary amines. Non-treated PLA was used as a negative control. 
2.14.6 Derivatisation of PLA with benzaldehyde 
Aminolysed PLA was prepared using the two methods described in sections 
2.14.3 and 2.14.4. Untreated PLA and hydrolysed PLA were also prepared. All 
pieces were immersed in a solution of benzaldehyde in MeOH and stirred (10 
mM, 5 mL, 2.5 h). The pieces were washed in MeOH (10 mL, 12 h, 37oC) and then 
dH2O (3 x 10 mL, 30 mins, 37 oC). Finally, HCl (1 M, 10 mL) was added to the PLA 
overnight to remove the benzaldehyde. Absorbances at 220 nm were taken of 
the HCl solutions for detection of benzaldehyde using a UV-vis spectrometer.  
2.14.7 Deprotection and detection of FMOC from FMOC lysine 
FMOC-lys-OH HCl (10 mg) was dissolved in MeOH (800 μL). Piperidine (5% wt in 
EtOH, 200 μL) was added and left to react for 40 mins. Samples before and after 
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deprotection were run on the electrospray ionisation mass spectrometer (ESI-
MS), see section 2.14.8. 
2.14.8 ESI-MS 
Excess solvent was removed by evaporation and samples were then dissolved in 
MeOH. Mass Spectrometry data was collected using MicroTOF-Q MS instrument 
with an electrospray ionisation source (ESI), (Bruker Daltonics Ltd, Coventry, UK) 
spectra were recorded in positive ion mode. 
2.14.9 Derivatisation of PLA with FMOC-lysine-OH 
PLA was washed in ethanolic aqueous solution (1/1 v/v) for 1 h then dH2O. For 
the EDC/NHS activated surface the PLA was then placed in NaOH (1M, 5mL, 5 
mins) then washed in dH2O. The PLA was then immersed in a solution of EDC 
(0.1M, 0.038 g) and NHS (0.2 M 0.046 g) in 2mL dH2O for 1 h on ice and then 
rinsed with dH2O. Both EDC/NHS activated and PLA which was to undergo direct 
aminolysis with FMOC-lys-OH HCl were placed in a solution of FMOC-lys-OH HCl 
(0.04 g/mL) in 2.5 mL EtOH. For the EDC/NHS activated PLA the solution was 
stirred for 30 mins on ice and then 30 mins at RT. For the aminolysis PLA the 
solution was stirred at 50oC for 1 h. The PLA was then washed in EtOH (3 x 5mL, 
10 mins, 37 oC) and samples collected for UV-vis measurement. The PLA was 
then immersed in 5% piperidine in EtOH (5mL, 40 mins, RT). UV-vis 
measurements were taken for piperidine measurements. The samples were then 
rotary evaporated and then redissolved in MeOH and ESI-MS spectra were taken.  
2.15 Methods for collagen adenovirus gel formation and 
coating onto stent surfaces 
2.15.1 Entrapping adenovirus into a collagen gel and coating 
onto PLA surfaces 
Bovine Type I collagen (5 mg/mL, Gibco, Life Technologies) was diluted with 1M 
NaOH and PBS to a concentration of 3 mg/mL as described in the manufacturer’s 
gelling protocol. To prepare the adenovirus collagen coated PLA squares, Ad5 
CMV lacZ (2.45 x 1012 VP/mL, 2.7 μL, 6.6 x 109 VP/surface) was mixed with the 
collagen solution (25 μL, 3 mg/mL), and spread onto the PLA square. The PLA 
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square was incubated at 37 oC for 1 h followed by 1 h RT. The PLA was then 
washed thoroughly with PBS before transduction with cells. 
2.15.2 555-Ad5 collagen gel on PLA preparation and 
visualisation 
Ad 5 was fluorescently tagged with Alexa Fluor™ 555 dye as described in section 
2.3.4. To prepare a fluorescent virus collagen gel, 555-Ad5 was used at same 
concentration and prepared as described previously (section 2.15). A negative 
control was prepared by coating PLA + collagen gel without 555-Ad5. In order to 
compare the collagen virus gel PLA surfaces with PLA surfaces without collagen, 
555-Ad5 was applied directly to the PLA. Images of the PLA squares were taken 
using a fluorescent microscope. Images were taken at 4x magnification, 1000 ms 
exposure time, 572 nm excitation.     
2.15.3 Quantification of amount of virus on surface 
2.15.3.1 Quantification by MicroBCA 
A serial 10 fold dilution of Ad5 CMV lac Z in PBS was made to make 10 solutions 
ranging from 5.0 x 1010 VP/mL to 50 VP/mL. A microBCA assay was performed on 
these solutions using the instructions provided by the supplier as explained in 
section 2.3.3 (MicroBCA Protein Assay Kit, Thermo Scientific).  
2.15.3.2 Quantification by quantitative reverse transcription polymerase 
reaction (qRT-PCR) 
DNA was extracted from the virus solutions prepared at concentrations 5.0 x 1010 
VP/mL to 50 VP/mL (1000 µL) using the QIAamp UltraSens Virus Kit following the 
manufacturer’s instructions (Qiagen, Limburg, Netherlands). Briefly, each virus 
solution was added to a 2 mL microcentrifuge tube and 800 µL of buffer AC was 
added as well as carrier RNA solution (5.6 µL, 1 µg/µL), the tube was inverted 3 
times and then vortexed for 10 seconds, the tube was then left for 10 mins, RT. 
Buffer AC contains a compound which can complex with DNA allowing 
sedimentation by low g force centrifugation to form a cell pellet. The tube was 
centrifuged at 1200 x g for 3 mins. The supernatant was discarded and the pellet 
re-suspended in Buffer AR, pre-heated to 60 oC and proteinase K (20 µL). The 
tube was vortexed until the pellet was completely re-suspended. The tube was 
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then incubated in a water bath for 10 mins, 40 oC. Buffer AB (300 µL) was added 
and mixed thoroughly by vortexing. The solution was then applied to a Qiamp 
spin column and centrifuged (4000 x g, 1 min). The spin column was then placed 
into a new collection tube, AW1 was added to the column (500 µL) and 
centrifuged for (6000 x g, 1 min). The spin column was then placed into another 
spin column and buffer AW2 (500 µL) was added and centrifuged for 3 mins, 
16000 x g. The spin column was finally placed into a 1.5 mL microcentrifuge 
tube and buffer AVE was applied to the column (30 µL). The tube was 
centrifuged for 6000 x g, 1 min. AVE buffer was added again to the spin column 
(30 µL) and centrifuged for 6000 x g, 1 min. The extracted DNA was stored at -20 
oC. 
For the qRT-PCR, each reaction contained Power SYBR® green PCR Master Mix 2x 
(6.25 μL), Forward Primer (0.05 μL), Reverse Primer (0.05 μL), H2O (5.15 μL), 
and extracted DNA (1 μL), triplicates of each sample were run in a 384 well 
plate, using ABI 7000 qRT-PCR machine (Applied Biosystems). A standard curve 
was plotted cycle threshold (Ct) value vs concentration VP/mL of the known 
virus concentrations; this enabled unknown virus concentrations to be 
determined. To measure the amount of virus washed off from the surfaces, the 
surfaces were washed with PBS (1 mL), the viral DNA was then extracted and 
quantified by qRT-PCR as described above.  
2.16 PLA coating onto SS methodology 
2.16.1 Preparation of PLA coated onto SS discs 
PLA filament was dissolved in chloroform at 10%, 15%, 20% wt/wt, stirring 
vigorously. Stainless steel discs (Agar Scientific) were then dipped into the PLA 
chloroform solution, removed and then left to dry at room temperature 
overnight. For in vitro testing, transduction of adenovirus from PLA coated SS 
was performed by coating collagen-Ad5 gels as described in section 2.8.5. 
2.16.2 Coating PLA onto mouse stents 
For in vivo experiment, mouse stents (2.5 x 0.6 mm, Cambus medical, Galway, 
Ireland) were threaded onto a western loading tip and coated with PLA dissolved 
in chloroform (10% wt/wt) and left to air-dry. Dichloromethane was heated to 
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65oC in a lidded beaker, the stent was placed into the vapour for 10 seconds and 
then removed to smooth the PLA. 
2.16.3 Coating PLA onto pig stents 
For in vivo work, the stents were removed from the balloon and the exterior 
surface of bare metal Gazelle™ stents was coated manually with 2.5% PLA in 
chloroform wt/wt and left overnight to dry in sterile conditions. Stents were 
placed over a pipette tip to aid the coating process. After the stents were 
coated with PLA, the stent was smoothed by vaporisation with DCM (as described 
above, section 2.16.2). The stents were then crimped onto the balloon catheter.   
2.17 Transfection of miRNA in vitro 
2.17.1 Transfection of rat A10 cells with cel-miR-39-3p at 
different concentrations 
In order to modulate miRNA delivery from stent surfaces initially a miRVana™ 
miRNA mimic was used. The miRNA mimic is a double stranded miRNA molecule 
that has been chemically modified so that it acts like a mature miRNA strand. A 
miRNA mimic from Caenorhabditis elegans (cel-miR-39-3p, Life Technologies) 
was chosen initially to investigate whether it was possible to deliver the miRNA 
to mammalian cells and tissues due to this miRNA not being expressed in 
mammals. Rat SMCs (A10s) were plated at a seeding density of 100,000 
cells/well in a 12 well plate and maintained at 37 oC, 5% CO2 for 24 h. siPORT™ 
Neo FX™, (Thermo Scientific) was used as a transfection agent. siPORT™ (3 μL) 
was added to cel-miR-39-3p  (0.15, 1.5, 15 μL, 20 μM, 10 mins). MEM was 
replaced on the cells with the SiPORT™ cel-miR-3p solutions, so that a final 
concentration of 3, 30, 300 nM was obtained and left for 48 h, 37 oC, 5% CO2. 
After 48 h, RNA was extracted and quantified as described in sections 
2.19&2.20. 
2.17.2 Transfection of rat A10 cells with cel-miR-39-3p from 
PLA and SS surfaces ± collagen 
Rat SMCs (A10s) were plated at a seeding density of 100,000 cells/well in a 12 
well plate and maintained at 37 oC, 5% CO2 for 24 h. siPORT™ Neo FX™, (Thermo 
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Scientific) was used as a transfection agent. siPORT™ (3 μL) was added to cel-
miR-39-3p  (1.5 μL, 20 μM, 10 mins). A collagen solution was prepared by adding 
bovine type I collagen (5 mg/mL, 15 μL) with NaOH(aq) (1 M, 10 μL). The siPORT-
miR-39 mix was then added to collagen solution and spread onto PLA surface (as 
prepared in section 2.14.1) or SS surface (Agar Scientific). The collagen coated 
PLA and SS surfaces were left in the incubator (37 oC, 1 h) and then removed 
from the incubator (RT, 1 h). For the SS and PLA surfaces without collagen, the 
miRNA-siPORT solution was simply applied directly to the surfaces and the same 
procedure was followed as described above. The surfaces were washed 
thoroughly with PBS (3 x 1 mL) before being placed face down onto the cells and 
left for 48 h. A mock control was prepared by having siPORT (3 μL) and PBS (1.5 
μL) instead of cel-miR-39-3p. The in solution control was prepared by adding the 
same amount of cel-miR-39-3p-siPORT mix directly to the cells, a non-treatment 
control was made simply by replacing the medium at the point of transfection to 
the other wells. After 48 h, RNA was extracted and quantified as described in 
sections 2.19&2.20. 
2.17.3 Transfection of rat A10 cells with miR-145-5p and miR-
145-inhibitor 
Rat SMCs (A10s) were plated at a seeding density of 100,000 cells/well in a 12 
well plate and maintained at 37 oC, 5% CO2 for 24 h. siPORT™ Neo FX™, (Thermo 
Scientific) was used as a transfection agent. siPORT™ (3 μL) was added to miR-
145-5p (1.5 μL, 20 μM, 10 mins) or miR-145-5p inhibitor (1.5 μL, 20 μM, 10 mins). 
The siPORT-miR-145/miR-145-5p inhibitor mix was then spread onto PLA surface 
(as prepared in section 2.14.1). The surfaces were washed thoroughly with PBS 
(3 x 1 mL) before being placed face down onto the cells and left for 48 h. The in 
solution control was prepared by adding miR-145-5p/miR-145-5p inhibitor- 
siPORT mix directly to the cells, a non-treatment control was made simply by 
replacing the medium at the point of transfection to the other wells, a control 
mimic control was made by using pre-miR™ precursor negative control and 
mixing with siPORT™. After 48 h, RNA was extracted and quantified as described 
in sections 2.19&2.20. 
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2.18 Transfection of miRNA ex vivo 
2.18.1 miRNA transfection from PLA squares: 
Mouse aortas were dissected from MF1 mice and cut longitudinally. miRNA mimic 
from Caenorhabditis elegans (cel-miR-39-3p), (20 µM, 1.5 µL) was incubated 
with siPORT™ Neo FX  (3 µL) for 10 mins. The cel-miR-39-3p-siPORT mix was 
applied onto the PLA square, or for the mimic in solution control, added directly 
to the aorta. Mock PLA squares were prepared by adding siPORT™ Neo FX™ 
transfection reagent (3 µL) to the PLA squares but not miRNA. Non-treated 
aortas were also used as a negative control. The PLA squares were placed 
directly onto the inner arterial surfaces in a 12 well plate, and aortas were kept 
in MEM (1 mL, 37 oC, 5% CO2, 48 h). The PLA squares were removed from the 
plates and the aortas were washed thoroughly with PBS. RNA extraction was 
then performed on the tissue and quantification of transfected miRNA was 
determined by qRT-PCR as described in sections 2.19.2, 2.19.4&2.21. 
2.18.2 miRNA transfection from stents coated with PLA 
Custom-made SS murine stents stents (2.5 x 0.6 mm, Cambus medical) were 
coated with 10% and 15% wt/wt PLA dissolved in chloroform and left to air-dry, 
which were then smoothed by DCM vapourisation. They were then hand crimped 
onto a coronary dilation catheter (Abbott laboratories). The cel-miR-39-3p-
siPORT mix was made up as described above and applied directly onto the stent 
or onto the aorta. A non-treatment control was used, as well as an aorta which 
had siPORT™ Neo FX™, but not the miR, which was used as a mock control. After 
coating the stent with miRNA, it was left to air-dry for 5 mins and then it was 
washed with PBS before deploying into the aorta of the mouse ex vivo, details of 
this procedure can be found in section 2.24.1. Aortas were cultured in MEM for 
48 h before the stent was removed, the vessel washed and then miRNA 
expression was quantified by following the RNA extraction and qRT-PCR 
protocols (sections 2.19, 2.20&2.21). 
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2.19 Extraction of RNA from cells and tissues 
2.19.1 RNA sample preparation from cells: 
Cell medium was removed and the cells were washed twice with PBS. QIAzol 
lysis reagent™ (700 µL, Qiagen) was added to each well. Homogenisation of the 
cells was achieved by pippeting the cells prior to storage in 1.5 mL 
microcentrifuge tubes at -80 oC.   
2.19.2 RNA sample preparation from mouse aorta 
After transfection with miRNA, the aortas were washed with PBS. The aortas 
were then stored in RNAlater®-ICE (Life Technologies) (500 µL, -80 oC) until 
ready for extraction. The frozen aortas were dried and each placed into 2 mL 
eppendorfs with two 5 mm stainless steel balls and QIAzol lysis reagent™ (700 
µL). The tubes were placed into a QIAgen TissueLyser II machine, and shaken at 
25 Hz for 2 x 30 seconds pausing in between shakes. The tubes were then placed 
on ice for 1 min, the shaking procedure was repeated twice more. After lysing, 
the aortas were sufficiently broken up to enable efficient RNA extraction as 
described in section 2.19.4.           
2.19.3 RNA sample preparation from pig coronary arteries 
Vessels were removed from -80 oC storage and placed on dry ice. No more than 
four vessels were RNA extracted at the same time. All surfaces and instruments 
were treated with RNaseZap® RNase decontamination solution (Life 
Technologies). If the vessel had been stented, the vessel was cut longitudinally 
and the stent was removed. The vessel was placed into a ceramic mortar that 
was cooled on dry ice. Using a sterile scalpel blade, the vessel was cut into small 
pieces. Liquid N2 was then poured into the mortar and the pieces of vessel were 
ground with the pestle. This was repeated twice. The ground vessel was then 
transferred into a pre-cooled bijou containing QIAzol (1400 µL). A polytron was 
then used to homogenize the tissue further; samples were placed on ice after 30 
seconds of homogenisation to prevent degradation of the RNA through heating. 
Once the samples were sufficiently homogenised they were transferred to a 2mL 
eppendorf and chloroform was added (280 µL) and vortexed. The RNA procedure 
(described below, section 2.19.4) was then followed.      
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2.19.4 General RNA extraction procedure 
RNA was extracted from the homogenised samples (as prepared in sections 
2.19.1, 2.19.2&2.19.3) using a miRNeasy mini kit (Qiagen). The samples were 
left at RT for 5 mins this aids dissociation of nucleoprotein complexes. 
Chloroform (140 µL) was then added to each tube and vortexed for 15 seconds 
and left to settle at RT for 2 mins. The tubes were then centrifuged (12000 x g, 
15 mins, 4 oC). This allowed phase separation to occur, between the organic 
(containing proteins), intermediate (containing DNA) and aqueous layers 
(containing RNA). The upper aqueous layer containing the RNA was then 
removed and put into a new 1.5 mL RNAse free eppendorf. 100% Ethanol was 
added to each tube (525 µL) and mixed by pipetting up and down. Each sample 
was then placed into an RNeasy mini spin column and centrifuged at 8000 x g, 2 
mins. The RNA binds to the column membrane whereas the other contaminants 
such as phenol wash through and are discarded. The columns are then washed 
with buffer RWT (350 µL) and centrifuged (8000 x g, 15 s, RT).  
An on column DNAse digestion is done to remove contaminating genomic DNA 
using an RNAse free DNase set (Qiagen). DNase is diluted according to 
manufacturer’s instructions and then diluted 1:8 v/v with buffer RDD. This 
solution is then applied directly to each column (80 µL) and left for 15 mins, RT. 
Buffer RWT (350 µL, 8000 x g, 15 s) was then washed through the column, 
followed by buffer RPE (500 µL, 8000 x g, 15 s), buffer RPE (500 µL, 8000 x g, 2 
mins). The column was then placed into a new collection tube and spun at 16000 
x g, 1 min). Finally the column was placed into a 1.5 mL RNase free tube, RNase 
free water was applied to the column (50 µL) and then the column was 
centrifuged (8000 x g, 1 min) to elute the RNA through the column and into the 
tube. The RNA solution was run through the column again to increase the RNA 
yield. 
The concentration of RNA was determined using a NanoDrop 1000 
spectrophotometer (Thermo Scientific), by measuring the samples absorbance at 
260 nm. This purity of the RNA was also assessed by measuring the ratio of 
absorbance 260:280 nm for a pure sample of RNA without contaminants the 
260:280 nm ratios was ~2.   
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2.20 Reverse-transcription polymerase chain reaction 
(RT-PCR) 
The extracted RNA samples underwent reverse transcription to form 
complementary DNA sequences (cDNA) using Taqman® miRNA Reverse 
Transcription Kit (Applied Biosystems). The RNA was firstly diluted with RNase 
free water to 2 ng/µL. The PCR reactions were done in a 96 well PCR plate. Each 
well contained dNTPS (0.075 μL), multiscribe (0.5 μL), 10 x RT buffer (0.75 μL), 
RNA inhibitor (0.095 μL), RNAse free water (2.08 μL), 5 x RT primer (1.5 μL) and 
extracted RNA (2.5 μL, 2 ng/µL). The Taqman® miRNA Reverse Transcription 
primers contained the sequence for the mature form of the miRNA of interest 
(listed below). Reverse transcription was also performed on an endogenous 
control housekeeping genes U87, hsa-miR-103 and U6, and RNU48b for murine, 
porcine and human samples respectively in order to be able to normalise any 
anomalies in miRNA expression.  
miRNA sequence species 
cel-miR-39-3p 5’UCACCGGGUGUAAAUCAGCUUG3’ caenorhabditis 
elegans 
hsa-miR-145-5p 5’GUCCAGUUUUCCCAGGAAUCCCU3’ human, mouse, rat 
hsa-miR-145-3p 5’GGAUUCCUGGAAAUACUGUUCU3’ human, mouse, rat 
hsa-miR-let7e-5p 5’UGAGGUAGGAGGUUGUAUAGUU3’ human 
hsa-miR-99b-5p 5’CACCCGUAGAACCGACCUUGCG3’ human 
hsa-miR-125a-5p 5’UCCCUGAGACCCUUUAACCUGUGA3’ human 
hsa-miR-let7e-3p 5’CUAUACGGCCUCCUAGCUUUCC3’ human 
hsa-miR-99b-3p 5’CAAGCUCGUGUCUGUGGGUCCG3’ human 
hsa-miR-125a-3p 5’ACAGGUGAGGUUCUUGGGAGCC3’ human 
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PCR cycling conditions were 16 oC for 30 mins, to enable the RT primer to bind 
to the RNA, 42 oC for 30 mins, to enable reverse transcription to occur and 
finally 85 oC for 5 mins, to inactivate the reverse transcriptase, the plate was 
then kept at 4 oC. 
A non-template control was run where RNase free water was used in place of 
RNA. The plates containing the cDNA were stored at 4 oC for short term or -20 oC 
for longer term storage, until qRT-PCR was run on the samples section 2.21.  
2.21 Taqman quantitative real time PCR (qRT-PCR) 
qRT-PCR is a technique which enables the amount of cDNA to be quantified by 
measuring the amount of fluorescence detected during each PCR cycle. Taqman 
probes are used which are complementary oligonucleotide sequences to the 
target cDNA which have a fluorescent tag at 5’ end and a quencher at the 3’ 
end. In this format, when the fluorophore is excited by a light source any 
fluorescence is quenched by fluorescence energy resonance transfer (FRET) due 
to the quenchers close proximity to the fluorophore. When the taqman probe 
binds to the target cDNA sequence it is cleaved by Taq polymerase which 
releases the fluorophore so it is no longer in close proximity to the quencher, 
this emission of fluorescence is proportional to the amount of target sequence 
present in the sample. The number of cycles a product takes to reach a fixed 
threshold is known as the cycle threshold (Ct). The lower the Ct value the higher 
the amount of product. An endogenous control which is stably and uniformly 
expressed in the cell line or tissue was used to normalise the target RNA 
expression values. To measure fold changes in RNA expression, the calculation 2-
ΔΔCt was taken, as described (Schmittgen and Livak, 2008). 
The reverse transcription product for each sample were then run in triplicate on 
a 384 well plate, with each well containing 2 x Taqman mastermix (5 μL), 20 x 
miR probe, H2O (3.8 μL) and reverse transcription product (0.7 μL). The 
thermocycling conditions were95 °C for 15 mins, followed by 40 cycles of 95 °C 
for 15 secs and 60 °C for 1 min, using an ABI 7900 qRT-PCR machine (Applied 
Biosystems). 
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2.22 Cell Proliferation EdU Assay 
Cell proliferation was assessed using a Click-iT® EdU Alexa Fluor® 488 Flow 
Cytometry Assay Kit (Life Technologies). This assay works by using EdU (5-
ethynyl-2’-deoxyuridine) which is an alkyne tagged thymidine analogue that is 
incorporated into newly synthesised DNA. Detection of EdU takes place by 
reacting with an Alexa Fluor® 488 dye which has an azide tag by a copper 
catalysed click reaction. Fluorescence-activated Cell Sorting (FACS) is then used 
to determine the population of proliferating cells. 
HVSMC were plated at 3.5 x 104 cells/well in a 12 well plate and transfected 
with miRNA mimics, has-let-7e 3p and 5p strands, hsa-99b 3p and 5p strands, 
hsa-125a 3p and 5p strands, and Pre-miR scramble control at the same time as 
plating. This was done by adding siPORT™ Neo FX™ (3 µL) to optiMEM (47 µL) and 
miRNA mimics/scramble control (5 µM stock, 0.6 µL) to optiMEM (47 µL) for 10 
mins. 15% FCS SMC medium was then added to each well (900 µL).The siPORT™ 
Neo FX™ and miRNA solutions were then added together and left for 10 mins and 
then applied to each well (100 µL). 
Virus transductions were done 24 h after plating the cells. Lenti-virus cluster 
(LV-cluster) and control Lentivirus-GFP (LV-GFP) were added incubating with 
polybrene (1 µL, 37 oC, 30 mins) and then adding to wells at a concentration of 
20 MOI.   
The cells were then left for 24 h (37 oC, 5% CO2). The cells were then arrested by 
replacing medium with 0.5% FCS MEM (1 mL). The cells were then left for 48 h, 
the medium was replaced with 15% FCS DMEM, and EdU was added to each well 
(10 mM stock, 10 µL), the cells were left for another 48 h and then harvested by 
adding trypsin to each well (200 µL, 5 mins, 37 oC), and then SMC medium (800 
µL). The cells were then put into 1.5 mL eppendorfs and centrifuged (600 x g, 6 
mins, RT), the supernatant was then discarded and then the cells were 
resuspended in PBS (100 µL) and then fixed by adding 70% EtOH (900 µL, 
overnight), light vortexing helped cells not clumping together. The cells were 
then centrifuged (600 x g, 5 mins, RT) and the supernatant was discarded. A 
solution of 0.2% Triton X-100 was applied (750 µL) to re-suspend the pellet, the 
samples were then left for 30 mins, RT. PBS + 1% BSA w/v (750 µL) was added to 
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each tube, left for 1 min and then centrifuged at (600 x g, 5 mins, RT). The 
supernatant was discarded and the pellet was re-suspended it in click it reagent 
(0.5 mL per tube, 60 mins, dark, RT). The Click-iT® reagent was prepared by 
adding PBS (438 µL), CuSO4(aq) (100 mM stock, 10 µL), Alexa Fluor® 488 azide (18 
ng/µL, 0.8 µL), 1 x Click-iT® EdU reaction buffer additive (50 µL). After 1 h PBS 
+ 1% BSA w/v was added to each tube (750 µL) and the cells were centrifuged 
(600 x g, 5 mins, RT) and the supernatant discarded. The cells were re-
suspended in PBS + 1% BSA (350 µL) and transferred to FACS tubes and cell 
counted as described in section 2.23. Each group had 2 biological replicates and 
also 2 samples were taken for RNA extraction and q-RT-PCR to verify 
overexpression of the miRNA either from viral transduction or miRNA 
transfection as described in sections 2.19, 2.20&2.21.  
2.23 Flow assisted cell sorting 
For the FACS, control tubes were prepared and run first, these were: positive 
control for proliferation (cells stimulated 15% FCS, + EdU, + Alexa Fluor), 
negative control for proliferation (cells not stimulated kept in 0.5% FCS, + EdU, 
+Alexa Fluor™), negative control for EdU (cells stimulated with 15% FCS, -EdU, + 
Alexa Fluor™), background cells (cells stimulated 15% FCS, -EdU, - Alexa Fluor™). 
Samples were processed using a BD Biosciences FACS Canto II with a two laser 
setup (Red and Blue lasers). Analysis of the data was performed using FlowJo 
software (TreeStar, Ashland, USA).               
2.24 In vivo models 
2.24.1 Mouse stenting model 
In vivo experiments were done in accordance with the United Kingdom Home 
Office Guidance and the Animals Scientific Procedures Act of 1986. Male 30 g + 
MF1 mice were purchased from Harlan laboratories (Derby, UK), the mice were 
housed and procedures were performed at the Central Research Facility at the 
University of Glasgow. Mice were fed on normal chow diet and had free access 
to food and water and were kept on a 12 h light/dark cycle. 
The mouse stenting model used was first described by Ali et al., which requires 
the use a donor and a recipient mouse per operation (Ali et al., 2007). Custom 
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made mouse stents as used for the ex vivo testing (section 2.18.2), were 
crimped onto the coronary dilation catheter. Stents were sterilised by 
submerging into Actril® cold sterilant (Guardline technologies ltd, Norfolk, UK), 
prior to deployment.  
The donor mouse was euthanised by an intraperitoneal (IP) injection of sodium 
pentabarbitol (150 mg/kg). The abdomen and ribcage were opened so that an 
incision can be made in the right atrium followed by perfusion of heparin saline 
(100 IU/mL) via an injection in the left ventricle. The thoracic aorta was 
isolated, removing any excess fat lining the vessel and a small incision was made 
to the distal end of the aorta so that the coronary dilation catheter could be 
inserted into the vessel. The stent was expanded by applying a pressure of 10 
atm for 30 secs; the catheter was then removed leaving the stent in place. The 
stent was excised by cauterisation of the vessel and was left in PBS whilst the 
recipient mouse was prepared.  
Recipient mice were anaesthetised using vapourised isoflurane (1-3%, Abbott), 
the common carotid was isolated and ligated using two 7-0 sutures (Ethicon, 
Edinburgh,UK) distal to bifurication. The carotid was then dissected between the 
sutures and each end of the carotid was passed through a 0.65 mm cuff (Smiths 
medical, Kent, UK) and secured with a microhemostatic clamp. The sutures were 
then removed and the free end of the carotid was everted over the cuff and 
sutured in place using 8-0 silk sutures (Ethicon). The donor aorta was then 
sleeved over the everted ends and sutured in place. The microhemostatic clamps 
were removed, and blood flow was restored to the vessel. The skin was closed 
using 5-0 sutures (Ethicon). Following the surgery the mice were transferred to a 
37 oC chamber for recovery.  
Prior to surgery recipient mice received a 7 day course of aspirin (10 mg/kg), 
and for each day afterwards until they were euthanised. Euthanasia was 
performed at 48 h post-surgery by administration of a lethal amount of 
anaesthetic, followed by an excision to the heart.  
For the 48 h mouse stenting study, murine stents were coated with PLA dissolved 
in chloroform (10% wt/wt) and miR-39-3p (1.5 μL, 20 μM) as described in section 
2.18.2. Stents were also prepared in this manner for the PLA BMS group but were 
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not coated with miR-39-3p. Untreated aorta was kept during the procedure and 
used as a non-treatment control. After 48 h of being deployed the stented 
segment were excised from the mouse, the stent was removed and the vessel 
bathed in PBS, prior to RNA extraction and quantification of the miRNA by qRT-
PCR as described in sections 2.19.2, 2.19.4, 2.20&2.21. 
2.24.2 Pig stenting model 
Male Large White/Landrace Pigs were purchased from SAC commercial ltd 
(Edinburgh, UK) (12 weeks old, 30-35 kg). Pigs were housed and procedures were 
performed in the Biological Procedures Unit at the University of Strathclyde. In 
line with the local animal guidelines, the animals had a period of at least 7 days 
acclimatisation prior to any procedures being performed. Pigs were kept in 
controlled conditions on a 12 h light/dark cycle with free access to water and 
were fed twice a day.  
All operations were done in a designated operating theatre under sterile 
conditions. During the operation, the electrical activity of the pigs heart was 
monitored by continuous single lead ECG which was connected subcutaneously, 
the blood pressure, heart rate and %O2 saturation of the blood were also 
monitored. The temperature of the pig was monitored by a rectal probe. A 
monophasic direct current defibrillator was also present in the operating room 
to be used in the case of a cardiac arrest.  
2.24.2.1 Periprocedural pharmacotherapy 
A day prior to surgery, the pigs were dosed orally with aspirin (150 mg, Teeva, 
Leeds, UK) and clopidogrel (150 mg, Sanofi-Aventis, Guildford,UK). On the day of 
surgery the pigs were dosed with a further 75 mg of both aspirin and clopidogrel 
this was continued every second day until sacrifice. Once stable anaesthesia had 
been reached the pigs were dosed intravenously with an anti-arrhythmic cocktail 
of drugs, amidarone (75 mg, Sanofi-Aventis) and lidocaine hydrochloride (50 mg, 
Taro Pharmaceuticals, Ireland) via a 20G canula in the large ear vein. 
Anticoagulant was also administered intravenously following the insertion of the 
arterial sheath (3000 units heparin, ). After anaesthesia the pigs were given 0.15 
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mg, buphrenorphine as a painkiller and 300 mg ampicillin as an antibiotic which 
were administered by an intramuscular injection.  
2.24.2.2 Anaesthesia 
All procedures were performed with the pig being under anaesthesia. Initially 
the pigs were sedated by an intramuscular injection of tiletamine/zolazepam 
(100 mg Zoletil, Virbac, Suffolk, UK) this enabled the pig to be transported from 
the animal enclosure to the operating table. Using a snout mask the pigs 
anaesthesia was further induced through inhalation of 4% isoflurane (Abbott 
laboratories ltd, Maidenhead, UK) in O2 (7 L/min) and NO (2 L/min). The pigs 
were moved into a supine position and intubated by insertion of a lubricated 6F 
endotracheal tube through the vocal cords by direct vision. To aid the intubation 
procedure propofol was administered intravenously (30 mg, Rapinovet, Schering-
Plough, Welwyn Garden City, UK). Anaesthesia was maintained with 2% 
isoflurane in nitrous as described above. Saline was injected intravenously to 
maintain hydration.  
2.24.2.3 Arterial Access 
Arterial access was secured via the left femoral artery. The groin area was 
wiped down with a povidone-iodine solution and surgical drapes were placed 
around the area where the incision was to be. The left femoral artery was 
dissected and freed from peripheral fascia using a cut-down approach. The 
artery was sutured proximally and distally. Using a modified Seldinger technique 
to obtain safe access into the vessel, the artery was punctured using a sharp 
hollow needle from a human transradial artery access kit (Arrow® International 
UK ltd, Middlesex). A soft tipped guidewire (0.0025 in) was threaded through the 
needle and into the lumen of the artery, the needle was then removed and a 6F 
radial sheath was placed over the guidewire, the wire was removed and the 
sheath was sutured to the skin.  
2.24.2.4 Coronary Catheterisation and Stenting Procedure 
A human 6F guide catheter and 0.035 inch guidewire was inserted through the 
descending aorta, around the aortic arch and into the coronary ostia using 
angiography by injecting radiographic contrast agent (Ominipaque 140, GE 
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healthcare, Buckinghamshire, UK). Once the catheter was in the correct position 
for stenting the coronary artery, the guidewire was removed and the Gazelle™ 
bare metal stents which was mounted onto a balloon delivery catheter was 
inserted through the guide catheter. The balloon delivery catheter had two 
radiopaque markers which marked the ends of the stent; angiography confirmed 
that the stent was in the correct position. The balloon was inflated using a 
indeflator (Boston Scientific, MA, USA) up to 12 atm, then deflated and 
removed, leaving the stent deployed in the artery. Two stents were deployed 
per pig into the left anterior descending artery and the right coronary artery or 
left circumflex.       
2.24.2.5 Closure 
To close the wound, the guide catheter was removed and the proximal suture 
was tightened to allow removal of the sheath. The artery was then ligated and 
the wound was closed using absorbable sutures (Dexon™, Covidien, Dublin, 
Ireland).  
2.24.2.6 Recovery 
Animals were extubated and left to recover from anaesthesia under supervision, 
once the animals were awake they were taken back to the enclosure and fed a 
normal chow diet. The animals were given a course of antiplatelets post-
procedure.  
2.24.2.7 Animal Sacrifice 
After 48 h, animals were given an intramuscular injection of tiletamine 
/zolazepam (100 mg Zoletil, Virbac), to sedate them and allow transport to the 
operating theatre. Following cannulation of the large ear vein a lethal injection 
of pentobarbital (100 mg/kg, Merial, Harlow, UK) was given. Bone cutters and 
rib retractors were used to access the thoracic cavity. The heart was mobilised 
by stripping back the visceral and parietal pericardium. The great vessels were 
cut and the heart was then removed from the thoracic cavity. The coronary 
arteries were then quickly dissected out of the heart. If the artery was to be 
used for and RNA extraction, it was immediately stored in RNAlater®-ICE (2 mL 
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per vessel) at -80 oC. RNA extraction from pig coronaries is described in section 
2.19.3.   
2.24.2.8 Stent based delivery of miRNA 
Gazelle™ stents were coated with PLA as described in section 2.16.3. Prior to 
surgery the stents were then coated with miRNA/siPort mix. siPort™ (9 µL) was 
added to miRNA (20 µM, 4.5 µL) and left for 10 mins, this solution was then 
applied to the stent, air-dried and then deployed as described in section 
2.24.2.4. For the miR-39-3p coated stents, 6 stents were coated and deployed, 
with 6 BMS and 6 PLA BMS for the control groups. 2 stents were deployed per 
pig, ensuring that the same group were not deployed in the same pig. For the 
miR-145-5p coated stents, 4 stents were coated and deployed. For the antimiR-
21 coated stents, 3 stents were deployed and 2 stents were coated with antimiR-
21 scramble control.  
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3 Development of methods for coating adenovirus 
particles to stent materials and surfaces 
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3.1 Introduction 
Adenovirus vectors are the most commonly used vector for gene therapy (Wiley, 
2015). They are particularly suitable for this application because they can be 
relatively easily manipulated, they can be made under GMP conditions to 
produce high-titre stocks and they transduce many different cell types, including 
quiescent and proliferating cells, without integrating into the host genome 
(Bradshaw and Baker, 2013).  
The virus serotype most commonly used for gene therapy is adenovirus 5 (Ad5). 
However, despite Ad5 being a popular choice for gene therapy, there are a 
number of limitations associated with it. High seroprevalence in the human 
population and consequent neutralisation by anti-Ad5 Ab can decrease  the 
overall transduction of target tissues (Bradshaw and Baker, 2013, Barouch et al., 
2011). The Ad5 vector has also been shown to trigger an innate immune response 
following intravascular delivery, resulting in the virus being removed from 
circulation (Bradshaw and Baker, 2013, Schoggins and Falck-Pedersen, 2006, 
Muruve et al., 2008, Di Paolo et al., 2009). Despite these drawbacks, it was 
chosen to develop stent coating methods, due to its efficient vascular uptake 
and it being one of the most well-characterised gene therapy vectors. Coating 
methods developed have also been tested for compatibility with other more 
novel virus vectors that have been assessed specifically for delivery to the 
vasculature, such as Ad49 (Lemckert et al., 2006).  
In stent restenosis occurs as a result of acute vessel wall injury endured during 
deployment of the stent. This stimulates platelet aggregation, which in turn 
causes smooth muscle cell proliferation and migration into the intima (Mitra and 
Agrawal, 2006a). Targeting the cell proliferation pathway by coating the stent in 
anti-proliferative drugs has been extensively investigated, to provide localised 
delivery to the vasculature. These drug eluting stents (DES) have been shown to 
have a drastic effect on SMC proliferation; however they have been associated 
with late stent thrombosis, which is often fatal (Bradshaw and Baker, 2013, 
Stone et al., 2007b, Yeh et al., 2011). DES are also costly and require patients to 
take long-term anti-thrombogenic medication. Furthermore, the drugs that are 
coated onto the stent often do not discriminate between proliferating VSMC and 
EC which can therefore delay re-endothelialisation (Santulli et al., 2014).   
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There is therefore a window of opportunity for a novel, more SMC specific and 
sophisticated treatment to be applied to the stent surface which would target 
the in stent restenosis pathway, to prevent SMC proliferation and no hinder re-
endothelialisation. It has been envisaged that coating the stent in therapeutic 
virus vectors could provide a powerful way to maximise the potential for viruses 
to deliver therapeutic genes for treatment of ISR, by enhancing transduction of 
the virus by local delivery and avoiding distal spread of the virus. Therefore, 
methods for attaching Ad5 vectors to stent surfaces were investigated. 
To date there have been a number of studies which have investigated the 
delivery of virus vectors from stent surfaces. A successful way to enable virus 
delivery has involved coating the stent with adenovirus antibodies which act as a 
surface for virus capture and release. Levy and co-workers used a stainless steel 
stent coated in collagen with anti-adenoviral monoclonal antibodies covalently 
bound to the collagen surface; this provided a surface upon which the Ad5 GFP 
vector could be selectively tethered via antigen-antibody specific interactions. 
This method proved successful in vitro and in vivo, with a transduction 
efficiency of 5.9% of porcine arterial smooth muscle cells and 17% of cells in the 
neointima of pig coronaries showing expression of GFP after stent deployment 
for 7 days (Klugherz et al., 2002a). Fishbein et al. bound an anti-Ad antibody to 
a bare metal stent surface using polyallylamine bisphosphonate as a linker 
molecule; the phosphonate groups coordinated with the metal surface and the 
amine group was then reacted with crosslinker SPDP, leaving a thiol group, 
which could then bind to the anti-ad antibody by formation of a disulfide bond 
(Fishbein et al., 2006a). 
Another method for adenoviral attachment to the stent surfaces exploited the 
adenoviruses net negative charge, and used electrostatic interactions to bind to 
a positively charged phosphorylcholine coating on BiodivYsio stents (Sharif et al., 
2006, Johnson et al., 2005a). This concept of using surface charge to attach the 
adenovirus vector has provided some inspiration for the work carried out here, 
by using poly(electrolyte) multilayers as a charged base to attach the adenovirus 
to. This chapter aims to describe and evaluate different methods for coating of 
Ad5 to stent surface materials both in vitro and ex vivo, with the objective of 
discovering a delivery system which would function in vivo to deliver a 
therapeutic Ad from stent surfaces to treat ISR locally at the point of injury.  
Chapter 3  109 
 
3.1.1 Aims 
 To develop a method for coating of Ad5 onto stent surfaces that enables 
localised delivery to arteries from mice and pig stents 
 Quantify the amount of virus deposited onto the stent surface 
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3.2 Results 
3.2.1 Poly electrolyte multilayers 
Polyelectrolyte multilayers (PEMs) were investigated as a method for the 
attachment and delivery of adenoviral particles from stent surfaces. PEMs were 
formed by depositing oppositely charged polymers onto surfaces in a layer by 
layer fashion to form a polymer film on the surface (Figure 3-1). 
 
Figure 3-1 Diagram of method for poly(electrolyte) multilayer formation. 
In order to form a poly electrolyte multilayer on a surface, the surface is first immersed into a 
polycationic solution for 1 min, they are then washed in dH2O and then immersed into a polyanionic 
solution for 1 min, and washed in dH2O. This process is repeated until the desired number of layers 
have been deposited onto the surface. 
It was hypothesised that because adenovirus particles carry a net negative 
charge, if they were deposited onto a cationic polyelectrolyte layer they would 
be adsorbed and held onto the surface through electrostatic interactions. This 
principle has been used to successfully deliver DNA from stent surfaces coated 
with a PEM (Saurer et al., 2013). PEMs have previously been shown to be able to 
be deposited uniformly onto a stent surface, which is important since stents 
have a complex geometry and are therefore often difficult to coat (Dimitrova et 
al., 2007). Two different PEM systems were tested; chitosan-hyaluronan (chi-ha) 
which are both biopolymers, and poly(allyl amino hydrochloride)-poly(styrene 
sulfonate) (PAH-PSS) which are synthetic polymers. These systems were chosen 
because they are well characterised and have been studied previously for 
adenoviral delivery (Dimitrova et al., 2007).   
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Figure 3-2 Chemical structures of polycationic and polyanionic species used for the 
formation of PEMs. 
The polycationic group species, chitosan and poly(allylaminohydrochloride) both exhibit amine 
groups which when protonated will become catatonically charged. The polyanionic species 
poly(styrenesulfonate) contains a sulfonate group which will is anionically charged and hyaluronan 
which has carboxyl groups which when deprononated will become anionically charged.   
In order to monitor the formation of the PEMs, they were initially deposited onto 
quartz slides which have a low absorbance range. Before deposition the slide 
was washed in piranha solution to clean the surface, the slide was then 
submerged into the polycationic solution, washed with dH2O followed by the 
polyanionic solution, this procedure was then repeated 8 times to form a PEM. In 
order to confirm that the PEM was forming on the quartz, a UV-visible spectrum 
was taken after each deposition (Figure 3-3). The PEM formation procedure is 
detailed in section 2.4. 
 
 
Chapter 3  112 
 
 
 
Figure 3-3 UV-vis spectra of PAH-PSS and chi-ha PEMs forming on quartz slides. 
Quartz slides were submerged into polycationic solution for 1 min, washed with dH2O and dried 
with N2, they were then submerged into the polyanionic solution for 1 min, this was repeated 8 
times to form a PEM. UV-vis spectra were recorded after each layer of polycation-polyanion was 
deposited. A) The UV-vis spectra for PAH-PSS PEM formation: black (baseline), red (after PEM 1), 
green (after PEM 2), dark blue (after PEM 3), light blue (after PEM 4), pink (after PEM 5), yellow 
(after PEM 6), olive green (after PEM 7), purple (after PEM 8) B) The UV-vis spectra for the chi-ha 
PEM formation: maroon (baseline), black (after PEM 1), green (after PEM 2), dark blue (after PEM 
3), light blue (after PEM 4), pink (after PEM 5), yellow (after PEM 6), olive green (after PEM 7), 
purple (after PEM 8). Representative graphs of three independent experiments. 
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The layer by layer deposition of both the PAH-PSS and the chi-ha PEMs was 
clearly observed by UV-vis spectroscopy, as each layer added corresponds to an 
increase of the absorbance. For the PAH-PSS PEM the sequential increase in 
absorbance at 230 nm was more pronounced which was due to the presence of 
the phenyl rings on the poly styrene sulfonate which exhibits a high absorbance 
at this wavelength. This can be seen clearly in the absorbance spectra for PAH-
PSS PEM. It is not present in the CHI-HA PEM as neither of these 
poly(electrolytes) have groups which absorb UV and visible light strongly. 
Despite this, an increase in absorbance can be viewed for both PEMs as 
sequential layers are deposited.  
As it was clear that this methodology was successful at forming the two different 
PEMs, the next objective was to see if it was possible for adenovirus particles to 
adsorb onto the terminal polycationic layer of the PEMs. This was evaluated, 
using a virus which was fluorescently tagged with a dye molecule (Alexa Fluor 
555). The PEMs were prepared in the same way as described above, after which 
the fluorescent virus (Ad-555) or unlabelled virus (Ad5) at a concentration of 
(1.22 x 109 VP/surface) was deposited onto the PEM and left overnight, the 
surfaces were then washed with PBS, prior to visualisation of the fluorescence by 
confocal microscopy (Figure 3-4). Unlabelled Ad5 was used as a negative control, 
to confirm that the fluorescence observed from the surfaces could be attributed 
to the presence of the fluorescent virus and not materials or the virus itself. 
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Figure 3-4 Confocal micrographs of PEMs chi-ha and PAH-PSS incubated with 
fluorescently tagged adenovirus. 
The top row shows the surfaces which have been incubated with the unlabeled Ad5 control virus 
(1.22 x 109 VP/surface). The bottom row shows the surfaces which have been incubated with Ad5-
Alexa Fluor™ 555 (1.22 x 109 VP/surface). Untreated samples were the slide prior to PEM 
deposition, +chitosan and +PAH indicates a monolayer of the corresponding polycations. +(chi-
ha)8chi and +(PAH-PSS)8-PAH indicates an 8 layer PEM with an additional terminal layer of 
polycation. Images were taken at 60 x magnification, scale bar = 50 µm, 1000 ms exposure, 572 
nm excitation wavelength. Representative images from two independent experiments. 
As no fluorescence was observed for the surfaces which had unlabelled Ad5 
deposited onto it, we attributed any fluorescence observed as a result of the 
fluorescently tagged virus being adsorbed onto the surface. Both the PEMs 
showed that the virus had been effectively absorbed onto the surface after 
washing extensively with PBS. Quantitatively, there were higher levels of 
fluorescence observed for the PAH-PSS PEM; this may be because the virus had a 
higher binding affinity to this surface. When one layer of PAH was deposited, 
large swathes of fluorescence were observed (Figure 3.4), which indicates that 
the virus was not spread evenly on the surface. It is possible that this is due to 
an uneven distribution of PAH after one layer, as this effect is not observed for 
the (PAH-PSS)8PAH multilayer. This indicates that using the multilayer approach 
allows for a more even coverage of the poly(electrolyte) and therefore the virus, 
which is demonstrated by both the PAH-PSS and chi-ha PEMs.     
The topography of these surfaces was also recorded using atomic force 
microscopy (AFM) (Figure 3-5). AFM works by scanning a sharp tip across a 
surface whilst maintaining a constant force between the tip and the surface. As 
the tip scans along the surface and the surface topography changes, the tip will 
move up and down, in order to maintain a constant force between the surface 
and the tip. This movement will mirror the surface contours. In order to amplify 
+ (PAH-PSS)8
PAH
Ad 5
Ad 5-Alexa 555
Untreated + Chitosan + (Chi-Ha)8Chi + PAH
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this movement, a laser is directed onto the tip which is then reflected to a 
sensor. This information can be used to create an atomic force micrograph which 
is representative of the surface topography. 
Adenovirus particles are icosahedral in shape and have been reported to have a 
diameter of 60-90 nm (Volpers and Kochanek, 2004). The AFM images showed 
distinct particles on the monolayer and PEM surfaces close to this size range 
which, therefore, suggests that the ad particles had been efficiently deposited 
onto the surfaces. When comparing the monolayer + Ad5 group for the chitosan 
and PAH surfaces, there was a distinct difference in the size of the particles 
measured on the surface. The particles on the chitosan surface exhibited a 
height of approximately 30 nm, however for the PAH surface the particles a 
height of 60 nm was recorded. These differences may suggest that the virus 
particles on the chitosan surface were more submerged into the polymer layer. 
 
Figure 3-5 Atomic force height images of the microscope slides coated with PEMs. 
(chi-ha)8chi and (PAH-PSS)8PAH and chitosan and PAH monolayers were prepared on glass 
microscope slides and incubated with Ad5 (1.22 x 109 VP/surface). Control surfaces of PAH and 
chitosan without virus incubation were also prepared, the surfaces were washed with dH2O and 
dried with N2 prior to AFM. AFM images were taken using non-contact mode, at a scan rate of 1.01 
Hz. Differences in scales are used to allow for definition of the individual surfaces. Representative 
images from three independent experiments. 
As both the AFM and confocal microscopy results indicated that virus particles 
can adhere to surfaces by incubating on the two PEMs, it was important to 
evaluate whether the virus was able to elute from the surface and after doing so 
if it was still biologically active. Ad5 CMV lac Z was used in order to investigate 
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this which has been genetically modified so that it expresses β-galactosidase 
which can be used as a reporter for virus transduction (section 2.10). The Ad5 
serotype was chosen to model the stent delivery system because it is the most 
commonly used virus vector for gene therapy, it has been reported to transduce 
vascular cells with high efficiency in vivo and high titre stocks can easily be 
prepared (French et al., 1994, Sharif et al., 2006).  
To verify expression of β-galactosidase from the Ad5 CMV lac Z vector, rat A10 
SMC were plated and a serial dilution of virus was made and applied to the A10 
cells in the range of 500-5000 VP/cell (Figure 3-6). The virus was left on the 
cells for 3 h and then the medium was replaced and left for 72 h before 
harvesting the cells. Quantification of β-galactosidase expression was performed 
by doing a β-gal assay. For all the concentrations used, a significant expression 
of the transgene in comparison to the untreated control cells was observed.  
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Figure 3-6 Transduction of A10 cells with Ad5 CMV lac Z. 
A10 cells were treated with medium (control) or Ad5 CMV lac Z at concentrations of 500, 1000, 
2500, 5000 VP/cell for 3 h, the virus was then removed and replaced with fresh medium and left for 
72 h. A β-galactosidase assay was used to determine the β-gal expression by measuring the 
relative light units (rlu) normalised to the protein concentration (mg). Results are displayed as mean 
± SEM, statistical analysis was performed using an unpaired student’s t test, **p<0.01, ***p<0.001 
vs control, representative graph from three independent experiments, each with three technical 
triplicates per condition. 
The effect of the polycations on Ad5 CMV lac Z transduction of A10 cells was 
investigated by incubating the virus (2500 VP/cell) with the polycation solutions 
(chitosan and PAH) at concentrations in the range of 0.125-1 mg/mL for 3 h, the 
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virus polycation solutions were removed and replaced with fresh medium. 
Transgene expression was measured using a β-gal reporter assay. Non-treated 
cells were used as a negative control and were maintained in medium 
throughout the experiment (section 2.8.2). In order to see the effect that the 
polycations had on virus transduction, cells treated with virus but not with a 
polycation solution were used as a positive control (Figure 3-7). 
 
Chapter 3  118 
 
 
 
 
Figure 3-7 Transduction of A10 cells with Ad5 CMV lac Z treated with polycations, 
chitosan and PAH. 
A10 cells were treated with medium (control) or Ad5 CMV lac Z (2500 VP/cell) with polycationic 
solutions PAH and Chitosan at concentrations of 0, 0.125, 0.25, 0.5 and 1 mg/mL for 3 h, the virus 
was then removed and replaced with fresh medium and left for 72 h. A β-galactosidase assay was 
used to determine the β-gal expression by measuring the relative light units (rlu) normalised to the 
protein concentration (mg). Results are displayed as mean ± SEM, statistical analysis was 
performed using an unpaired student’s t test, ***p<0.001, **p<0.01, ns=non-significant vs 0 mg/mL 
control, n=3. Bottom displays representative images of x-gal stained A10 cells after incubation with 
Ad5 CMV lac Z in different cationic polymer conditions, 10x magnification, scale bar = 100 µm. 
Three technical triplicates per condition. 
It was observed that incubating the virus with chitosan solutions caused an 
increase in β-gal expression for all the concentrations used. The highest level of 
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transduction was at 0.5 mg/mL chitosan where the increase was 74 fold 
compared to 0 mg/mL chitosan control. This enhancement in viral transduction 
has been previously documented and is due to the cationic polymer facilitating 
entry of the adenovirus into the cells via a CAR independent pathway. This is 
driven by the attraction between the polymer and the net negative charge on 
cell surface membranes (Zhong et al., 2011, Kawamata et al., 2002). For the 
PAH polymer, a decrease in virus transduction was observed when compared to 
the adenovirus only positive control. The biggest decrease in viral transduction 
was at the highest concentration of PAH used (1 mg/mL) which showed a 12 fold 
reduction which was of a similar level to the non-treatment negative control 
cells. For these reasons, no further work was carried out using PAH as a platform 
for virus delivery. On the other hand, further in vitro testing was explored with 
the (chi-ha)8chi PEM as this augmentation of viral transduction could provide a 
very effective method for adenoviral delivery from chitosan coated surfaces. For 
both PAH and chitosan, a dose dependent response on β-gal expression wasn’t 
observed when the concentration of the polycations was increased, this variation 
could be due to the solubility of the polycations in solution, as increasing 
concentration could lead to saturation.    
Since the overall objective was to provide a system for coating a stent surface, 
an in vitro model was designed to emulate this by using 316L surgical grade 
stainless steel discs as a substitute for bare metal stent surfaces. The discs were 
coated with (chi-ha)8chi PEM using the layer by layer deposition techniques 
developed previously and then incubated with Ad5 CMV lac Z. Uncoated SS and 
SS-chi monolayer with Ad5 CMV lac Z were also used to enable a comparison to 
be made to the PEM, non-treated A10 cells were used as a negative control. 
Once the discs were coated they were washed with PBS and were placed face 
down onto A10 cells that had been plated for 24 h prior. This was to mimic the 
contact between the stent surface and the vessel wall which would occur in an 
in vivo setting. The discs were left for 72 h before the cells were harvested and 
the amount of virus transduction was quantified by performing a β-gal assay 
(Figure 3-8) (section 2.8.4). 
 
Chapter 3  120 
 
C
o
n
tr
o
l
S
S
S
S
 +
 C
h
it
o
s
a
n
 m
o
n
o
la
y
e
r
S
S
 +
 C
h
it
o
s
a
n
 P
E
M
0
5.0106
1.0107
1.5107
*
ns ns
+ Ad 5 CMV lac Z
R
L
U
/m
g
 p
ro
te
in
 
Figure 3-8 Transduction of A10 cells with Ad5 CMV lac Z from Stainless Steel surfaces 
A10 cells were treated with medium (control) or Ad5 CMV lac Z (4.8 x 1010 VP/disc) incubated on 
SS discs, SS + chitosan disc, or SS (chi-ha)8chi PEM discs and left for 72 h. A β-galactosidase 
assay was used to determine the β-gal expression by measuring the relative light units (rlu) 
normalised to the protein concentration (mg). Results are displayed as mean ± SEM, statistical 
analysis was performed using an unpaired student’s t test, *p<0.05, ns=non-significant vs SS 
control. Representative graph from three independent experiments. 
From each of the SS surfaces virus transduction was observed. Using the SS (chi-
ha)8chi PEM as a method for depositing the virus onto the SS surface yielded a 
1.7 fold increase, compared to the SS control, however this did not reach 
significance. The chitosan monolayer deposited onto the SS yielded a 0.7 fold 
increase in virus transduction.  
In order for chitosan to act as a polyelectrolyte it was dissolved in acetic acid 
solution, to protonate the amine groups (Rinaudo et al., 1999). To work out the 
optimal conditions for viral transduction the %weight (wt) acetic acid was 
probed. Different %wts of acetic acid were used to modify the pH of the chitosan 
solution the virus was incubated in and then were applied to the A10 cells for 3 
h. The virus chitosan solution was then removed and then medium was replaced 
and the cells left for 72 h in culture. Virus Transduction was monitored by 
performing a β-gal assay (Figure 3-9) (section 2.8.3). 
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Figure 3-9 Transduction of A10 cells with Ad5 CMV lac Z in chitosan solution with 
different concentrations of acetic acid. 
A10 cells were treated with medium (control) or Ad5 CMV lac Z (1000 VP/cell) with polycationic  
chitosan (0.1% wt) dissolved in acetic acid at concentrations 0, 0.002, 0.006, 0.01, 0.02, 0.05, 0.1, 
0.2% wt, for 3 h, the virus was then removed and replaced with fresh medium and left for 72 h. A β-
galactosidase assay was used to determine the β-gal expression by measuring the relative light 
units (rlu) normalised to the protein concentration (mg). Results are displayed as mean ± SEM, 
statistical analysis was performed using an unpaired student’s t test,***p<0.001 **p<0.01, *p<0.05 
ns=non-significant vs 0 mg/mL control. Three biological triplicates were performed per condition. 
Prior to this experiment the chitosan (0.1% wt) and acetic acid (0.2% wt) 
concentrations were used as described in the literature (Meng et al., 2009a). 
The %wt acetic acid was varied from 0.2% to 0% and comparisons were made to 
the original concentration of 0.2%, the concentration of chitosan was kept 
constant at 0.1% wt. An optimal concentration of 0.006% wt acetic acid was 
found which increased virus transduction by 58 fold. Increasing the % of acetic 
acid in chitson solution and therefore lowering the pH of the solution has an 
initial beneficial effect on virus transduction, however at higher concentrations 
of acetic acid the low pH is likely to disrupt the structure of the adenovirus, 
which will prevent viral transduction.    
Using this optimised concentration of acetic acid for virus transduction, PEMs 
were deposited onto a SS disc and the virus was incubated onto the surface. The 
discs were placed face down onto pre-plated A10 cells and left for 72 h. Virus 
transduction was measured using a β-gal assay (Figure 3-10). 
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Figure 3-10 Transduction of A10 cells with Ad5 CMV lac Z deposited on (chi-ha)8chi PEM 
coated SS disc. 
A10 cells were treated with medium (control) or Ad5 CMV lac Z (4.8 x 1010 VP/disc) incubated onto 
an uncoated SS disc or on a SS disc coated with (chi-ha)8-chi PEM. The chitosan solutions in the 
PEM were prepared; (0.1% wt) dissolved in the original and optimised concentrations of acetic acid 
(0.2%and 0.006% wt).The discs were left for 72 h. A β-galactosidase assay was used to determine 
the β-gal expression by measuring the relative light units (rlu) normalised to the protein 
concentration (mg). Results are displayed as mean ± SEM, statistical analysis was performed 
using an unpaired student’s t test, **p<0.01, ns=non-significant vs 0.2% wt acetic acid PEM 
control.Representative graph from three independent experiments; each with three biological 
replicates per condition. 
Using the optimised concentration of acetic acid (0.006% wt) for virus 
transduction an increase of 2.2 fold was recorded when the virus was delivered 
to the cells by a chi-ha PEM coated SS disc compared to when 0.2% wt acetic 
acid was used. This indicated that by changing this parameter a better delivery 
system for the virus was obtained.  
The next step was to see whether delivery could be achieved from a SS bare 
metal stent (BMS) as a platform instead of a SS disc in an ex vivo setting. Gazelle 
BMS were coated with (chi-ha)8chi PEM and Ad5 luciferase, using the methods 
developed (section 2.8.4), the stents were deployed into rat carotid arteries ex 
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vivo. No virus transduction was observed using this system; this could have been 
because the electrostatic interactions that the virus was attached to the stent 
surface with were not strong enough to withstand stent deployment. Therefore, 
methods for covalently bonding the virus directly to the surface were 
investigated. 
3.2.2 Covalent attachment of virus to PLA surfaces 
3.2.2.1 Hydrolysis of PLA 
To enable a covalent bond to form between the stent surface and the virus 
capsid, a suitable material needed to be carefully chosen which would allow 
chemical modification of the stent material. Poly lactic acid (PLA) was chosen 
for this role because it is the most commonly used material for biodegradable 
stents and is an organic polymer, therefore, chemical modification of the 
surface was considerably more straightforward than for BMS (Wiebe et al., 
2014).  
 
Figure 3-11 Chemical structure of PLA. 
 
PLA does not have any reactive side chains so introduction of reactive groups 
was needed if a covalent bond was to be formed between the virus and the PLA 
surface. One method of doing this is by alkaline hydrolysis of the polymer to 
form hydroxyl and carboxyl groups. These groups could then be used to react 
with other chemical species (Yang et al., 2003). 
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Scheme 3-1 Mechanism for hydrolysis of PLA (Maharana et al., 2009).   
In order to investigate the extent of hydrolysis occurring on the PLA surface 
after exposure to 1 M NaOH solution, the %wt loss of the PLA squares were 
measured as a function of time. A higher %wt loss of the PLA indicated a greater 
degree of hydrolysis (Figure 3-12).  
 
 
Figure 3-12 %wt loss of PLA after exposure to 1 M NaOH solution at different time points. 
PLA squares were weighed prior to exposure of 1 M NaOH solution and after exposure for 5 mins, 
4 h and 24 h. The control PLA was exposed to dH2O for 24 h. Representative graph from three 
independent experiments, n=1 per condition. 
It was observed that increasing the length of treatment of the PLA in the 1 M 
NaOH solution increased the %wt loss of PLA indicating that hydrolysis had 
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occurred. As the proposed function of the PLA is for a cardiovascular stent it was 
important to maintain the structural properties of the polymer and achieve a 
balance between surface functionality and structure. Therefore, for future 
experiments it was decided that exposing the PLA to 1M NaOH for 5 mins would 
be adequate to ensure the generation of carboxyl groups but not cause bulk 
degradation of the PLA. As increasing the time of exposure of biodegradable 
polymers to degrading solutions increases the amount of bulk degradation 
occurring in the polymer structure (von Burkersroda et al., 2002)   
3.2.2.2 Activation of carboxyl groups on PLA surfaces by treatment with 
EDC/NHS 
After the hydrolysis of the PLA surface, activation of the carboxyl groups was 
needed in order to create a surface that would covalently bind viruses or other 
biological materials to the stent surface. A proposed route of carboxyl activation 
using 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and N-
hydroxysuccinimide (NHS)  was envisaged  to yield NHS esters as reactive 
intermediates (Scheme 3-2). NHS esters can readily undergo condensation 
reactions with primary amines to form a covalent bond. Since the virus capsid 
has lysine residues, which have a primary amine functional group, it could 
therefore be possible to link the virus to the PLA surface using this route.   
 
Scheme 3-2 EDC/NHS activation of PLA surface. 
 
To test this reaction pathway for surface activation, the PLA was hydrolysed, 
treated with EDC/NHS and then reacted with hexamethyldiamine (HMD). A 
ninhydrin test was then performed to test for the presence of amines on the 
surface.  
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Figure 3-13 Treatment of PLA with ninhydrin to test for primary amines on the PLA 
surface. 
 
It was observed that the PLA control tested negative for amines whereas the 
NHS/EDC modified PLA was positive (section 2.14.3), exhibiting a purple PLA 
surface. Interestingly, it was observed that direct aminolysis could occur 
between the PLA surface and the HMD bypassing the need for EDC/NHS 
activation (Figure 3-13) (section 2.14.5). Quantification of the amount of 
aminolysis occurring was attempted by dissolving the PLA in solvent and then 
measuring the UV-absorbance, however the process of exposing the PLA to the 
solvent caused the purple compound to degrade. 
Since an established route to yield a PLA surface modified with primary amine 
groups was achieved. We wanted to test whether it would be possible to get a 
controlled binding and elution from the PLA surface of benzaldehyde by imine 
formation. Benzaldehyde was chosen because it can readily react with amine 
groups to form imines and is UV active so it could be detected by UV-vis 
spectroscopy (Scheme 3-3). 
 
Chapter 3  127 
 
 
Scheme 3-3 Reaction of aminolysed PLA with benzaldehyde to show controlled elution. 
 
 
Figure 3-14 UV absorbance at 220 nm of 1 M HCl solutions after exposure to PLA surface 
following benzaldehyde conjugation. 
PLA squares were aminolysed using the two methods detailed in Figure 3-13 and reacted with 
benzaldehyde, the squares were washed with dH2O and then treated with 1 M HCl solution. The 
absorbance at 220 nm was measured of the HCl solutions to test for benzaldehyde elution from the 
surface. Results are displayed as mean absorbance at 220 nm± SEM, statistical analysis was 
performed using an unpaired student’s t test, ns=non-significant vs PLA non-treatment 
control.Representative graph from three independent experiments; each with three replicates per 
condition. 
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After treatment of the PLA with benzaldehyde, the PLA was washed with dH2O 
to ensure any residual unbound benzaldehyde was rinsed away. To remove and 
detect the benzaldehyde, that had bound to the PLA, the surface was treated 
with 1 M HCl. UV-vis spectroscopy was used to monitor the HCl solutions to test 
for the presence of benzaldehyde; however a change in the absorbance at 220 
nm was not observed (Figure 3-14). This could have been due to imine formation 
being a reversible process and susceptible to hydrolysis by dH2O in the washing 
steps. Due to the instability of the imine bond, a different method was needed 
which yielded a bond which was not susceptible to water hydrolysis. Protecting 
group FMOC-lysine was proposed; as the lysine group would be a good ‘model’ 
for the virus capsid (which would also react through the lysine amino acid 
residue). The FMOC group could be cleaved and detected by UV-vis spectroscopy 
and ESI-MS, enabling verification of the success for this PLA surface modification 
procedure by controlled binding and elution (Figure 3-15). 
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Figure 3-15 A) Chemical structure of FMOC-lysine, B) Deprotection of PLA-FMOC-lysine 
using piperidine. 
 
In order to follow the deprotection of the FMOC-lysine, electrospray ionisation 
mass spectra were taken before and after deprotection (Figure 3-16) (section 
2.14.7).  
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Figure 3-16 ESI-MS of FMOC lysine deprotection in solution after treatment with 
piperidine. 
A)FMOC lysine before piperidine deprotection B)FMOC lysine after piperidine deprotection. 
As characteristic spectra of the protected and deprotected FMOC-lysine were 
obtained, using ESI-MS. Testing to see whether FMOC-lysine could be deposited 
on the PLA surface and then FMOC cleavage could be monitored to verify that 
attachment of the FMOC-lysine to the surface had been successful. 
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Figure 3-17 UV-vis of washes with EtOH of PLA surface after FMOC functionalisation. 
A) Aminolysis and B) EDC/NHS activated PLA surface.  
Two different methods were tested for FMOC-lysine functionalisation of the 
PLA;direct aminolysis of the amine group on FMOC-lysine reacting with PLA 
surface and via hydrolysis followed by EDC/NHS activation of carboxyl groups, 
with the resulting NHS-ester reacting with the amine group from FMOC-lysine. 
After FMOC-lysine was left to react with the surface, it is important to wash the 
surface thoroughly to ensure any unbound FMOC lysine was washed off. This was 
monitored by UV-vis spectroscopy (Figure 3-17). 
As demonstrated by the UV-vis traces in Figure 3-17, we can see that all the non-
bound FMOC-lysine was efficiently removed from the surface as the UV signal of 
the EtOH washes drops to zero with successive washing. 
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In order to test for the presence of FMOC-lysine to see whether the conjugation 
to the PLA had been successful, piperidine was then added to the PLA surface, 
which would release the fluorenyl group that could be detected by and UV 
spectra and ESI-MS (Figure 3-18&Figure 3-19). 
 
 
Figure 3-18 UV-vis spectra of piperidine solutions after removal of FMOC group. 
Black) aminolysis PLA, red) EDC/NHS activated PLA. 
 
 
Figure 3-19 ESI-MS of PLA after FMOC deprotection. 
Above) Deprotected FMOC/lysine in solution Below) Deprotected solution from EDC/NHS activated 
PLA. 
By comparison with the spectrum of the deprotected FMOC-lysine (Figure 3-19) 
it was observed that, the peak at 264 m/z, which corresponds to the fluorenyl-
piperidine adduct appears in both spectra, confirming that the FMOC-lysine was 
Chapter 3  133 
 
successfully attached and eluted off from the PLA surface. A spectrum from the 
direct aminolysis PLA was also taken but no corresponding peaks were found, 
which was consistent with the UV-vis data (Figure 3-18).   
As a successful method for attachment and elution of FMOC-lysine to the PLA 
surface was found, it was important to repeat the methodology, to make sure 
that the method was robust before moving on to viral attachment and elution. 
However, disappointingly this method did not always work reliably; therefore 
other methods for attaching the adenovirus to the surface were investigated. 
3.2.3 Collagen Entrapment of Virus onto PLA surfaces 
A different method for coating stent materials with virus was investigated by 
entrapping the virus into a collagen gel, which was set onto the stent material. 
Atthoff et al. had previously reported the observation that collagen could be 
directly deposited onto PLA surfaces, and that modification of the PLA by 
hydrolysis prior to collagen deposition did not enhance that amount of collagen 
deposited, however the absorption kinetics did vary when monitored by a quartz 
crystal microbalance (QCM) (Atthoff and Hilborn, 2007). Therefore it was 
hypothesised that PLA would be a promising material to use for collagen 
deposition; firstly entrapment of the adenovirus into the collagen gel would be 
achieved by mixing the two components together, this could then be spread onto 
a PLA surface and heated to 37 oC in order to form a collagen-adenovirus gel.    
3.2.3.1 Visualisation of Ad-555 in collagen gel set onto PLA surfaces 
Initially, we wanted to test whether it would be possible to encapsulate the 
virus into a collagen gel, and set onto a PLA disc. In order to visualise whether 
encapsulation of the virus had been successful, Ad5 labelled with Alexa Fluor™ 
555 was used so that, after washing the PLA, we could see if the virus was still 
retained on the PLA surface within the collagen gel. Figure 3-20 shows that the 
Ad5 can be successfully retained onto the PLA surface by entrapment within the 
collagen gel. This method could therefore provide a route for attachment onto a 
PLA stent, providing the virus is able to be released from the collagen gel and is 
still biologically active.     
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Figure 3-20 Fluorescent micrographs of PLA surfaces with fluorescently tagged Ad5. 
PLA + collagen and PLA surface + Ad555 were used as controls. PLA collagen Ad555 as test for 
collagen entrapment of virus and retention on the PLA surface. Scale bar = 100 μm. Images taken 
at 40 x magnification. 
3.2.3.2 In vitro transduction of adenovirus from collagen coated PLA and SS 
surfaces 
Since we could visualise the adenovirus successfully encapsulated and secured 
onto the PLA surface within the collagen gel, it was important to find out 
whether the virus maintained its biological viability and whether it would be 
able to be released from the collagen gel and transduce cells. 
This was tested in vitro by coating PLA surface with Ad 5 either encapsulated 
within the collagen gel or directly onto the PLA surface. A positive control for 
Ad5 transduction was used to ensure the reporter assay was working and a 
negative control of non-treated rat SMC was used to gauge background levels of 
absorbance. Once the surfaces were prepared they were washed thoroughly with 
PBS before being placed face down onto the rat SMC. These washing processes 
were to test the robustness of the collagen gel because if this was applied in 
vivo, blood flow would cause a similar obstacle. A β-galactosidase assay was 
performed after 72 h of incubation of the surfaces with the cells (Figure 3-21).  
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Figure 3-21 Transduction of A10 cells with Ad5 CMV lac Z encapsulated in collagen and 
deposited on PLA surfaces. 
A10 cells were treated with medium (white), or Ad5 CMV lac Z (blue),Ad5 CMV lac Z directly onto 
PLA (red), PLA + collagen + Ad5 CMV lac Z (red), the virus concentration was(6.6 x 109 VP/disc). 
The discs were placed onto the A10 cells and left for 72 h, they were then removed, the cells were 
washed and a β-galactosidase assay was used to determine the β-gal expression by measuring 
the relative light units (rlu) normalised to the protein concentration (mg). Results are displayed as 
mean ± SEM,statistical analysis was performed using an unpaired student’s t test, ***p<0.001, 
**p<0.01, vs non-treated cell control, representative graph from three independent experiments 
with three biological replicates for each condition. 
It was observed that the virus maintains its biological activity when encapsulated 
into the collagen gel and is released from the collagen gel within the 72 h 
timeframe. High levels of β-galactosidase expression are observed from the PLA 
+ collagen and give levels of transduction, which are significantly higher than 
when the virus is coated onto the PLA directly without the collagen. When β-
galactosidase expression of the PLA collagen is compared to the Ad5 in solution 
control, at 72 h are significantly higher for the Ad5 in solution. This could be due 
to some virus particles being washed off during the preparation procedure, 
similarly it could also indicate that residual virus is still trapped in the collagen 
gel. Further testing at different timepoints would be required to give more 
information on the elution profile of the virus from the collagen gel.  
Although PLA stents can be purchased, currently commercial PLA stents have an 
everolimus coating on them and would interfere with SMC proliferation (Khamis 
et al., 2014, Abbott, 2015). Therefore in order to test the efficacy of virus 
transduction from stent surfaces, it was important to develop a delivery system 
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from 316 L stainless steel which is the material that most bare metal stents are 
made from. As BMS are a longer established cardiovascular technology there is a 
broader range of different stent sizes for animal models such as pigs and mice 
and can be obtained without anti-proliferative drugs coated on them. It would 
be advantageous if we could translate the collagen-virus encapsulation onto SS 
surfaces. 
In order to compare collagen encapsulation of the virus on PLA and SS surfaces, 
a β-galactosidase assay was carried out comparing the two surfaces with Ad5 in 
solution as a positive control and non-treated rat SMC cells as a negative control.  
 
Figure 3-22 Transduction of A10 cells with Ad5 CMV lac Z encapsulated in collagen and 
deposited on PLA and SS surfaces. 
A10 cells were treated with medium (white), or Ad5 CMV lac Z (blue),Ad5 CMV lac Z onto PLA + 
collagen (red), and SS + collagen (grey), virus concentration was (6.6 x 109 VP/disc/well). The 
discs were placed onto the A10 cells and left for 72 h, they were then removed, the cells were 
washed andaβ-galactosidase assay was used to determine the β-gal expression by measuring the 
relative light units (rlu) normalised to the protein concentration (mg). Results are displayed as mean 
± SEM,statistical analysis was performed using an unpaired student’s t test ***p<0.001, **p<0.01, 
vs non-treated cell control, representative graph from three independent experiments with three 
biological replicates for each condition. 
After 72 h, cells were harvested and the amount of transgene expressed was 
quantified (Figure 3-22). It was observed that the PLA surface is a more efficient 
Chapter 3  137 
 
platform for the collagen virus encapsulation, with 2 fold increase in transgene 
expression from the PLA collagen compared to the SS surface. This could be due 
to improved adherence of the collagen gel onto the PLA surface and therefore 
more of the collagen virus gel could have been removed during the washing 
steps from the SS surface. 
3.2.3.3 Quantification of virus deposited on PLA and SS surfaces 
In order to gain more insight into the amount of virus on the surface, a method 
for quantification needed to be developed. Two different methods were 
investigated microBCA and qRT-PCR. The microBCA assay works by quantifying 
the amount of protein present from the viral capsid whereas qRT-PCR measures 
the amount of viral DNA. A ten-fold dilution of the stock virus solution was made 
to obtain concentrations from 5 x 1010 – 5 x 101 VP/mL. These solutions were 
tested for protein concentration by performing a microBCA assay or for viral DNA 
concentration by qRT-PCR.  
 
Figure 3-23 microBCA assay of serial dilution of Ad5 CMV lac Z 
A 10 fold serial dilution of Ad5 CMV lac Z was made to make concentrations 5 x 1010 – 5 x 101 
VP/mL range and microBCA assay was run for these solutions to measure the protein content. 
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Figure 3-23 shows the results for the microBCA assay performed on the viral 
dilutions. It was clear that this method is only effective at relatively high 
concentration of adenovirus (1 x 109-1 x 1011VP/mL), so would not be sensitive 
enough to detect the amount of virus deposited on the surfaces. In addition, the 
method used for binding the virus to the surface uses encapsulation in a collagen 
gel, which is also a protein, this would cause background levels of absorbance 
and may saturate the signal caused by virus deposition. 
 
Figure 3-24 qRT-PCR from a serial dilution of Ad5 CMV lac Z. 
A 10 fold serial dilution of Ad5 CMV lac Z was made to make concentrations 5 x 106 – 5 x 1010 
VP/mL range, quantification of the DNA was done by performing DNA extraction on all the samples 
followed by reverse transcription and qRT-PCR. 
Using the qRT-PCR method would give access to greater sensitivity ranging from 
1 x 109-1 x 105 VP. Although this method was more time consuming, it offers a 
higher sensitivity which would be suitable for monitoring the amount of virus on 
a surface. 
The general approach for measuring the amount of virus on a surface was 
reported (Johnson et al., 2005a), whereby the amount of virus attached to the 
surface, is estimated to be equal to the total amount of virus added, minus the 
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virus removed in the washing steps. DNA extraction and qRT-PCR was used to 
determine the virus concentrations before being applied to the surface and using 
the PBS wash solution (to infer how much virus was retained on the surface 
within the collagen gel) (Figure 3-25).  
 
Figure 3-25 qRT-PCR of serial dilution of Ad5 CMV lac Z and of washings from collagen 
coated PLA surfaces. 
A 10 fold serial dilution of Ad5 CMV lac Z was made to make concentrations 5 x 1010 – 5 x 101 
VP/mL range (blue), samples were also made using the total amount of virus deposited onto the 
surfaces (orange), washings after collagen gel virus deposition on SS surface (grey) and from PLA 
surface (red). Quantification of the DNA was done by performing DNA extractions on all the 
samples followed by qRT-PCR. 
In agreement with the observations made previously (Figure 3-22), more virus 
was retained on the PLA collagen surface compared to the SS surface. An 
estimate for the amount of virus left on the PLA collagen surface was 1.20 x 109 
VP/mL, and for the SS collagen it was 1.01 x 109 VP/mL.  
Having identified that PLA retains more virus particles on the surface using the 
collagen entrapment of the adenovirus method than the SS. PLA surfaces were 
used in the next experiments. For all the experiments up to this point 
adenovirus 5 was chosen as a model virus vector for attachment to the stent 
surfaces. This was because it can be produced in high titre stocks, it has a high 
levels of transduction in a broad range of cell types, and insertational 
mutagenesis is uncommon, and is the most commonly used viral vector for gene 
Chapter 3  140 
 
therapy (Bradshaw and Baker, 2013). However, one of the disadvantages with 
Ad5 is the existing level of anti-Ad5 antibodies within the human population, it is 
therefore important to develop rare or non-human serotypes of virus for gene 
therapy. Ad 49, is a promising novel vector for gene therapy because it does not 
cross react with Ad5 neutralising activity (Lemckert et al., 2006). Ad 49 was 
therefore chosen to see whether it could be incorporated into the collagen 
coating and maintain its biological activity (Figure 3-26). However as shown in 
Figure 3.26, incorporation of Ad 49 into the collagen gel was not successful, 
indicating that this technique may be sensitive to different adenoviral serotypes.  
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Figure 3-26 Transduction of Ad5 CMV lacZ and Ad49 from collagen coated PLA surfaces. 
Above) Ad5β-galactosidase activity in lysates of A10 rat SMCs, for PLA+ collagen+Ad5 (red), PLA 
surfaces – collagen + Ad5 (red) and Ad5 in solution (blue). Below) lysates of A10 SMCs tested for 
luciferase activity after culture with PLA + collagen+Ad49luc (red), PLA surfaces – collagen + Ad49 
luc (red) and Ad49luc in solution (green). Error bars are shown as mean ± SEM, significance was 
determined by student’s t-test compared to control, ns= non-significant, ***p<0.001. Each group 
was run as a biological triplicate. 
PLA stents are not currently manufactured for mice, and human PLA stents are 
coated with anti-proliferative drug everolimus (Abbott, 2015). Therefore, in 
order to move from in vitro testing of the delivery system to ex vivo and in vivo 
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testing, a method for coating PLA onto SS was needed to be developed. This 
would allow BMS coated with PLA to be used as a platform for collagen Ad5 gel 
to be applied to. A method for doing this was investigated by dissolving the PLA 
in chloroform and then applying onto the SS surface and leaving it to dry. This 
method worked well and the PLA coating adhered well to the SS surface and did 
not get removed after extensive washing. Using this method, the PLA coated 
onto the surface was not very uniform, so methods for smoothing the PLA layer 
was achieved by exposing the PLA to vapourised dichloromethane.  
To test the effect of PLA concentration (%wt/wt) applied to the SS on Ad5 
transduction from the collagen gel, SS discs were coated with 10% wt/wt, 15% 
wt/wt and 20% wt/wt PLA in chloroform and then collagen-Ad5 gel and applied 
to the surfaces. PLA discs with collagen Ad5 gel, and Ad5 in solution were used 
as positive controls and to provide a point of comparison for the SS surfaces. 
Non-treated cells were used as a negative control. The discs were on the cells 
for 72 h, before being removed and a β-galactosidase assay was used to evaluate 
the amount of transgene expressed.    
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Figure 3-27 Transduction of A10 cells with Ad5 CMV lacZ encapsulated in collagen and 
deposited on PLA and SS and SS coated in PLA surfaces. 
β-galactosidase activity in lysates of A10 rat SMCs after culture with PLA and SS surfaces coated 
with collagen virus gel for 72 h. NTC (white), Ad5 in solution (6.6 x 109 VP) (blue), PLA coated with 
collagen Ad5 gel (red), SS coated with collagen Ad5 gel (grey), SS coated with different %PLA 
dissolved in chloroform wt/wt then coated in collagen virus gel (grey). Error bars are shown as 
SEM, significance determined by students t test compared to non-treatment control, ns= non-
significant, *p<0.05, **p<0.01, ***p<0.001. 
When SS was coated with 20% PLA we observed a significant difference in β-
galactosidase expression when compared to control cells. However, using a 20% 
of PLA on the metal surface is likely to cause logistical problems for the stent as 
it may be too thick to fit into the guide catheter. The coating may also fill the 
space in between the stent struts and could alter and prevent inflation of the 
stent when it is expanded by the balloon. 
To move forward with ex vivo testing of the coatings, a suitable concentration of 
virus was needed to be identified. This was determined by bathing mouse aorta 
in different concentrations of Ad5 CMV lac Z, leaving in medium for 72 h then 
staining with X-gal to visualise β-galactosidase expression. Mouse aortas were 
exposed to Ad5 at concentrations varying from 5 x 109 VP/mL to 5 x 1011VP/mL. 
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Blue cells were visible for the 5 x 1010 VP/mL and 5 x 1011 VP/mL so therefore 
the amount of virus put into the coatings will need to be within this range 
(Figure 3-28). 
 
Figure 3-28 X-gal stained mouse aorta after incubation with Ad5 CMV lac Z for 72 h. 
Microscope images were taken at 4 x magnification after incubation with Ad5 for 72 h and then 
fixed with PFA and X-gal stained. Control was not treated with Ad5, the other aortas were exposed 
to Ad5 at concentrations5 x 109 VP/mL Ad5, 5 x 1010 VP/mL, and 5 x 1011 VP/mL. 
Since a concentration of Ad5 CMV lac Z had been determined which achieve 
transduction of mouse aortas ex vivo, testing to see whether transduction could 
now be achieved from PLA surfaces coated with the Ad5 collagen gel was 
undertaken (Figure 3-29). PLA surfaces were coated with Ad5 CMV lacZ collagen 
gel at concentration 5 x 1011 VP/mL.  
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Figure 3-29 X-gal stained mouse aorta after incubation with Ad5 CMV lacZ collagen gel 
coated onto PLA for 72 h. 
Microscope images were taken at 4x magnification after incubation with Ad5 for 72 h and then fixed 
with PFA and X-gal stained. Control was not treated with Ad5, Ad5 positive control was exposed to 
Ad5 CMV lac Z solution at 5 x 1011 VP/mL, and the PLA collagen Ad5 was PLA coated with 
collagen Ad5 gel at the same concentration of 5 x 1011 VP/mL. 
Since transduction of Ad5 CMV lac Z was observed from the PLA Ad5 collagen gel 
(Figure 3-29), we now wanted to simulate stent deployment to see whether 
damaging the vessel would alter and enhance Ad5 delivery to the aorta. To test 
this, aortas were damaged by inflating a balloon that would usually be used for 
stent deployment, the balloon was removed and the aortas were cut 
longitudinally.  Ad5 collagen coated PLA were placed onto the aorta and left in 
culture medium for 72 h and were then stained with X-gal to visualise transgene 
expression (Figure 3-30).  
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Figure 3-30 X-gal stained mouse aorta ± balloon damage after incubation with Ad5 CMV 
lac Z collagen gel coated onto PLA for 72 h. 
Microscope images were taken at 4 x magnification after incubation with Ad5 for 72 h and then 
fixed with PFA and X-gal stained. Control was not treated with Ad5, Ad5 positive control was 
exposed to Ad5 CMV lac Z solution at 5 x 1011 VP/mL, and the PLA collagen Ad5 was PLA coated 
with collagen Ad5 gel at the same concentration of 5 x 1011 VP/mL. Aortas in the + balloon damage 
group were damaged by inflating a coronary balloon for 10 seconds placement of the PLA surfaces 
onto the vessels.   
From the resulting images of the vessels (Figure 3-30), we did not observe any 
difference in the amount of Ad5 transduction when the vessel is injured with the 
balloon. The next step for was to translate this delivery system, which works 
very effectively on the PLA surfaces, to work from murine stents. This was 
tested by coating the murine stents with 10% wt/wt PLA and then applying the 
collagen-Ad5 gel onto the PLA coated stent and deploying into mouse aortas ex 
vivo. However, after leaving for 72 h and staining with X-gal, no virus 
transduction was observed from the stents. 10% wt/wt PLA was the highest 
concentration of PLA that allowed full expansion of the mice stents. However, if 
we look at previous in vitro results using this concentration of PLA applied on SS 
discs, very low levels of Ad5 transduction are observed (Figure 3-27), which may 
explain why this concentration of PLA did not enable Ad5 transduction ex vivo.   
In order to develop a stent which could be used in the porcine model, human 
Gazelle BMS stents were coated with higher concentrations of PLA. It was 
hypothesised that due to the human stents inherent greater mechanical strength 
they would still allow for stent expansion by the balloon despite the 
concentration of PLA being greater than for the murine stents. The stents were 
therefore coated with 20% wt/wt PLA. To test whether Ad5 delivery from the 
BMS coated with PLA was possible, Ad5 collagen gel was applied to the BMS PLA 
and then deployed into a pig coronary ex vivo (Figure 3-31).  
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Figure 3-31 X-gal stained pig coronary arteries after Ad5 CMV lac Z collagen gel was 
coated onto PLA 20% wt/wt BMS for 72 h. 
Images were taken after incubation with Ad5 for 72 h and then fixed with PFA and X-gal stained. A) 
Control was not treated with Ad5, b) Ad5 positive control was exposed to Ad5 CMV lac Z solution 
at 1.25 x 1012 VP, and c) the PLA collagen Ad5 was PLA coated with collagen Ad5 gel at the same 
concentration of 1.25 x 1012 VP/mL. 
The images in Figure 3-31, show that Ad5 transduction can be achieved from BMS 
surfaces, after coating with PLA (20% wt/wt) followed by the Ad5-collagen gel. 
However the same problem occurred as with the mice stents, the stent was 
unable to inflate properly due to the PLA coating restricting the stents 
flexibility. Further testing was done to try and find a concentration of PLA that 
would allow full inflation of the stent, but also ensure adherence of the Ad by a 
sufficient coating of PLA.  
In order to do this, three different concentrations of PLA were tested, 10%, 5% 
and 2.5% wt/wt PLA dissolved in chloroform. The stents were coated in collagen-
Ad5 gel and then inflated and deployed into pig coronary arteries. Transduction 
of the virus was measured, the results of which are shown in (Table 3).  
%PLA wt/wt Can the stent inflate? Virus transduction 
observed? 
10 No Yes 
5 Yes No 
2.5 Yes No 
Table 3          Results on %wt/wt PLA coating on BMS ability to be inflated and whether virus 
transduction was observed after the PLA coated BMS were then coated with Ad5 CMV lacZ 
collagen gel. 
Stents were coated with 10% wt/wt, 5% wt/wt, and 2.5% wt/wt PLA in chloroform. The stents were 
deployed into pig coronary arteries ex vivo and left for 72 h, the stents were then removed and 
virus transduction was visualised by fixing and staining the tissue with X-gal.   
These results indicate that when the stent is coated with 10% wt/wt PLA 
dissolved in chloroform, virus transduction can be achieved; however the stent 
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was not able to fully inflate due to the thickness of the coating. This would 
prevent it being used to deliver virus in vivo. However, when lower 
concentrations of PLA were used no virus transduction was observed, suggesting 
that adherence of the Ad5- collagen gel to the lower concentrations of PLA was 
not effective, although at these lower concentrations the stent could be 
deployed properly.  
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3.3 Discussion 
In this chapter three different methods for virus attachment to stent surfaces 
were investigated and evaluated using in vitro and ex vivo models. Due to the 
Ad5 virus’s net negative charge, it was thought that electrostatic interactions 
could provide the basis for adsorption onto stent materials which were coated 
with oppositely charged PEMs. Two different PEM systems were investigated, 
chi-ha and PAH-PSS, both of these systems demonstrated that the virus could be 
held onto SS surfaces coated with the PEM systems after extensive washing 
procedures as monitored by confocal microscopy; visualisation of the virus was 
enabled by using a fluorescently tagged virus, and by AFM.  
After confirmation that we could create a SS surface coated with Ad5 particles 
superficially, biological testing of Ad5 was completed in order to see if exposure 
of Ad5 to the polycationic solutions had an effect on viral transduction. A 
striking difference in activity was observed between the two polycations, 
chitosan and PAH. When Ad5 was incubated with a solution of chitosan, a 73 fold 
increase in β-galactosidase experession was observed when compared to the Ad5 
without the polycation, this increase in transduction could be attributed to 
increased viral uptake through a CAR independent pathway, via interaction of 
the negatively charged cell surface and the positively charged polycationic 
coating on the viral capsid (Zhong et al., 2011, Kawamata et al., 2002). It has 
also been suggested that electrostatic interactions alone cannot solely be 
attributed for the enhanced viral transduction with chitosan, and in addition we 
should consider the effect that chitosan has on decreasing the elasticity of cell 
membranes; a decrease in cell membrane elasticity has been linked to higher 
levels of virus transduction (Pavinatto et al., 2009).  As PAH and CHI are both 
polycationic amine based polymers, it would be expected that they would  
behave in a similar way and increase virus transduction as a result of their 
electrostatic interactions through the charged amine groups. In a study by 
Pavinatto et al.,a comparison between PAH and Chi  was made on phospholipid 
membranes, in which chitosan was shown to decrease the elasticity of the 
membrane whereas PAH did not exhibit the same effect (Pavinatto et al., 2009). 
This could therefore explain the observation that exposure of the Ad5 to the PAH 
polycation, did not cause the same augmentation in viral transduction that was 
present when the virus was exposed to the chitosan solutions.  
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The (chi-ha)8chi PEM was therefore taken forward for further in vitro testing 
from SS discs and the composition was optimised to get enhanced virus 
transduction. Whilst this PEM did show positive results as a surface for virus 
retention and delivery, it did not perform well in the ex vivo testing and 
therefore did not warrant in vivo testing. PEMs were chosen as a potential 
method for delivery of virus’ from stent surfaces because they are suitable for 
delivery of biomacromolecules unlike more traditional methods for delivery of 
smaller drug molecules, which rely on mixing polymers with the drug molecule 
and then coating onto the stent surface; the drug molecules then diffuses out of 
the polymer over time providing localised temporal delivery (Saurer et al., 
2011). There are a few studies which have demonstrated virus incorporation and 
delivery from PEMs using various in vitro set ups (Dimitrova et al., 2007, Yoo et 
al., 2008); however despite in depth characterisation of the PEMs, translation of 
the PEMs as a material for delivery ex vivo and in vivo has not been reported. 
This could be due to a number of reasons, however in the context of PEMs on 
stent surfaces, the most likely explanationis that they are not stable enough as 
there are no covalent bonds formed between the PEM and the SS surface, 
therefore they could detach from the surface during the involved stenting 
procedure. 
The following approach to create a surface for viral attachment to stent surfaces 
consequently involved devising a method in which the virus was bound to the 
surface by covalent interactions, thereby providing a robust link between the 
virus and the stent surface that would be able to withstand stent deployment 
procedures. SS has been used for medical implants since 1930, and is still widely 
used today (Niinomi, 2002). The reason for its suitability for this role is that it 
has structural strength needed for applications such as intravascular stents, but 
also it is inert and unreactive and does not react adversely with the body. It is 
also for this reason that surface modification of SS is extremely limited due to 
the inherent inert behaviour. Therefore other stent materials were considered 
as starting points to develop a covalent link between the stent surface and the 
virus.  
Recently we have observed the emergence of bioresorbable stents onto the 
market, which are made from materials which biodegrade over time such as PLA; 
therefore the implanted stent is a transient scaffold unlike previous bare metal 
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and drug eluting stents. This ability to biodegrade is thought to reduce the risk 
of late stent thrombosis, neoartherosclerosis and local inflammation because 
there will be no residual stent/polymer left in the artery. It would also decrease 
the need for long-term dual-anti platelet therapy, thereby reducing side effects 
such as bleeding. They could also avoid problems associated with permanent 
scaffolds such as the blockage of side branches and is compatible with IVUS 
imaging(Serruys et al., 2012, Bourantas et al., 2012). 
Although PLA itself does not contain reactive groups on its surface which could 
be used to covalently link the virus to the surface, there are several methods 
available which can generate reactive sites by wet chemistry methods; one way 
to introduce reactive groups on to the surface is by alkaline hydrolysis, 
generating hydroxyl and carboxyl groups which will then be able to react with 
other chemical species (Yang et al., 2003). Another method is by direct 
aminolysis by reacting PLA with 1,6-hexanediamine this method generates amine 
groups on the surface of the PLA which can then be conjugated with other 
molecules such as caffeic acid (Chuysinuan et al., 2012). Both these routes of 
hydrolysis and aminolysis were successful in generating reactive groups on the 
surface of PLA as demonstrated by %wt loss and using the ninhydrin assay for 
amines.  
Instead of using the virus directly to bind to the surface, using small molecules 
such as benzaldehyde and FMOC-lysine as a ‘model virus’ would enable a simple 
readout to see if the chemistry modification of the PLA surface was successful. 
Benzaldehyde was used initially as this can readily form imines with primary 
amine groups, and can be removed using HCl. Benzaldehyde is also UV active, 
thus detection of benzaldehyde is straightforward, however due to the 
reversible nature of the imine bond formation, and the necessity of the dH2O 
washing steps, detection of benzaldehyde was not observed. 
FMOC-lysine was then chosen as a compound to react with the derivatised PLA 
surface. FMOC-lysine, provided a more relevant model as a virus, because the 
lysine moiety on adenovirus particles would have the same reactivity as the 
FMOC lysine group through the primary amine group. In order to react the 
carboxyl groups on the PLA surface with the amine group from FMOC-lysine, 
EDC/NHS activation was employed. FMOC-lysine has a protecting group on the 
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amine group that would usually react with carboxylic acid groups of adjacent 
amino acids to form peptide chains, it was envisaged therefore that after 
reacting FMOC-lysine with the PLA surface, the FMOC protecting group could 
then be deprotected with piperidine, releasing fluorenyl-piperidine, which could 
be detected by ESI-MS, as well as UV-vis spectroscopy. This proved to be 
successful; however using this methodology FMOC-lysine did not reliably bind to 
the surface. In order to progress to a workable virus covalently bound stent 
surface, whereby the virus could elute off, further investigation and 
development of the polymer would be needed in order to introduce a labile site 
to enable the virus to detach and enter the surrounding cells. Different 
approaches were therefore investigated which would provide an intermediate 
between the robustness and permanency of covalent bonding and the instability 
of the PEMs for this application.    
The next approach that was investigated involved mixing the virus with collagen 
and then setting onto SS and PLA surfaces. Using collagen as a method for 
adenovirus attachment had previously been documented by Levy and co-
workers, however they also employed anti-adenoviral monoclonal antibodies 
which were covalently bound to the collagen surface; this provided a surface 
upon which the adenovirus could be selectively tethered. This method proved 
successful in vivo, with a transduction efficiency of 5.9% of porcine arterial 
smooth muscle cells (Klugherz et al., 2002a). In the present study a comparison 
of SS and PLA surfaces for deposition of the collagen virus gel and subsequent 
transduction of A10 cells, revealed that twice the amount of transduction was 
monitored from the collagen virus gel on the PLA surface than the SS surface. 
This differed in the approach as documented by Levy and co-workers as the virus 
was encapsulated within the collagen gel and antibodies were not used to aid 
tethering, allowing for a more simplified method of attachment (Klugherz et al., 
2002a). To confirm that this was due to more virus retained on the PLA surface, 
qRT-PCR was used to quantify how much virus was washed off the surface prior 
to incubation of the surfaces with A10 cells. This confirmed that more virus was 
washed off from the SS surfaces compared to the PLA surface, indicating that 
PLA was the optimal material for further development of the collagen 
encapsulation technique. Further in vitro testing revealed that higher 
concentrations of PLA deposited onto SS surfaces exhibited higher transduction 
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levels of the adenovirus, in line with observation that PLA was an effective 
material for collagen deposition.  
Moving from in vitro to ex vivo models, the concentration for adenoviral 
transduction was found to be much higher in order to observe mouse aorta 
transduction of Ad5 than it was for the rat A10 cells, this could be due to the 
endothelial cells presenting a barrier for Ad5 transduction. After determining 
the concentration for viral transduction, a collagen-virus gel was incubated on 
PLA squares and placed onto mouse aortas, after 72 h transduction of the Ad5  
CMV lacZ was observed through expression of the reporter gene. This was also 
tested on porcine coronary arteries and expression of the virus was observed 
using this model as well.  
Progressing from virus delivery from PLA squares to stent surfaces, a method 
needed to be developed that would enable coating of the BMS with PLA. This 
was done by dissolving PLA in different wt/wt ratios of chloroform and the 
spreading a thin layer over the stent surface. Smoothing of the surface was then 
done by solvent vapour evaporation of CH2Cl2. When testing the stents to see 
whether the PLA coating had affected their ability for stent balloon expansion, 
we observed that at the highest %PLA (10% wt/wt), the stent was not able to 
fully expand due to the PLA coating, however at the lower PLA concentrations of 
PLA (5 and 2.5% wt/wt), inflation of the stent was possible, however, when 
coating the stent in the collagen-virus gel we only observed transduction at the 
highest PLA concentration, therefore prohibiting further in vivo testing, due to 
incomplete stent expansion.   
Taken together these data demonstrate the potentials and pitfalls of different 
methods for coating adenovirus onto stent surfaces. Using a pure biodegradable 
PLA stent and coating with collagen virus gel could provide the answer to the 
logistical problems faced with the coating BMS with PLA manually. However, 
currently PLA commercial stents are not available without antithrombotic drugs 
already coated on them, so obtaining a pure PLA stent would be optimal for 
future development of the collagen/virus delivery system.  
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4 Development of methods for coating miRNA 
onto stent materials and stent surfaces 
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4.1 Introduction 
In stent restenosis (ISR) is defined as >75% narrowing of the cross-sectional 
luminal stented area by neointimal tissue (Chaabane et al., 2013), it occurs as a 
healing response to the injury of the vessel caused by the process of stent 
implantation during percutaneous coronary intervention (PCI). Stenting can 
damage the vessel in a number of ways (as described in section 2); de-
endothelialisation, whereby the endothelium can be denuded, crushed or torn as 
a result of stent implantation which can trigger a wound healing cascade (Costa 
and Simon, 2005, Sanborn et al., 1983).In addition to this, the process by which 
the stent is deployed, by inflating a balloon, exerts a considerable amount of 
mechanical pressure on the VSMCs. Furthermore, potential for the VSMCs to 
come into contact directly with the blood flow can also expose them to shear 
stress. The mechanical trauma endured by the VSMCs has been attributed as a 
key factor governing neointima formation as it modulates a phenotypic switch 
for the VSMCs from contractile to the synthetic state, this ultimately promotes 
the migration from the media to the intima (Clowes et al., 1989).     
The cellular cascade caused by damage to both ECs and VSMCs induces platelet 
aggregation, thrombus formation as well as inflammatory reactions at the site of 
injury (Welt and Rogers, 2002). Both platelets and macrophages play a leading 
role by the secretion of cytokines and growth factors which trigger phenotypic 
switching of VSMCs and secretion of extracellular matrix which ultimately forms 
the scaffold for the neointima to form (McDonald et al., 2012). As VSMCs 
proliferate and migrate into the intima, the lumen will continue to narrow until 
a new layer of endothelial cells has re-established itself on the inner arterial 
surface (Douglas et al., 2013).  
MiRNAs are an endogenous class of small non-coding RNA molecules (approx. 22 
nucleotides), which can regulate genes and proteins, operating primarily through 
promoting the degradation or suppression of the translation of mRNA molecules. 
Using miRNAs as a therapeutic to help suppress neointima formation and restore 
vessel homeostasis induced by stent implantation was at the time this work was 
carried out an unexplored area of research. However, the first paper detailing a 
therapeutic miRNA eluting stent was published in July of this year, highlighting 
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the potential for miRNA based therapy for ISR prevention, which successfully 
delivered antimiR-21 (Wang et al., 2015).     
Several miRNAs and miRNA clusters have been identified as therapeutic targets 
in the vasculature setting. miR-145 is the most abundant miRNA present in 
vascular walls, and has been identified as a marker and a modulator for 
neointimal formation (Ji et al., 2007a, Cheng et al., 2009a). It was observed 
that miR-145 levels changed upon differentiation of the VSMC phenotype, with 
high levels of miR-145 characteristic of the contractile phenotype. Upon 
stimulation of PDGF, miR-145 levels dropped in conjunction with the phenotype 
switching to the synthetic state. It was found that inhibition of miR-145 had the 
effect of suppressing the action of PDGF, maintaining the VSMCs in their 
contractile phenotype, this suggested that miR-145 had a regulatory effect on 
SMC phenotype. Further investigation identified Krüppel-like factor 5 (KLF5) as a 
target gene for miR-145, which could explain these miR-145 mediated effects on 
VSMC phenotype modulation (Cheng et al., 2009a).  
miR-145 is just one example of the many different miRNA gene regulator targets 
which could be used to prevent neointimal growth following stent implantation. 
Other examples include miR-21, miR-143 and miR-221, which are discussed in 
detail in section 1.6.2 However, delivery of these novel therapeutics remains a 
barrier, particularly in the in vivo setting.  
Drug eluting stents (DES) have evolved from BMS, as it was realised that as well 
as fulfilling the structural role of re-widening the artery, they could also be 
coated in anti-proliferative drugs and therefore act as a delivery medium to the 
stented region. It is in this context that we wish to develop a delivery system for 
the miRNAs that would be able to coat a BMS surface to achieve this localised 
delivery to the target region. 
miR-39-3p was chosen as the miRNA mimic to deliver from stent materials in 
vitro, because it originates from a nematode, caenorhabditis elegans (c.elegans) 
and, therefore, background levels of this miRNA are not present in mammalian 
cells. It was thought that detection of the miR-39-3p would therefore be facile, 
and probing different materials for their suitability for miRNA delivery would be 
easy to interpret. 
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4.1.1 Aims 
The aims of this chapter were: 
 To develop a delivery platform for miRNA from stent materials in vitro 
using c.elegans as a model miRNA that would be suitable for in vivo 
setting. 
 To extend the delivery platform capabilities to test for delivery of 
therapeutic target miRNAs for the prevention of ISR in vitro.  
 To examine therapeutic target miRNAs effects on proliferation and target 
gene regulation.  
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4.2 Results 
4.2.1 Transfection of miRNAs in vitro 
Initially, A10 cells were transfected at three different concentrations of miR-39-
3p, (3 nM, 30 nM and 300 nM), this range of concentrations of the miR-39-3p was 
chosen because the manufacturers’ protocol suggested that the miRNA mimics 
could be detected as low as 1 nM but often required higher levels of miRNA in 
the region of 50 nM. miRNA mimics are small chemically modificed double 
stranded miRNA molecules which mimic the function of endogenous miRNAs. 
Transfection was carried out as described using the guidelines provided by the 
manufacturer.    
 
Figure 4-1 miR-39-3p expression in A10 cells transfected with miR-39-3p mimic. 
A10 cells were plated in a 12 well plate at a seeding density of 100,000 cells/well. miR-39-3p (3 
nM, 30 nM & 300 nM) was incubated with transfection reagent siPORT Neo FX™ (3 μL)for 10 mins 
prior to being applied to the cells. The cells were left for 48 h before being washed with PBS, 
harvested, RNA extracted, quantification was done using qRT-PCR and was normalised to U87 
housekeeper gene expression. Data is expressed as RQ values ± RQ max. Data was analysed by 
performing a one way ANOVA and post-hoc Tukey test relative to the mock control, ***p<0.001. 
Representative graph of three independent experiments with three biological replicates per 
condition. 
These results indicate that for all the concentrations tested we can reliably 
detect miR-39-3p expression following the transfection protocol for A10 cells. 
For each concentration, we could detect miR-39-3p expression and found a 
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direct correlation between the level of expression of the miR-39-3p observed 
and the amount applied to the cells, i.e., for a 10 fold increase in concentration 
we observed a corresponding 10 fold increase in miR-39-3p expression. As the 
overall aim was to eventually use endogenous therapeutic miRNAs, 30 nM was 
chosen as a suitable benchmark concentration to use for further testing, based 
on information given in the manufacturers’ protocol and current miRNA 
literature and the data shown in Figure 4-1 (Cheng et al., 2009a). 
Using PLA and SS as model stent materials, we tested the ability for miR-39-3p 
to be delivered to A10 cells in vitro, following application to the surfaces. 
Thorough washing steps with PBS (3 x 1 mL), which was pipetted directly onto 
the surfaces, were included in order to mimic the environment that the coating 
would have to withstand when deploying through the femoral artery, as 
exposure to the blood flow would inevitably wash off some of the miRNA and 
cause systemic delivery. 
Following the success which collagen had demonstrated for Ad delivery (Chapter 
3), collagenentrapment of miRNA was tested for both surfaces. In order to 
achieve transfection of the miRNA mimic into cells, it was necessary to incubate 
the miRNA with a transfection reagent siPORT Neo FX™, which is a lipid based 
formulation that complexes to the miRNA mimic, enabling transfection of the 
cells.  
It was hypothesised that application of the siPORT-mimic complex to the PLA 
surface could provide a good platform for delivery as the PLA is lipophilic, the 
lipid based siPORT-mimic complex could therefore adhere to the PLA surface 
through hydrophobic interactions; providing an environment for efficient 
adsorption, and delivery. This concept has been demonstrated before by loading 
PLA with lipophilic drug molecules (Fan et al., 2013).  
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Figure 4-2 miR-39-3p expression in A10 cells transfected with miR-39-3p mimic coated 
onto PLA and SS surfaces ±collagen. 
A10 cells were plated in a 12 well plate at a seeding density of100,000 cells/well. miR-39-3p (30 
nM) was incubated with transfection reagent siPORT Neo FX™ (3 μL)for 10 mins and then applied 
directly onto PLA, SS or directly onto cells. For the collagen coated PLA and SS the miRNA-
siPORT complex was mixed with collagen prior to being set onto the PLA surface. Final 
concentrations of miR-39-3p were 30 nM. All surfaces were washed prior to be being place onto 
the cells. The cells were left for 48 h before being washed with PBS, harvested, RNA extracted, 
quantification was done using qRT-PCR and was normalised to U87 housekeeper gene 
expression. Data is expressed as RQ values ± RQ max. Data was analysed by performing a one 
way ANOVA and post-hoc Tukey test relative to the in solution control, ***p<0.001, ns=non-
significant. Representative graph of three independent experiments with three biological replicates 
per condition. 
We observed that using the PLA as a surface for delivery of the miRNA-siPORT 
complex, we can detect expression of the miR-39-3p in the cells, indicating that 
PLA could be used as a material for miRNA delivery. A comparison of the in 
solution control to the PLA- collagen shows approximately 10 fold decrease in 
miR-39-3p expression, this could be due to loss of the miRNA during the washing 
steps, or the miRNA may be retained within the polymer, a temporal release 
study would need to be conducted to clarify this. A 4 fold increase in expression 
of miR-39-3p from the PLA surface compared to the PLA-collagen surface, 
therefore indicating that unlike the adenovirus, miRNA is retained better on the 
PLA surface without collagen. Comparison of the SS as a material for miRNA 
delivery did not show any miR-39-3p expression, indicating that it would not be 
suitable as a material for this purpose.  
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Since the overall objective is to deliver therapeutic miRNAs this delivery system 
from PLA was tested with potential therapeutic miRNAs for prevention of ISR. In 
order to investigate the role of different miRNAs role within the ISR pathway, it 
would be useful to upregulate and downregulate a miRNA delivered from stents, 
to do this miR mimics and miR inhibitors can be used. miR 145 was chosen as the 
model miRNA to deliver, in both mimic and inhibitor forms. This miRNA was 
chosen because overexpression of miR-145 has been shown to inhibit 
proliferation of VSMCs. Conversely, deficiency of miR-145 has been shown to 
promote the synthetic phenotype of VSMCs which promotes increased VSMC 
migration (Cordes et al., 2009a, Cheng et al., 2009a, Marx et al., 2011). Both of 
these systems have been shown in vitro using transgenic mice. In our group we 
have also demonstrated this relationship in vivo using a murine stenting model 
on 145-/- mice which showed a significant reduction in neointima formation when 
stenting was done on the 145-/- mice, which is contradictory to what would be 
intuitive following the in vitro studies (Robinson, Baker, unpublished). Therefore 
it would be interesting to further probe the relationship miR-145 has with 
neointima formation by locally delivering miR-145 and the inhibitor from stent 
surfaces. 
Chapter 4  162 
 
 
Figure 4-3 miR-145-5p expression in A10 cells transfected with miR-145-5p mimic and 
miR-145-5p inhibitor coated onto PLA surfaces. 
A10 cells were plated in a 12 well plate at a seeding density of100,000 cells/well. miR-145-5p 
mimic or inhibitor was incubated with transfection reagent siPORT Neo FX™3 μL for 10 mins and 
then applied directly onto PLA or directly onto the cells. Final concentrations of miR-145-5p mimic 
and inhibitor were 30 nM. All surfaces were washed prior to be being place onto the cells. The cells 
were left for 48h before being washed with PBS, harvested, RNA extracted, quantification was 
done using qRT-PCR and was normalised to U87 housekeeper gene expression. Data expressed 
as RQ values ± RQ max. Data was analysed by performing a One way ANOVA and post-hoc 
Tukey test relative to the mock control,***p<0.001,**p<0.05, ns=non-significant. Representative 
graph of three independent experiments with three biological replicates per condition. 
Testing of PLA as a candidate delivery material for the siPORT-miRNA (miR-145-
5p and miR-145-5p inhibitor) precursor complex was conducted, using the same 
experimental set up as described for the miR-39-3p (Figure 4-2). It was 
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observed, that upregulation and downregulation of miR-145-5p could be 
achieved from the PLA surface when administering the miR-145-5p and miR-145-
5p inhibitor respectively (Figure 4-3). A 12 fold increase in miR-145 expression 
compared to control scramble mimic when using the miR-145 mimic, and a 5 fold 
decrease in miR-145 expression when delivering the miR-145 inhibitor from the 
PLA surface was observed. 
As detailed in chapter 3, when developing adenovirus eluting stent methodology, 
moving from in vitro delivery on flat discs to ex vivo delivery from stent surfaces 
exposed several logistical problems. Therefore, testing in the ex vivo setting was 
a priority. A preliminary ex vivo test was carried out, whereby, mouse aorta 
were transfected with miR-39-3p, in solution and from the PLA surfaces (Figure 
4-4).  
 
Figure 4-4 Ex vivo delivery of miR-39-3p from PLA squares to mice aorta. 
Mouse aorta were harvested and placed in 12 well culture dishes. PLA was coated with miR-39-3p-
siPORT mix, washed thoroughly with PBS and then placed onto the aortas, or the miR-39-3p was 
applied directly to the aorta at 30 nM. Aortas were incubated in medium for 48 h then the aortas 
were homogenised and RNA was extracted from them. Quantification of the miR-39-3p was done 
by qRT-PCR and normalised to U87 housekeeper gene. Data expressed as RQ values. 
Preliminary experiment with one condition per aorta. 
Delivery of miR-39-3p from PLA surface ex vivo to mouse aorta was achieved and 
detected at high levels as it is a non-endogenous miRNA to mice. Using this non-
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endogenous miRNA mimic for delivery provides a good platform to evaluate the 
delivery system and performance for in vivo set-ups.   
Murine stents were coated in PLA using the optimised procedure as developed 
for the adenovirus delivery system, 10% and 15% wt/wt PLA dissolved in 
chloroform was used to coat the stents, which were then coated with siPORT-
miR-39-3p, washed and deployed into the mice aorta ex vivo.    
 
Figure 4-5 Ex vivo delivery of miR-39-3p from PLA coated stents to mouse aorta at 
different PLA concentrations. 
Mouse aorta were harvested and placed in 12 well culture dishes. PLA was coated onto murine 
stents at concentrations 10% and 15% wt/wt PLA dissolved in chloroform with miR-39-3p-siPORT 
mix, washed thoroughly with PBS and then placed onto the aortas, or the miR-39-3p was applied 
directly to the aorta at 30 nM. Aortas were incubated in medium for 48 h then the aortas were 
homogenised and RNA was extracted from them. Quantification of the miR-39-3p was done by 
qRT-PCR and normalised to U87 housekeeper gene. Data expressed as RQ values. Preliminary 
experiment with one condition per aorta. 
Using the PLA coated stents to deliver the miR-39-3p, we observed higher levels 
from the PLA coated stents than from the mimic in solution (2 fold increase for 
15% PLA coated stent and 4 fold increase for the 10% PLA coated stent), this 
could be attributed to the direct contact between the stent surface and the 
mouse aorta and the fact that the stent is locked in place. This therefore 
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indicates that the localised delivery would be possible using this delivery system. 
Comparing the two concentrations of PLA, it was observed that 10% w/v PLA in 
chloroform yields a two fold increase in miR-39-3p expression compared to 15% 
wt/wt, therefore furthertesting was carried out using this concentration of PLA 
for the coating.  
Using the preliminary data from the ex vivo testing as a reference detailed in 
Figure 4-4 and Figure 4-5, ex vivo testing was now carried out using the 
optimised PLA concentration of 10% w/v on a bigger scale, with three aortas per 
condition.  
 
Figure 4-6 Ex vivo delivery of miR-39-3p from PLA coated stents to mouse aorta. 
Mouse aortas were harvested and placed in 12 well culture dishes. PLA was coated onto murine 
stents at concentrations 10% wt/wt PLA dissolved in chloroform with miR-39-3p-siPORT mix, 
washed thoroughly with PBS and then placed onto the aortas, or the miR-39-3p was applied 
directly to the aorta at 30 nM. Aortas were incubated in medium for 48 h then the aortas were 
homogenised and RNA was extracted from them. Quantification of the miR-39-3p was done by 
qRT-PCR and normalised to U87 housekeeper gene. Data is expressed as RQ values ± RQ max. 
Data was analysed by performing a One way ANOVA and post-hoc Tukey test relative to the mock 
control, ***p<0.001, ns=non-significant. Three aortas were treated per condition.  
The results from this ex vivo study indicate that by using this delivery method 
we can detect miR-39-3p after 48 h in medium. Using the PLA at this 
concentration did not cause logistical problems and the stents were all able to 
fit into the aortas of the mice and be fully expanded. This, therefore, represents 
a good platform for testing in vivo stent models to find out whether the miRNA 
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coating is able to withstand the procedure of deployment, which is tested in 
chapter 5. 
4.2.2 Using miRNAs to inhibit SMC proliferation as a potential 
therapeutic for prevention of ISR 
As discussed in depth in section 1.3, ISR is caused by the proliferation and 
migration of SMC in response to the injury caused by stent implantation. A 
strategy for preventing ISR, therefore, would be to inhibit SMC proliferation, 
which could be achieved by treatment of the vessel with therapeutic miRNAs. To 
investigate the biological effects of treating VSMCs with miRNAs on cell 
proliferation, an EdU (5-ethynyl-2’-deoxyuridine) assay was performed. EdU is a 
thymidine analogue and therefore incorporates into the DNA during DNA 
synthesis (Salic and Mitchison, 2008). Detection of the EdU is performed by a 
reaction of the ethynyl group with an Alexa Fluor® tagged azide through a click 
reaction (3 + 2 cycloaddition) (Breinbauer and Köhn, 2003, Wang et al., 2003). 
After labelling the cells, they can then be fixed and analysed using flow 
cytometry. 
The function of miR cluster 99b/let 7e/125a, has been unexplored in the context 
of the cardiovascular system and for the purposes of inhibiting ISR, it therefore 
represents a novel potential therapeutic. Other work in the group identified this 
miRNA cluster as a suitable candidate for this purpose as it was downregulated 
in a pig vein graft experiment. The cluster has also been associated with 
suppression of  tumour angiogenesis of ovarian cancer cells when over expressed 
(He et al., 2013). Therefore the miR cluster 99b/let7e/125a was administered to 
HVSMC in vitro, to observe the effect it had on SMC proliferation using the EdU 
assay as described above.  
HVSMC were treated with the miR cluster 99b/let 7e/125a at a concentration of 
3 nM. A lentiviral vector expressing the the miR cluster was also administered at 
20 MOI. The cells were maintained in 15% FCS MEM for 24 h and then serum 
starved for 24 h prior to addition and incorporation of the EdU into the newly 
synthesised DNA. Detection of the EdU was done by employing ‘click chemistry’ 
to react an Alexa Fluor™ tagged- azide. Cells were then analysed using FACS. 
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Figure 4-7 EdU Assay measuring the effect of miR cluster 99b/let7e/125a on HVSMC 
proliferation. 
HVSMC were plated in a 12 well plate at a density of 3.5 x 104 cells/well. The cells were 
transfected with miR cluster 99b/let7e/125a at concentration of 3 nM, using siPORT™ Neo FX™ as 
a transfection reagent (3 μL). The cells were treated with both the 3p and the 5p strands, or the 3p 
and 5p strands separately. LV-miR 99b/let7e/125a was also applied to the cells at a concentration 
of 20 MOI. The cells were serum starved after 24 h, the EdU was applied on Day 4 and the cells 
were harvested at Day6. The EdU assay was then performed by labelling with Alexa-Fluor tagged 
azide® as described in manufacturers protocol. FACS analysis was done on the cells and data 
analysed using FlowJo software to obtain the %cells proliferating. Representative graph of three 
independent experiments with each condition having two biological replicates. Data was analysed 
using a  one way ANOVA and post-hoc Tukey test relative to the scramble control (black), 
***p<0.001, *p<0.05, ns=non-significant. 
Results from the EdU assay indicate a 5% decrease in the %of proliferating cells 
when treated with the 3p strands of the miR 99b/let 7e/125a cluster, however 
we did not observe a significant decrease in proliferation for any of the other 
treatment groups. When treated with the LV-cluster however, a 50% decrease in 
proliferation was observed, therefore indicating that using the LV to aid delivery 
and transfection of the miRNA may result in a bigger biological effect for this 
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purpose. Quantification of the miRNA was also done by RNA extraction and qRT-
PCR to confirm that the miRNA was effectively being upregulated.   
 
Figure 4-8 Relative expression of miR-99b-3p and 5p strands of HVSMC after 48 h 
treatment with the miRNA at 3 nM. 
RNA was extracted and quantified by qRT-PCR. Data is expressed as RQ relative to expression of 
housekeeper gene RNU48b. One biological replicate per condition. 
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Figure 4-9 Relative expression of miR-let7e-3p and 5p strands of HVSMC after 48 h 
treatment with the miRNA at 3 nM. 
RNA was extracted and quantified by qRT-PCR. Data is expressed as RQ relative to expression of 
housekeeper gene RNU48b. One biological replicate per condition. 
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Figure 4-10 Relative expression of miR-125a-3p and 5p strands of HVSMC after 48 h 
treatment with the miRNA at 3 nM. 
RNA was extracted and quantified by qRT-PCR. Data is expressed as RQ relative to expression of 
housekeeper gene RNU48b. One biological replicate per condition. 
 
From the expression profiles of the miRNAs it can be seen that the miRNAs were 
overexpressed for both the LV and miR mimic delivery of the cluster (Figure 
Figure 4-8, Figure 4-9 & Figure 4-10). It is interesting to note that the LV 
expression of the miRNAs is much less than when treated with the cluster 
mimics.  
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4.3 Discussion 
In this chapter a method for delivery of miRNA mimics has been developed that 
is able to deliver miRNA in vitro to rat SMC from PLA surfaces, through to 
delivery from murine stent surfaces ex vivo. This method therefore holds much 
promise for miRNA delivery from stent surfaces in an in vivo setting. However, 
different factors will be present that are not present within the ex vivo model, 
such as blood flow and the logistics of intravascular stent deployment (advancing 
the stent through the arteries), both of which could result in the miRNA coating 
becoming detached from the surface prior to deployment. This was compensated 
for to an extent in the in vitro and ex vivo model by including extensive washing 
steps prior to deployment; however exactly how this coating will respond to the 
demands of an in vivo environment will be interesting to find out. 
These results agree with the findings detailed in Chapter 3, with respect to PLA 
performing the best as a material for adherence and delivery of the therapeutic, 
for miRNA and adenovirus when compared to SS. Collagen encapsulation, which 
was found to be a useful technique for delivering virus, was not found to be 
beneficial in the miRNA delivery setting. Instead it was found that the miRNA 
mimic-siPORT™ complex could be applied directly onto the PLA surface and 
dried; this coating was able to withstand significant washing steps with PBS, 
indicating that it might be suitable for in vivo applications. Use of transfection 
reagent siPORT™ Neo FX™, which is a lipid based polyamine was likely to have 
aided the adherence to the PLA surface, which is hydrophobic in nature, with a 
contact angle of 80°(Rasal et al., 2010). PLA has been approved by the FDA for 
use with direct contact with biological fluids and is currently being used as a 
biodegradable stent material in the clinics, the Abbott Absorb Stent is an 
example of a commercially available PLA stent  (Rasal et al., 2010, Dörr et al., 
2014). Using the methodology described in this chapter for coating a BMS with 
PLA and subsequent miRNA coating steps, could be translatable in the clinical 
setting and represents a simple methodology for the preparation of miRNA 
eluting stents.  
Non-endogenous miR-39-3p was coated onto stent materials and stent surfaces 
and tested for delivery in vitro with rat A10 cells and ex vivo using murine 
vessels, throughout this testing expression of the miR-39-3p was always 
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demonstrated, showing clear evidence to support this delivery system as suitable 
for miRNA mimics. Using miR-39-3p as the miR for delivery allowed for analysis 
and detection to be straightforward and worked well as a pilot model to show 
the concept worked.  
Testing was also done in vitro using miR-145-5p mimic and inhibitor from PLA 
surfaces to A10 cells, to demonstrate that upregulation and downregulation of 
miRNAs of interest can be achieved using this system. In the case of miR-145; 
overexpression of this miRNA has been previously shown to inhibit VSMC 
proliferation, and therefore represents a potential therapeutic for prevention of 
ISR (Cordes et al., 2009a). However, observations within our own research 
group, showed that 145-/- mice exhibited significantly less neointima formation 
following murine stent deployment (Robinson, Baker, unpublished).  The ability 
to induce overexpression and suppression of miR-145 from local stent delivery 
would allow further observations on the effect of miR-145 expression on 
neointima formation and provide more clarity to its exact role.  
Another potential miRNA cluster was investigated, miR99b/let7e/125a, which 
has been previously shown to suppress tumour angiogenesis in ovarian cancer 
cells when overexpressed (He et al., 2013). It was therefore hypothesised that 
this miRNA cluster could also be used to prevent ISR by preventing proliferation 
of VSMC. This was assessed using an EdU assay, which can be used to measure 
the %proliferating cells. It was found that, by delivering the cluster using a LV 
vector, a decrease in cell proliferation of 20% was observed. However, when 
delivering the miRNA as 3p & 5p strands a decrease in proliferation was not 
observed. Delivering the 3p strands alone, a decrease in proliferation by 7% 
could be achieved and therefore does show potential for a novel therapeutic for 
ISR, these findings are in agreement with previous work within our group 
(Garcia, Baker, unpublished). It is clear however, that the true biological 
function of this cluster of miRNAs is complex and further investigation is needed.   
In order to progress to mouse ex vivo stenting, a method was developed for 
coating the mouse stents with PLA. This was achieved by dissolving the PLA in 
chloroform, and then coating a thin layer of PLA onto the stent surfaces. 
Optimisation for the concentration of PLA dissolved in chloroform was performed 
and it was found that 10% wt/wt worked sufficiently. A technique to achieve a 
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smooth surface was also needed to ensure that the stent surface was smooth. 
DCM vaporisation was used to ensure that the PLA was smoothed by dipping the 
coated stent into a vapour chamber for 5 seconds. Using this method for coating 
the mouse stent, transfection of miR-39-3p was delivered and detected after 48 
h from PLA coated SS mouse stents. Further work, using this model system in 
vivo using the porcine and murine stenting models is detailed in Chapter 5. 
The method for coating and delivering miRNA from biodegradable stent surfaces 
is the first of its kind. To date the only method for miRNA delivery from stent 
surfaces was published in July 2015, which included a specialised custom 
microporous stent for delivery of antimiR-21 (Wang et.al., 2015). The method 
presented here therefore represents a more simplified approach, which does not 
require specialised stents. The use of PLA to as a biodegradable polymer to 
adhere the miRNA to is novel, and could easily be applied in the context of 
biodegradable stents.      
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5 Local delivery of miRNA in murine and porcine 
in vivo stenting models 
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5.1 Introduction 
In order to increase the complexity of the miRNA delivery environment, it was 
important to establish whether the miRNA eluting stents developed in Chapter 4 
would be able to deliver miRNA mimics in vivo animal models. There are a 
number of different stenting models which could be used to this effect. 
The murine stent model developed by Ali et al. involves stenting the aorta of a 
mouse, ex vivo using a custom-made mouse stent, with the stented section then 
being excised and grafted into another mouse in vivo (Ali et al., 2007). Aside 
from the logistical advantages of using a mouse stenting model, the main 
advantage for testing miRNA eluting stents using this model is the scope to 
extend the methodology so that it can be used on transgenic mice. This would 
further probe miRNAs function in neointima formation and test the efficacy of 
miRNA eluting stents for prevention of ISR.  
The pig stenting model is a more clinically relevant model, as human stents can 
be used because artery dimensions are similar between the two species and the 
stenting operation is the same as with the human stenting deployment 
procedure.  
5.1.1 Aim 
The aim of this chapter was: 
 To evaluate whether the methodology for miRNA eluting stents could be 
used to deliver miRNA from stents in murine and porcine in  vivo stenting 
models, through detection at 48 h after deployment. 
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5.2 Results 
5.2.1 Transfection of miRNA in murine in vivo stenting model 
Testing the methodology developed in Chapter 4, for localised delivery of miRNA 
from stent surfaces to stented arteries, was initially conducted using the murine 
in vivo stenting model. MF1 mice were stented with custom made murine stents, 
which had been coated with miRNA-39-3p, using the PLA coating methodology as 
described in Chapter 4. The stents were sterilised by soaking in sterilising 
solution for 10 minutes prior to coating with the miRNA. The mice were 
sacrificed at 48 h post deployment, the stented segments were excised for RNA 
extraction and quantification of the miRNA-39-3p expression was analysed using 
qRT-PCR (Figure 5-1). A time-point of 48 h was chosen in line with the 
manufacturer’s protocol for miRNA transfection.  
 
Figure 5-1 Local delivery of miR-39-3p from PLA coated stents to mouse aorta, 48 h 
after deployment using murine in vivo stenting model. 
10% wt/wt PLA dissolved in chloroform was coated onto murine stents and dried overnight. miR-
39-3p (20 μM, 1.5 μL) was added to siPORT (3 μL) and then applied to the PLA coated stents. 
Stents were washed in PBS before deployment into the mouse aorta Mice aortas were harvested 
at 48 h post deployment, and immediately stored at -80 oC. RNA was extracted from the aortas and 
miR-39-3p expression was quantified by Taqman®qRT-PCR.Data is expressed as RQ values ± 
RQ max. Data was analysed by performing a One way ANOVA and post-hoc Tukey test relative to 
the BMS control, *p<0.05, ns=non-significant. n=5 stents/group for PLA BMS +miR-39-3p and n=3 
stents/group BMS and BMS PLA control. 
miR-39-3p expression was recorded at 48 h from the stented artery, after 
coating with PLA and the miRNA. This demonstrates that this methodology is 
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able to withstand deployment procedures and blood flow within the mouse 
model.  
5.2.2 Transfection of miRNA in porcine in vivo stenting model 
Testing for localised miRNA stent delivery using a larger animal model to allow 
for a more clinically relevant setting was conducted using the porcine stenting 
model. Human BMS were initially coated with PLA, followed by siPORT/miRNA 
and allowed to dry before deploying using the methodology developed in 
Chapter 4. After 48 h the pigs were sacrificed and the arteries harvested for RNA 
extraction, and quantification of the locally delivered miRNA was carried out 
using qRT-PCR. 
It was important to identify a suitable housekeeper to allow meaningful 
comparisons to assess whether delivery of the miRNA had been successful. U6 
and miR-103 were tested as potential candidates for the endogenous control on 
the pig samples, the standard deviation when miR-103 was used across the 
groups was 0.988735 whereas the standard deviation when U6 was used was 
1.800209, therefore, miR-103 was used as a housekeeper for the study (Figure 
5-2).  
 
Figure 5-2 Comparison of U6 and miR 103 as endogenous controls for in vivo porcine 
stenting study. 
Relative expression of miR-103 and U6 following RNA extraction and quantification by 
Taqman®qRTPCR from porcine coronary arteries from in vivo stenting study. Data is expressed as 
Ct value, U6 n=31/group, miR-103 n=30/group. 
 
  
Chapter 5  178 
 
Using the same methodology for coating the stents for the murine in vivo study, 
stents were deployed and harvested and after 48 h. Delivery of miR-39 was 
observed at this time point, so evaluation as to whether the delivery system 
worked was straightforward as the expression levels for miR-39 were ~7500 fold 
above the background levels from the control groups (Figure 5-3). 
 
Figure 5-3 Local delivery of miR-39-3p from PLA coated stents to porcine coronary 
arteries, 48 h after deployment using porcine in vivo stenting model. 
2.5% wt/wt PLA dissolved in chloroform was coated onto porcine stents and dried overnight. miR-
39-3p (20 μM, 4.5 μL) was added to siPORT (9 μL) was then applied to the PLA coted stents. 
Stents were washed in PBS before deployment into the porcine coronary arteries.Arteries were 
harvested at 48h post deployment, and immediately stored at -80oC. RNA was extracted from the 
arteries and miR-39-3p expression was quantified by Taqman®qRT-PCR and normalised to miR-
103 expression. Data is expressed as RQ values ± RQ max. Data was analysed by performing a 
One way ANOVA and post-hoc Tukey test relative to the BMS control, ***p<0.001, ns=non-
significant, n=6/group. 
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Delivery of miRNAs that are relevant to the process of neointima hyperplasia, 
miR-145-5p and antimiR-21, were attempted. However, expression of miR-145-
5p was not upregulated enough to signify significance within the porcine in vivo 
setting, although the RQ value for PLA BMS miR-145-5p stent was doubled. This 
could have been due to the fact that miR-145-5p was highly expressed within the 
artery walls. Ct values for the control groups were, BMS 15.1 and PLA BMS 16.7, 
therefore saturation of the signal from the miRNA which was delivered from the 
stent could have occurred (Figure 5-4).         
 
 
Figure 5-4 Local delivery of miR-145-5p from PLA coated stents to porcine coronary 
arteries, 48 h after deployment using porcine in vivo stenting model. 
2.5% wt/wt PLA dissolved in chloroform was coated onto porcine stents and dried overnight.miR-
145-5p (20 μM, 4.5 μL) was added to siPORT (9 μL) was then applied to the PLA coted stents. 
Stents were washed in PBS before deployment into the porcine coronary arteries.Arteries were 
harvested at 48h post deployment, and immediately stored at -80oC. RNA was extracted from the 
arteries and miR-145-5p expression was quantified by Taqman®qRT-PCR and normalised to miR-
103 expression. Data is expressed as RQ values ± RQ max. Data was analysed by performing a 
One way ANOVA and post-hoc Tukey test relative to the BMS control, ns=non-significant, n=4 for 
PLA BMS + miR-145-5p and n=6 for control BMS and PLA BMS groups. 
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AntimiR-21 was also delivered from the porcine stent surface and the levels of 
miR-21 were recorded at 48 h post-deployment. Firstly, we noted a change in 
the miRNA-21 expression profile between the non-stented arteries (NTC) and the 
control groups (PLA BMS and PLA BMS + S/C), which agrees with other reports 
which have documented miR-21 release after response to stent deployment and 
corresponding vessel injury (McDonald et al., 2015). miR-21 expression was 
decreased by 50% after local delivery of antimiR-21 from the stent surface; 
however the change was not statistically significant. This study was not highly 
powered however, with low numbers in the treatment group (n=3) and the 
scramble control group (n=2), so further testing to elicit whether the trend 
continued. Increasing the concentration of antimiR-21 could also help to ensure 
a decrease in miR-21 expression was observed at the 48 h time-point which we 
could then use to investigate the therapeutic potential and efficacy of this miR-
based treatment (Figure 5-5).  
 
 
Figure 5-5 Local delivery of antimiR-21 from PLA coated stents to porcine coronary 
arteries, 48 h after deployment using porcine in vivo stenting model. 
2.5 % wt/wt PLA dissolved in chloroform was coated onto porcine stents and dried 
overnight.antimiR-21 (20 μM, 4.5 μL) was added to siPORT (9 μL) was then applied to the PLA 
coted stents Stents were washed in PBS before deployment into the porcine coronary 
arteries.Arteries were harvested at 48h post deployment, and immediately stored at -80oC. RNA 
was extracted from the arteries and miR-21 expression was quantified by Taqman®qRT-PCR and 
normalised to miR-103 expression. Data is expressed as RQ values ± RQ max. Data was analysed 
by performing a One way ANOVA and post-hoc Tukey test relative to the PLA BMS + antimiR 
scramble control, *p<0.05, ns=non-significant, n=3 for antimiR 21 PLA BMS group, n=2 for antimiR 
21 S/C PLA BMS, n=6 for PLA BMS and n=8 for NTC group. 
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5.3 Discussion 
In summary, it has been demonstrated that localised delivery of miRNA from 
stent surfaces can be achieved in both murine and porcine in vivo stenting 
models, using the technique of coating the BMS stent initially with PLA and then 
with the miRNA/siPORT. This was clearly demonstrated when using miR-39-3p as 
a reporter miRNA, as it is non-endogenous to mammals and therefore detection 
was easier to recognise.  
When preliminary studies were conducted delivering antimiR-21 and miR-145-5p 
from the stent, we did not observe significant differences in miRNA expression 
between the control groups and the treatment groups. This could be due to a 
number of reasons. Firstly, since miR-145 is one of the most abundantly 
expressed miRNAs in arteries, saturation of the miR-145 expression signal could 
occur as the high background levels of miR-145 could prevent the detection of 
the miR-145 delivered from the stent being observed. In the case of antimiR-21, 
the experiment was not highly powered enough to ascertain conclusively 
whether antimiR-21 could be delivered from the stent and correspond to a 
decrease in arterial miR-21 expression, so a more highly powered study would 
aid this. In addition higher concentrations of therapeutic miRNA could be 
administered to ensure the change in miRNA expression was observed. Finally a 
method for spray coating the stent with miRNA/siPORT could ensure uniform 
distribution of miRNA coating (as done with DES) and this could decrease the 
variability within the treatment groups, which does seem to be an issue to 
enable consistent results to be generated. 
The ability to deliver the miRNA in two different animal models has a lot of 
future potential for further scientific investigations, as genetically-modified 
mice could be used to further probe miRNA action on development of ISR. The 
porcine model however, has the advantage of being much more relevant to the 
human stent setting. Therefore further investigation using therapeutic miRNAs 
attached to the surface using this model to see whether alteration of the miRNAs 
usual expression profile could be altered and most importantly whether a 
therapeutic response can be monitored would provide a novel therapy for the 
prevention of ISR. 
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Recently, the first example of a miRNA eluting stent was published in the rat 
model, whereby antimiR-21 was delivered from the stent surface which 
exhibited a decrease in neointima formation (Wang et al., 2015) and also 
circumvented issues which were present with systemic delivery of the miRNA 
when delivered intravenously. This has highlighted the advantages of localised 
delivery and the powerful effects which therapeutic miRNA could have when 
administered in this way. 
Further to the in vitro testing detailed in Chapter 4 of miR 99b/let 7e/125a on 
the effect of VSMC proliferation, a porcine in vivo 28 day efficacy study was 
carried out delivering this cluster from stent surfaces. Although completed, at 
the time of writing the RNA extractions and analysis of the vessels by optical 
coherence tomography have not yet been completed. These results will indicate 
whether or not the cluster miRNA eluting stent would be effective at preventing 
ISR.        
Finally, using a PLA platform for miRNA delivery would enable BMSs to be used as 
demonstrated in these studies; it also however could be used with the new 
technology of biodegradable stents which are composed of PLA, to create a 
transient PLA miRNA eluting stent. This could aid prevention of ISR through 
miRNA action and then dissolve overtime which would avoid chronic 
inflammatory responses caused by the stent struts.  
To date the work presented here represents the second study detailing 
methodology for miRNA-eluting stents, with the first study being published a few 
months before the completion of the writing of this text (Wang et.al., 2015). 
The methods which have been used here are novel in that they can be 
universally applied to any BMS, and represent a simple approach for miRNA 
delivery within this setting. In addition this is the first time that PLA has been 
used to absorb miRNA onto for use as a miRNA delivery device in the context of 
coronary stents. Since PLA is a common material for medical implants this 
technique for miRNA delivery could be applied in different medical contexts. 
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6 General discussion 
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6.1 General discussion 
This thesis has focused on developing novel methodology for coating stents with 
adenovirus vectors and miRNA. The aim of the research conducted was to 
provide systems which would enable localised delivery of Ad vectors/miRNA to 
the stented region, which would be used to deliver therapeutic Ad 
vectors/miRNA to prevent ISR, much like the action of drug-eluting stents. In 
order to develop the coating technology, virus vector Ad5 and c.elegans (miR-39-
3p) were used as a ‘model’ virus and miRNA to deliver from the stent/stent 
material surfaces. Evaluation of Ad delivery was assessed by monitoring viral 
transduction in vitro and ex vivo using pig coronary arteries, following the 
coating of the Ad onto stent material surfaces and stents. Three different 
techniques for virus coating were tested; PEM formation, covalent attachment 
and collagen entrapment. Evaluation of miRNA delivery was assessed by 
monitoring miRNA expression following coating on stent material surfaces and 
stents, in vitro, ex vivoand in vivo testing in both porcine and murine stenting 
models. 
Linking adenoviruses to surfaces is a significant undertaking. Adenoviruses are 
complex biological structures and care is needed to preserve the innate 
biological activity to ensure that the virus is capable of delivering the transgene 
efficiently, following linkage to the surface. Methods which have been used to 
create DES cannot therefore be applied to virus linkage methodology as they 
involve organic solvents required to dissolve the polymer, which would have 
detrimental effects on the virus biological activity profile. Therefore simple, 
methods for virus attachment were investigated initially which relied on 
electrostatic interactions between the negatively charged virus capsid and a 
positively charged polyelectrolyte layer. To date, a few studies have been 
reported adherence methods of viruses to stent surfaces using electrostatic 
interactions. One method used the native adenoviruses net negative charge 
which could bind to a positively charged phosphorylcholine stent surfaces 
through electrostatic interactions (Sharif et al., 2008, Johnson et al., 2005b). 
Similarly a study reported by Saurer et al. (2011), demonstrated that 
poly(electrolyte) multiplayers (PEMs), could be used to deliver DNA from stent 
surfaces in vitro through electrostatic interactions. Therefore, it was 
hypothesised that PEMs could be used to attach virus particles to stent surfaces 
Chapter 6  185 
 
via electrostatic interactions, although successful for in vitro testing, this 
technique proved not robust enough to withstand deployment ex vivo into rat 
arteries. This suggested that a more permanent linkage could provide a more 
suitable delivery system. 
Direct covalent linkage of viruses to stent surfaces was attempted by modifying 
PLA, a biodegradable polymer, which is often used as a stent material. Using this 
organic biodegradable polymer, allowed access to a wider range of organic 
chemistry techniques for bio-conjugation of the virus to the polymer surface, 
which would not be possible if trying to attach directly to SS surfaces. One of 
the reasons which SS is suitable for its role as an implant material is due to the 
fact it is very unreactive. Modification of PLA, so that it could react with the 
virus worked well, although the chemistry involved proved difficult to reliably 
reproduce and therefore other delivery methods were investigated. This was 
partly due to restrictions on the solvents and reagents which could be used to 
ensure that the virus was still biologically active.  
One of the advantages of using a covalent modification strategy for direct virus 
linkage to the surface was for the permanency of the bond, which would be able 
to withstand the stent deployment procedure. If this strategy was taken further 
it would be important to incorporate mechanisms for the virus to detach from 
the surface, enabling the virus to transduce the surrounding cells within its 
lifespan. Although the PLA is biodegradable and would release the virus particles 
it may be important to introduce more labile linkages to achieve this and 
develop this methodology further. Using a variety of different labile linkages 
could create a system whereby temporal virus elution was achieved by fine-
tuning the chemistry, which could be useful for enabling a sustained gene 
delivery profile.  
Methodologies were then investigated which did not require covalent bonding 
and instead used collagen gel encapsulation. Initial testing revealed that the 
virus retained its biological activity when encapsulated within the gel and could 
transduce cells. Better adherence of the collagen gel was demonstrated when 
deposited directly onto PLA surfaces as opposed to SS. Difficulties were 
encountered when trying to coat the PLA onto the SS as high %PLA wt/wt 
dissolved in chloroform were required in order to retain high virus transduction 
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levels. This created a logistical problem, as when coating the SS stents, high 
%PLA solutions meant that the stent could no longer fit through the guide 
catheter and expand fully. Therefore testing using a commercially available PLA 
stent would be essential for investigating further whether the collagen 
encapsulation methodology would function in vivo. 
With both the miRNA and adenovirus eluting stents, future work will need to 
focus on efficacy studies, in order to demonstrate that therapeutic 
miRNA/adenovirus can be used to effectively prevent ISR from occurring. The 
most relevant model to test this in would be the pig in vivo stenting model, due 
to similarities in vessel size, anatomy and the similarity in operational 
procedures between pigs and humans. Care will need to be given to elucidate 
whether the miRNA/adenovirus is efficacious as ISR is a complex multi-factorial 
disease. It will be imperative to ensure that the targets of the relevant 
adenovirus/miRNA are subsequently upregulated or downregulated as intended. 
But even after confirmation of target upregulation/downregulation, off-target 
effects may hinder the desired outcome. For miRNA therapy this poses as a 
significant problem as they are known to have multiple targets, control over this 
innate binding ability of the miRNAwill therefore be difficult, but key for 
progression to the human clinical trials. 
As mentioned before, until recently miRNA-eluting stents had not previously 
been reported and at the time of conducting this research no miRNA-eluting 
stent research literature was available for reference. The success found with the 
adenovirus collagen encapsulation methodology provided the rationale for 
investigating whether miRNA delivery could be achieved from these platforms. It 
was found that the collagen was surplus to requirements and the miRNA could be 
efficiently delivered in vitro from PLA surfaces by direct application onto the 
surface following mixing with transfection reagent siPORT™ Neo FX™. Although 
not tested experimentally, it was likely that adherence of the miRNA onto the 
PLA surface was due to hydrophobic interactions between siPORT™ and the PLA 
surfaces. This therefore could be used when developing future miRNA delivery 
systems. 
Results from in vivo studies, through application of miRNA/siPORT to PLA coated 
murine and porcine BMS, were very promising. At 48 h, the non-endogenous 
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c.elegans miR-39-3p that was coated onto the stent surfaces could be detected 
from the surrounding stented vessel. Initial results also demonstrated that 
therapeutic miRNAs could be delivered in vitro using miR-145-5p and anti-miR-21 
in vivo, although a more highly powered study would need to be done to 
supplement these preliminary in vivo findings.  
Although expression of the c.elegans miR-39-3p was observed which provided 
good evidence that this delivery system was suitable for in vivo delivery of 
miRNA from stent surfaces; when targeting endogenous miRNAs such as miR-145 
and miR-21, great variability was observed with expression profiles in both in 
vitro and in vivo settings after delivery of the miRNAs and miRNA inhibitors. This 
could reflect the method for coating the miRNA/siPORT not being uniform 
enough. In order to progress these delivery systems further, it would be 
important to implement spray-coating methodology of the miRNA onto the stent 
surface, to ensure a uniform distribution of the miRNA onto the surface.  
Variability introduced from the PLA coating onto the SS stent surfaces, which 
was done by hand, would also need to be improved by using industrial methods 
for polymer coatings on stent surfaces, or simply by using a commercially 
available PLA stent such as the Abbott BioAbsorb scaffold (Abbott, 2015). 
Although currently this stent is manufactured with everolimus coated onto it, 
which would inhibit neointima formation. It would therefore be important to 
obtain a non-anti proliferative drug eluting PLA stent for further studies. 
Concerns about the manual coating methodology have also been raised for 
longer term efficacy studies, as the thickness of the coating could cause an 
increase in neointima formation. Commercial stent struts which are available in 
the clinic have thicknesses in the range of 60-150 μM (Stefanini et al., 2013), 
therefore measuring the PLA coating thickness would also needed to be done in 
order to allow efficacy testing to be done effectively.  
In summary, despite these suggested improvements and considerations for 
further testing of the miRNA eluting stents, the methodology presented here 
represents a novel way in which miRNAs can be delivered from stent surfaces, 
which has been shown to deliver miRNA in the porcine and murine in vivo 
models. This is the first of example of miRNA eluting stents using these animal 
models and the first study to employ the biodegradable polymer PLA in order to 
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do so. The findings presented here, I hope will form the foundations for a fully 
functional biodegradable miRNA eluting stent, which will show-case the ability 
of miRNAs as a new-class of therapeutic for the prevention of ISR. 
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